UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

[X] Annual Report Pursuant to Section 13 or 15(D) of the Securities Exchange Act of 1934

for the fiscal year ended December 31, ~~2015~~2016

[ ] Transition Report Under Section 13 or 15(D) of the Securities Exchange Act of 1934

for the transition period from _______________ to _______________

Commission File Number: 000-53392

ACCELERA INNOVATIONS, INC.

(Exact name of ~~small~~registrant ~~Business Issuer~~ as specified in its charter)

Delaware

26-2517763

(State or other jurisdiction

of incorporation or organization)

(IRS Employer

Identification No.)

20511 Abbey Drive

Frankfort, Illinois

60423

(Address of principal executive offices)

(Zip Code)

~~Issuer~~Registrant’s telephone number, including area code: (866) 866-0758

Not applicable.

Former address if changed since last report

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, par value $0.0001 per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ ] No [X]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.[ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer		Accelerated Filer		Non-Accelerated Filer [ ]		Smaller Reporting Company
[ ]		[ ]		(Do not check if a smaller reporting company)		[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. $31,857,450, based on 27,315,436 shares of the registrant’s common stock and a closing price of $0.00068 per share on June 30, ~~2015.~~2016

As of ~~August~~April 314, ~~2016~~2017 there were 4578,~~713~~158,~~716~~673 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS

PART I
ITEM 1.	BUSINESS		4
			4
ITEM 1A.	RISK FACTORS		13
ITEM 1.		BUSINESS	9
ITEM 1B.	UNRESOLVED STAFF COMMENTS		21
ITEM 1A.		RISK FACTORS	9
ITEM 2.	PROPERTIES		21
ITEM 1B.		UNRESOLVED STAFF COMMENTS	9
ITEM 3.	LEGAL PROCEEDINGS		22
ITEM 2.		PROPERTIES	9
ITEM 4.	MINE SAFETY DISCLOSURES		22
ITEM 3.		LEGAL PROCEEDINGS	10
ITEM 4.		MINE SAFETY DISCLOSURES	10
PART II
ITEM 5.	~~MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES~~	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	2210
ITEM 6.	~~SELECTED FINANCIAL DATA~~	SELECTED FINANCIAL DATA	2211
ITEM 7.	~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION~~	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	2312
ITEM 7A.	~~QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	2616
ITEM 8.	~~FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA~~	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	2616
ITEM 9.	~~CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE~~	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	2717
ITEM 9A.	~~CONTROLS AND PROCEDURES~~	CONTROLS AND PROCEDURES	2717
ITEM 9B.	~~OTHER INFORMATION~~	OTHER INFORMATION	2818
PART III
ITEM 10.	~~DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE~~	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	2919
ITEM 11.	~~EXECUTIVE COMPENSATION~~	EXECUTIVE COMPENSATION	3121
ITEM 12.	~~SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND ELATED STOCKHOLDER MATTERS~~	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND ELATED STOCKHOLDER MATTERS	3424
ITEM 13.	~~CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE~~	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE	3525
ITEM 14	~~PRINCIPAL ACCOUNTANT FEES AND SERVICES~~	PRINCIPAL ACCOUNTANT FEES AND SERVICES	3525
PART IV
ITEM 15.	~~EXHIBITS, FINANCIAL STATEMENT SCHEDULES~~	EXHIBITS, FINANCIAL STATEMENT SCHEDULES	3626
SIGNATURES			3829

- 2 -

FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements. The Securities and Exchange Commission (the “Commission”) encourages ~~companies~~ companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “will” and similar expressions in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, future performance or results of current and anticipated sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. Factors that could cause our actual results of operations and financial condition to differ materially are discussed in greater detail under Item 1A, “Risk Factors” of this ~~annual~~ report ~~on Form 10-K~~.

We caution that the factors described herein and other factors could cause our actual results of operations and financial condition to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

- 3 -

PART I

ITEM 1. BUSINESS

OVERVIEW

Accelera Innovations, Inc. (“we,” “us,” the “Company,” or “Accelera”), a Delaware corporation, is a healthcare service company ~~which is~~ focused on integrating its licensed ~~technology~~ technology assets into ~~our newly~~ acquired companies ~~Behavioral Health Care Associates, Ltd~~. ~~and SCI Home Health, Inc. (d/b/a Advance Lifecare Home Health) to reduce operating costs and expand operations.~~ The technology was licensed to us by our ~~majority~~significant shareholder Synergistic Holdings, LLC, a privately-held company organized under the laws of Illinois, ~~pursuant~~in ~~to which~~ the ~~Company~~form ~~was~~of ~~granted~~ a thirty (30) year exclusive, non-transferrable worldwide license for proprietary Internet-based, software platform (the “Accelera Technology”) that is designed to ~~provide~~improve the ~~interoperable~~functionality ~~technology~~and ~~that~~performance isof ~~intended~~healthcare toservices ~~improve~~by ~~the~~making ~~quality~~clinical ofhealthcare ~~care~~data ~~while reducing~~available ~~the~~to ~~cost~~healthcare ~~as described below~~consumers.

We will not be able to commercialize the Accelera Technology without additional capital. If we do not raise additional funds of atapproximately ~~least~~ $5530 million for the advancement of the Accelera Technology over the next ~~three~~12 ~~years~~months, we will lose our rights to the technology. We will require significant additional financing in order to meet the milestones and requirements of ~~its~~our business plan and avoid discontinuation of the license. Funding ~~would~~is be required for staffing, marketing, public relations and the necessary distribution to expand ~~expanding~~ the scope of our ~~offering~~business to include the global market. We intend to seek an aggregate of $555 million in ~~2016~~financing ~~through~~in the near term through the sale of equity or convertible debt securities ~~and were unable to raise a sufficient amount of capital in 2015~~. The issuance of these securities will dilute existing shareholders’ interests in the Company. The Company intends to approach hedge funds, venture capital groups, private investment groups and other institutional investment groups in ~~its~~an ~~efforts~~effort to achieve ~~future~~its funding goals.

Health Care Services

Our mission is to improve patient outcomes and lower costs, through educating providers, leveraging our technology and changing the conventional model of payment to a value-based system.

~~The~~We ~~company~~aim ~~now~~to ~~provides~~provide the highest quality care in the home, spanning every age group and level of care — from pediatrics to geriatrics, to critical care or just being there. Our team of home health care professionals now includes nurses, physical therapists, occupational therapists, speech language pathologists, medical social workers, and home health aides.

We provide billing, practice management and administrative services to doctors and other clinicians who provide services to, nursing homes and individual clients. In support of the billing and practice management services, we provide in-house Psychiatric evaluations, complete neuropsychological testing, assessments and treatment services, counseling and medication management. Furthermore, we provide comprehensive laboratory services including EKG, Drug Screens, blood work ups and sleep lab evaluation. Detoxification services include alcohol and all drugs and substances with directorship to methadone maintenance programs. We also provide Military Entrance Processing Station (MEPS) screenings and performs research trials as a contracted site for several pharmaceutical firms.

In addition, we are engaged in the acquisition and operation of home health business that will allow the acquisitions the autonomy to continue to run their business, but also take advantage of our administrative services and business tools. Some of those services will include the use of clinical software, group purchasing and marketing expertise.

LICENSED ACCELERA TECHNOLOGY

Software Description

We plan to incorporate the following software applications into our recent acquisitions and license and sell such software separately:

● Accelera EMR- A certified Electronic Medical Record application designed to be used primarily in physician offices to automate the patient’s clinical chart ~~and meet the ARRA (Federal Mandated Meaningful Use) criteria~~. ● Accelera PM -The Practice Management application designed to be used primarily in physician offices to automate the physician’s revenue cycle management system. ● Accelera Patient Portal - The Patient Portal application designed to be used as a communication tool between patient and physician ~~office~~ staff. This application iswill ~~intended to~~ allow the patient to ~~access~~view their on medical record ~~information in a secure environment~~. ● Accelera HIE - The Health Information Exchange application is intended to allow providers and payors of healthcare to ~~exchange~~ secure patient’s data byand ~~creating~~lower healthcare cost. ● Accelera ACO - The Accountable Care Organization (“ACO”) application needed to operate an ACO environment. This application is designed to offer the ~~continuum~~ACO ofbusiness ~~care~~the ~~for~~ability to report to CMS the ~~patient,~~usage of Medicare benefits and ~~decreasing~~is intended to lower patient and healthcare cost. ● Accelera HIS - The Hospital Information System application is designed to includes all applications to manage most hospital information systems.

- 4 -

● Accelera ACO - The Accountable Care Organization (“ACO”) application needed to operate an ACO environment. This application is designed to offer the ACO business the ability to report to CMS the usage of Medicare benefits and is intended to provide tools to lower the cost of patient care. ● Accelera HIS - The Hospital Information System application is designed to includes all applications to manage most hospital information systems.

Accelera also intends to provide its cloud based healthcare services through monthly or yearly subscription agreements (“software-as-a-service” also known as “SaaS”) to the healthcare industry. The Company intends on positioning itself as a technology and service solution for providers and payers such as the hospitals, medical offices, medical insurance companies, Accountable Care Organizations, Patient Centered Medical Homes, and Provider Service Networks who are seeking to create an interoperable technology platform that is patient-centric.

The coordinated care would begin with the office visit using the Accelera Practice Management and Electronic Medical Record applications. The provider may also access disparate patient consults and share the patient’s record using the Accelera Health Information Exchange and Portal. When the patient is admitted to the hospital setting, all of the functions are intended to be automated using the Accelera Hospital Information System. The physician would continue to have full access to the patient’s information to receive accurate and efficient information. If the primary care physician is part of an Accountable Care Organization, then those reports required by Center for Medicare and Medicaid will be created and distributed using the Accelera Accountable Care Organization application.

The Accelera Patient Management Record is designed to identify patients with preventable, yet escalating associated costs, then directs intense online self-management services to improve the quality-of-life for the patient and deliver more effective health information. Patients would be electronically triaged using the Center for Medicare and Medicaid (CMS) rule-set for disease management, as well as proprietary evidence-based disease management rules. These rules are based on clinical standards from major health organizations. This is intended to allow providers, as well as patients, to monitor care through targeted interventions. The technology platform is intended to allow healthcare providers to anticipate patient care needs, motivate patient compliance, activate evidence-based standards of care, and improve efficiency.

The Accelera Analytic product is designed for potential customers that include healthcare payers, provider organizations, government entities worldwide, and employer groups. Accelera products are designed to identify, analyze, and minimize healthcare risk by data mining and predictive analysis while containing costs and improving the quality of care. Accelera also intends to develop modeling software to predict medical costs and help improve the financing, organization, and delivery of health services.

The Accelera Security solution is designed to reduce or stop the security breach at the point of care, by auditing the user and encasing the applications in a discrete shell. Without proper access, the application will separate the data elements from each other, patient name will not be associated with demographic or clinical information. Patient data is split into two parts, the patient identifier is separated from the clinic/medical data and both are encrypted. An encrypted data key unlocks the dual encryption bringing the information together and is intended to increase patients’ confidence in the information technology utilized.

The Accelera Solution is designed to improve patient care, reduce costs, eliminate redundant data entry, improve operational efficiency, but most importantly, bring together long term needs of the caregivers and is intended to satisfy the business requirements of the healthcare enterprise.

The intended benefits of our solutions include:

● Lowers administration costs through a less invasive call-back system - email alerts, text messages, online alerts

● A benefit of batch health care analytics is the use of “predictive modeling across multiple clinical conditions. This process is designed to identify undiagnosed conditions for patients within an insurer’s patient population, or suggest interventions to prevent conditions from developing.

● Reducing occurrences and cost related to a healthcare data breaches.

● Reducing the hardware environment and cost by using our cloud technology.

● Increased Mobility.

● Improving patient care and safety.

● Helping healthcare organizations maintain their market positions and meet their financial commitments.

Products

Accelera intends to offers the following products and services:

- 5 -

Accelera Analytics

Real-time health care analytics are programs that are intended to analyze clinical information at the point of care and support health providers as they make prescriptive decisions. Accelera’s real-time systems are designed to be “active knowledge systems”, which use two or more items of patient data to generate case-specific advice

Batch health care analytics is a technical application that is designed to retrospectively evaluate population data sets (i.e. records of patients in a large medical system, or claims data from an insured population). These evaluations can be used to supplement disease management or population health management efforts.

Accelera Analytic product is designed for potential customers that include healthcare payers, provider organizations, government entities worldwide, and employer groups. Accelera products are intended to help you identify, analyze, and minimize healthcare risk while containing costs and improving the quality of care. Accelera also intends develop modeling software to predict medical costs and help improve the financing, organization, and delivery of health services.

The Accelera Analytic engine is designed to help healthcare organizations better assess and reduce their risk from catastrophic perils such as hurricanes, earthquakes, floods, tornadoes, and tsunamis. This includes risk not only from physical damage but also from direct and contingent business interruption losses across the entire network.

Accelera Security

The Accelera Security is designed to provide a unified platform for managing security and systems compliance across all clients and servers regardless of location or network connectivity. The application is intended to prevent end users whether on-site, remote or off-line from copying or transmitting patient data to external devices or unauthorized locations.

Accelera EMR and PM

The Accelera Electronic Medical Record (EMR) and Practice Management application is intended to provide a comprehensive solution for medical groups and physician enterprises, whether they are independent or part of an integrated network. The practice management solution is designed to give physician groups the flexibility to manage their business under many different reimbursement models. The solution is designed to include risk management, managed care capabilities, and a clinical system for managing patient care. Additional capabilities to help accelerate cash flow; reduce cash flow and increase productivity included decision support, data quality analysis and electronic data interchange.

Accelera HIE and Portal

The Accelera Health Information Exchange (HIE) and Portal, is designed to link all health care data such as diagnosis, medications, laboratory results, patient behavioral health, radiology films, patient and doctor to the data repository. Besides increasing accuracy these applications are intended to help alleviate patient frustration with having to provide duplicate information from one setting of care to another; thereby enhancing customer satisfaction. The HIE unites disparate systems across rural and metropolitan locations, converting the data into useful clinical dashboards to help comply with preventive care guidelines and develop ACO’s.

Accelera HIS

The Accelera Hospital Information System solution automates the operation of individual departments and their respective functions within the inpatient environment. These hospital-based transaction and decision support systems form the core of systems that in conjunction with other tools designed to directly support clinical decision making, help streamline the care process over the continuum of care. They include applications for patient care, laboratory, pharmacy, radiology, surgery, materials management, emergency department, financials and management decision support.

Accelera ACO

Accelera Accountable Care Organization (ACO) application is a tool designed to accurately report to CMS (Centers of Medicare and Medicaid Services) the usage of provider claims and reimbursement. The tool also analyses ways to improve care and lower cost across the ACO.

Accelera’s differentiating factor, as mentioned above, is how we intend to securely integrate the virtual world into our overall strategies. We intend to use cloud technology to continuously get closer to the patient; respond to application issues within minutes and connect with other providers and payers.

- 6 -

Our keys to success over the next five years are:

● Acquiring health care Providers or groups with strong revenue and positive EBITDA of 10% to 20% of annual revenue. ● Decreasing the expenses and increasing revenue within our acquisitions by utilizing our technology applications and platforms. ● Becoming more involved in Telemedicine including acquisitions and using our cloud-based Health Information Exchange. ● Creating Best Practice within post-acute care acquisitions.

Target Market Segment Strategy

Accelera will work to align communication protocols so acute and post-acute care providers can communicate as seamlessly as possible. These protocols guide providers in discussing patient status, particularly when a patient’s condition changes. Clear channels of communication, a common approach for discussing patients and the information technology infrastructure to exchange clinical information are helping reduce readmissions and emergency department visits. Referring or attending providers feel more comfortable providing clinical guidance to Post Acute Care staff instead of requesting that the patient be sent to the emergency room. According to Brown-Wilson’s Black Book Rankings Survey, the annual healthcare spending in 2015 soared to $3.5 trillion; medical errors cost $19.5 billion a year. Providers understand the need for technology to lower the cost of care and mitigate risk.

As policy changes place more accountability for the selection of the most appropriate Post-Acute Care setting on referring providers, it will be increasingly important to support these providers in making the best choices for patients. As a first step, referring providers need more information on available Post-Acute Care options and data indicating the unique clinical capacities and quality outcomes for Post-Acute Care providers in the community. Once an individual patient has been admitted to the appropriate Post-Acute Care setting, acute-care clinicians need access to complete patient data that can be shared across settings, including from the Post-Acute Care setting back to the referring provider. Many of these data-sharing goals require a robust health information technology infrastructure that some facilities are just beginning to build. A Common Assessment Tool Could Help Providers Make the Best Decisions for Patients Policymakers and providers agree on the need for a single assessment tool that uses common data metrics for all Post acute Care settings. A uniform tool could not only help providers and patients work together to select the most appropriate Post-Acute Care setting and encourage efficient data sharing among providers, but also could improve data analysis. Currently, each Post-Acute Care setting has its own methods and tools for admitting and discharging.

Medicare and Medicaid are focused on reducing hospital readmissions and variations in spending and margins across PAC and LTC settings, as well as ensuring appropriate service utilization. Overall, we have significant opportunities to improve care and limit costs for populations with chronic conditions. Forces driving change include:

● Financial penalties for hospitals – and, soon, for SNFs and other PAC providers — for avoidable hospital readmissions. ● A shift to value-based (versus volume-based) payments and a commitment to population-health management to improve quality and control costs. ● Increased capitated managed care arrangements for elderly and disabled populations. To stay in network, PAC and LTC providers must demonstrate quality and cost effectiveness. ● A focus on standardized health and functional assessments to ensure patients are placed in the lowest-cost facility that meets their needs. ● A rise in quality measurement and reporting. PAC and LTC providers must develop metrics to assess their results—and implement needed improvements.

Intellectual Property

We rely on a combination of copyright, trademark and trade secret laws, as well as confidentiality procedures and contractual restrictions, to establish and protect our proprietary rights. These laws, procedures and restrictions provide only limited protection. We currently have no issued patents or pending patent applications.

We endeavor to enter into agreements with our employees and contractors and with parties with whom we do business in order to limit access to and disclosure of our proprietary information. We cannot be certain that the steps we have taken will prevent unauthorized use or reverse engineering of our technology. Moreover, others may independently develop technologies that are competitive with ours or that infringe on our intellectual property. The enforcement of our intellectual property rights also depends on any legal actions against these infringers being successful, but these actions may not be successful, even when our rights have been infringed.

Home Health Competitors

Home health care companies offer a wide range of skilled medical services such as nursing care, physical therapy and occupational therapy from qualified medical professionals in addition to various services from home health aides. Other home care companies might offer assistance with daily activities, such as bathing and eating. Home care services are conducted in the comfort of your home. There is a directory of 12,300 Medicare-certified home health agencies and 21,452 other home care companies in the United States.

- 7 -

We believe the health care industry is fragmented and rapidly evolving. Our competitors vary in size, scope and breadth of the products and services they offer. We offer a software-as-subscription program that provides health care services similar to or directly in competition with health care services offered by hospital groups, electronic medical record service providers and practice management service providers.

We believe that success in the health care industry, particularly in the areas of primary and chronic care, is dependent upon the ability of providers to:

● provide easy access, convenience, and a quality experience to consumers; ● lower the cost of health care by streamlining operations, lowering operating expenses, and reducing errors, and human intervention; ● automate the entire health care lifecycle and integrate the business and care aspects of health care; and ● use technology to facilitate evaluation and diagnosis, treatment, after-care management, and billing and collections.

Electronic Medical Record Competitors

Allscripts is one of the leading EMR companies which offer large volumes of data generated by high-acuity care. They provide customized views so individual clinicians can find the data they need to make timely, accurate decisions. This service has limited patient view into the data. A recent step towards entering this space occurred when Allscripts installed their EMR software at Sloan-Kettering Cancer Center to address the Joint Commission on Accreditation of healthcare Organizations (JCAHO) for hospital organizations to do a better job of patient supervision handoffs. But as of yet, the patient cannot see an online version of doctor recommended care as Accelera intends to provide.

Practice Management Competitors

Allscripts, eClinicalworks & Epic Systems Corporation focus their business on the practice side of the equation. Recently, these companies are bundling patient module which a patient logs onto the system to access patient data.

Some of our current or potential competitors are larger and have more resources than we do. Many of our competitors enjoy substantial competitive advantages, such as greater name recognition, longer operating histories, and larger marketing budgets, as well as substantially greater financial resources. In addition, these traditional health care providers are more widely accepted and known to consumers, whereas Accelera’s business model and service has yet to gain widespread recognition and acceptance. Furthermore, because of these advantages, existing and potential customers might accept any of our competitor’s services, even if they may be inferior to ours. If our potential customers choose to use any of these competitive offerings, our revenue could decrease and we could be required to make additional expenditures to compete more effectively.

Recent Industry Developments

Post-acute care is a critical part of healthcare reform in the US as more people with multiple illnesses are moved through the various parts of our healthcare system with suboptimal care and high cost overruns as a result. Each year nearly nine million people-24,000 per day are discharged from short term acute care hospitals and require some form of post-acute care. Patients typically see a range of providers and specialists promoting communication problems and other errors resulting in higher costs.

These problems result in a substantial number of hospital re-admissions. According to Medpac, among Medicare patients- 20% are re-hospitalized within 90 days. More than 75% of these re-admits (at a cost of more than $26 billion per year) are thought to be avoidable.

In an attempt to address this large expense Medicare started in October 2012, penalizing hospitals with high readmission rates. The penalties were up to 3% in 2014. The industry is motivated to address the lack of coordination in post-acute care. Medicare spending on post-acute care is estimated to be $63.5 billion market.

GOVERNMENT REGULATIONS

As a participant in the healthcare industry, our operations and relationships, and those of our customers, are regulated by a number of federal, state and local governmental entities. The impact of this regulation on us is direct, to the extent we are ourselves subject to these laws and regulations, and is also indirect in that, in a number of situations, even though we may not be directly regulated by specific healthcare laws and regulations, our products must be capable of being used by our potential customers in a manner that complies with those laws and regulations. Inability of our potential customers to do so could affect the marketability of our products or our compliance with our potential customer contracts, or even expose us to direct liability under the theory that we had assisted our potential customers in a violation of healthcare laws or regulations. Because our business relationships with physicians will be unique and the healthcare technology industry as a whole is relatively young, the application of many state and federal regulations to our business operations and to our potential customers is uncertain. Indeed, there are federal and state fraud and abuse laws, including anti-kickback laws and limitations on physician referrals, and laws related to distribution and marketing, including off-label promotion of prescription drugs that may be directly or indirectly applicable to our operations and relationships or the business practices of our potential customers. It is possible that a review of our business practices or those of our potential customers by courts or regulatory authorities could result in a determination that could adversely affect us. In addition, the healthcare regulatory environment may change in a way that restricts our existing operations or our growth. The healthcare industry is expected to continue to undergo significant changes for the foreseeable future, which could have an adverse effect on our business, financial condition and results of operations. We cannot predict the effect of possible future legislation and regulation.

- 8 -

Our Corporate History

We were incorporated on April 29, 2008 ~~in Delaware~~ under the name Accelerated Acquisitions IV, Inc. and engaged in the investigation and acquisition of a target company or business seeking the perceived advantages of being a publicly held corporation. We changed our name to Accelera Innovations, Inc. on October 18, 2011 ~~when we identified healthcare technology, obtained exclusive rights and became a healthcare technology service provider~~.

On June 13, 2011, Synergistic Holdings, LLC, a company owned or controlled by Geoff Thompson, Chairman of our ~~Board~~board of ~~Directors~~directors, and his wife Nancy Thompson (“Synergistic”), acquired 17,000,000 shares of ~~the~~our ~~Company’s~~ common stock ~~for~~at a price of $0.0001 per share. At the same time, Accelerated Venture Partners, LLC, our former controlling stockholder, cancelled 3,750,000 shares of ~~the~~our ~~Company’s~~ common stock. Following these transactions, Synergistic ~~Holdings, LLC~~ owned approximately 93.15% of ~~the~~our ~~Company’s~~ issued and outstanding ~~shares of~~ common stock. ~~Simultaneously~~Concurrent with the share purchase and cancellation, Timothy Neher, our former sole officer and director, resigned from the ~~Company’s~~board ~~Board~~ of ~~Directors~~directors and John Wallin was ~~simultaneously~~ appointed to the ~~Company’s Board of Directors~~board. ~~Such~~These ~~transaction~~transactions represented a change of control of the Company.

~~On August 22, 2011, the Company entered into a~~ Licensing Agreement ~~(“Licensing Agreement”)~~ with ~~our majority shareholder~~ Synergistic Holdings, LLC (“Licensor”) pursuant to which the Company was granted an exclusive, non-transferrable worldwide license for proprietary Internet-based, software that is designed to improve the functionality and performance of healthcare services by making clinical healthcare data available to healthcare consumers.

On ~~April~~August 1322, ~~2012~~2011, the Company entered into ana ~~amended~~licensing ~~Licensing~~agreement ~~Agreement~~ (the “Licensing Agreement”) with Synergistic ~~Holdings LLC,~~pursuant ~~(Licensor) whereas the Company and Licensor agreed~~ to ~~amend~~which the ~~August 22, 2011 Licensing Agreement. The~~ Company ~~licensed~~received ~~additional technology~~an ~~from Licensor and the parties agreed to modify the terms~~exclusive, ~~conditions,~~non-transferrable ~~representations~~worldwide ~~and~~license ~~warranties~~for ~~regarding~~ the ~~technology~~ ~~and~~Accelera ~~to clarify any obligations the Licensor may have with third parties~~Technology.

~~Pursuant~~On toApril ~~the~~13, ~~Agreement~~2012, the Company ~~was~~entered ~~granted~~into an ~~exclusive,~~amended ~~non-transferrable~~licensing ~~worldwide~~agreement ~~license~~(the ~~for proprietary Internet-based, software~~ “~~Accelera~~Amendment ~~Technology~~Agreement”) ~~that~~with isSynergistic whereby ~~intended to improve~~ the ~~functionality~~Company and ~~performance~~Synergistic ofagreed ~~healthcare services by making clinical healthcare data available~~ to ~~healthcare~~amend ~~consumers. This relevant data is intended to serve as~~ the ~~backbone~~Licensing ~~for~~Agreement. ~~self-management tools~~The ~~that~~Company ~~are~~licensed ~~designed~~additional totechnology ~~allow~~from ~~these same healthcare consumers to facilitate the self-management portion of their doctor-prescribed~~Synergistic ~~care plan~~ and ~~focus on~~ the ~~most~~parties ~~costly~~agreed ~~disease states. This is intended~~ to bemodify ~~accomplished through~~ the ~~proprietary~~terms, ~~technology~~conditions, ~~which~~ isrepresentations ~~designed to identify~~ and ~~measure~~warranties ~~the~~regarding ~~severity of~~ the ~~sickness~~Accelera ~~level~~Technology ~~based upon evidence-based clinical~~ and ~~medical rules~~to ~~and~~clarify isany ~~designed~~obligations toSynergistic ~~delivers~~may ~~the~~have ~~results~~with tothird ~~insurance companies, doctors, hospitals, and employers~~parties.

~~Except~~The ~~for~~Accelera Technology is intended to improve the ~~rights~~functionality ~~granted~~and ~~under~~performance of healthcare services by making clinical healthcare data available to healthcare consumers. This data is intended to serve as the ~~Agreement,~~backbone ~~Licensor~~for ~~retains~~self-management ~~all~~tools ~~rights,~~that ~~title~~are ~~and~~designed to ~~interest~~allow these same healthcare consumers to ~~Accelera~~facilitate ~~Technology~~the self-management portion of their doctor-prescribed care plan and ~~any~~focus on ~~additions~~the most costly disease states. This is intended to be accomplished through the proprietary technology, which is designed to ~~thereto—although~~identify and measure the ~~License~~severity ~~includes~~of the ~~Company’s~~sickness ~~right~~level based upon evidence-based clinical and medical rules and to ~~utilize~~deliver ~~such~~the results ~~additions~~to insurance companies, doctors, hospitals and employers.

~~The~~Except ~~term~~for of the ~~License~~rights ~~commenced~~granted onunder ~~August~~the 22Licensing Agreement, ~~2011 and~~ as amended ~~April 12~~, ~~2012~~Synergistic ~~and~~retains byall ~~oral agreement in fiscal 2014 will continue for thirty (30) years~~rights, ~~provided~~title ~~that~~and ~~the~~interest ~~Licensee is not in breach or default of any of the terms or conditions contained in this Agreement. In addition~~ to ~~other requirements, the continuation of the License is conditioned on the Company generating net revenues~~Accelera inTechnology ~~the~~and ~~normal~~any ~~course~~additions ofthereto—although ~~operations or~~ the ~~funding~~license byincludes the Company’s ofright ~~$30 million over three years for qualifying development and commercialization expenses related~~ to ~~Accelera~~utilize ~~Technology~~such additions.

The ~~Company~~term ~~and~~of ~~Synergistic~~the ~~Holdings,~~license ~~LLC~~commenced ~~(“Synergistic”)~~on August 22, a2011 ~~controlling~~and ~~shareholder~~by oforal ~~the~~agreement ~~Company,~~in ~~agreed~~fiscal to2014 ~~cancel 796,671~~will ~~shares~~continue offor ~~the~~thirty ~~Company’s~~(30) ~~common~~years, ~~stock~~provided that ~~owned~~we byare ~~Synergistic~~not ~~and~~in ~~forgive~~breach ~~certain~~or ~~indebtedness~~default ~~owed~~of byany of the ~~Company~~terms ~~to Synergistic~~or conditions contained in the ~~amount~~Licensing ~~of $1~~Agreement,~~018,618~~ as amended. In addition to other requirements, the ~~Company~~continuation ~~entered~~of ~~into an oral agreement to amend~~ the license ~~agreement entered~~is ~~into~~conditioned ~~between~~on the Company ~~and~~generating ~~Synergistic~~net torevenues ~~reduce~~in the ~~total~~normal ~~amount~~ course of ~~reimbursable~~operations ~~distribution~~or ~~and~~the ~~commercialization expenses~~funding ~~due~~by ~~under~~ the ~~license~~Company ~~agreement~~of byapproximately $~~585,181~~30 tomillion ~~$29,414,819~~over ~~and~~three ~~defer~~years ~~the~~for ~~commencement~~qualifying ~~date~~development ofand ~~the agreement until the~~commercialization ~~payment~~expenses ~~dates~~related ~~for~~to the ~~following~~Accelera ~~amounts:~~Technology.

On December 5, 2014, the Company and Synergistic agreed to cancel 796,671 shares of the Company’s common stock owned by Synergistic and forgive certain indebtedness owed by the Company to Synergistic in the amount of $1,018,618. In addition, the Company entered into an oral agreement to amend the terms of the Licensing Agreement to reduce the total amount of reimbursable distribution and commercialization expenses due under the License Agreement by $585,181 to $29,414,819 and defer the date of certain payment obligations by the Company under the Licensing Agreement as follows:

	(a)	$5,000,000 no later than December 31, 2015;

	(b)	An additional $7,500,000 no later than December 31, 2016;

	(c)	An additional $10,000,000 no later than December 31, 2017; and

	(d)	An additional $6,914,819 no later than December 31, 2018.

- 9 5-

InThe ~~addition, the~~ Company ishas ~~required~~not topaid ~~fund certain specified expenses related to~~ the ~~deployment~~December of31, ~~Accelera~~2015 ~~Technology~~payment ~~as specified in the Agreement. The Licensor will receive a royalty~~ of ~~fifteen percent (15%) of all gross revenues resulting from the use of the technology by Licensee in the first year~~$5,000,000 ~~ten percent (10%) the second year~~ and ~~one quarter of one percent (.025%) of all gross revenues resulting from~~ the ~~use~~additional of$7,500,000 ~~the~~due ~~technology~~on byDecember ~~Licensee for the remainder of the License Agreement~~31, ~~the cornerstone of which is the technology. The license is terminated upon the occurrence of events of default specified in the Agreement and outlined as followed:~~2016

IfThe ~~any~~Company ofis ~~the~~required ~~Parties~~to ~~are~~fund incertain ~~breach~~specified orexpenses ~~default~~related to the deployment of the ~~terms~~Accelera orTechnology ~~conditions~~as ~~contained~~specified in ~~this~~the Licensing Agreement. ~~and~~Synergistic dowill ~~not~~receive ~~rectify~~a orroyalty ~~remedy that~~of ~~breach~~fifteen orpercent ~~default~~(15%) ~~within~~of 90all ~~days~~gross revenues resulting from the ~~date~~use of the technology by the Company in the first year, ten percent (10%) in the second year and one quarter of ~~receipt~~one percent (.025%) of ~~notice~~all bygross revenues resulting from the ~~other~~use ~~party~~of ~~requiring~~the ~~that~~technology ~~default~~by orthe ~~breach~~Company ~~to be~~for ~~remedied,~~the ~~then~~remainder of the ~~other~~Licensing ~~party~~Agreement. ~~may~~The license ~~give~~can tobe terminated upon the ~~party~~occurrence inof ~~default~~events aof ~~notice~~default specified in ~~writing~~the ~~terminating~~Licensing ~~this~~ Agreement. and outlined as follows:

Licensee may, at its option, terminate this Agreement at any time by doing the following:

	●	If any of the parties are in breach or default of the terms or conditions contained in the Licensing Agreement and do not rectify or remedy that breach or default within 90 days from the date of receipt of notice by the other party requiring that default or breach to be remedied, then the other party may give to the party in default a notice in writing terminating the Licensing Agreement.

	●	The Company may, at its option, terminate the Licensing Agreement at any time by ceasing to use the Accelera Technology and offer the services facilitated by any Licensed Products (as defined in the Licensing Agreement); by giving sixty (60) days prior written notice to Synergistic of such cessation and of the Company’s intent to terminate, and upon receipt of such notice, Synergistic may immediately begin negotiations with other potential licensees and all other obligations of the Company under the Licensing Agreement will continue to be in effect until the date of termination; by tendering payment of all accrued royalties and other payments due to Synergistic as of the date of the notice of termination; and evidencing to Synergistic that provision has been made for any prospective royalties and other payments to which Synergistic may be entitled after the date of termination.

ByIn ~~ceasing~~addition, toSynergistic ~~use~~may alter the ~~Accelera~~license ~~Technology~~granted ~~facilitated~~ by ~~any~~the ~~Licensed~~Licensing ~~Products~~Agreement inwith ~~their~~regards ~~entirety~~to orits byexclusivity, ~~giving~~its ~~sixty (60) days prior~~territorial ~~written~~application ~~notice to Licensor of such cessation~~ and ofrestrictions ~~Licensee’s~~on ~~intent~~its toapplication ~~terminate,~~if ~~and~~the ~~upon~~Company ~~receipt~~is ofin ~~such~~breach ~~notice,~~or ~~Licensor may~~default ~~immediately begin negotiations with other potential licensees and all other obligations~~ of ~~Licensee~~the ~~under~~terms ~~this~~or ~~Agreement~~conditions ~~will continue~~contained ~~to be~~ in ~~effect until~~ the ~~date~~Licensing ofAgreement ~~termination.~~and Bydoes ~~tendering~~not ~~payment~~rectify ofor ~~all~~remedy ~~accrued~~that ~~royalties~~breach ~~and~~or ~~other~~default ~~payments~~within ~~due~~90 ~~to Licensor~~days asfrom of the date of ~~the~~receipt ~~notice~~ of ~~termination~~notice by ~~and~~Synergistic ~~evidencing~~requiring ~~to the Licensor~~ that ~~provision~~default ~~has~~or ~~been~~breach ~~made for any prospective royalties and other payments~~ to ~~which Licensor may~~ be ~~entitled after the date of termination~~remedied.

~~Licensor~~On ~~may~~May ~~terminate~~7, 2015, the Company and Synergistic agreed to further amend the Licensing Agreement ifto ~~Licensee~~eliminate isthe Company’s $29,414,819 funding requirement under Article 3 and replace it with a requirement to pay a license fee in ~~breach~~the oramount ~~default~~of $10,000 upon completion and acceptance of each installation of the ~~terms~~software at a location for each affiliate or ~~conditions~~subsidiary ~~contained~~of the Company and the sum of $10,000 on each anniversary after each such installation during the period of time in ~~this~~which ~~Agreement~~the ~~and~~software ~~does~~is used at such location. ~~not~~In ~~rectify~~addition, orthe ~~remedy~~Company ~~that~~will ~~breach~~be orresponsible ~~default~~for ~~within~~the 90reasonable ~~days~~installation ~~from~~costs incurred by Synergistic in connection with the ~~date~~installation ofand ~~receipt~~setup of ~~notice~~the software as required by ~~Licensor~~the ~~requiring~~Company. ~~that~~The ~~default or~~license ~~breach~~fee tomay be ~~remedied,~~paid ~~then~~in ~~Licensor,~~cash ~~may~~or ~~alter~~the ~~License~~Company’s common ~~granted~~stock. byIn ~~this~~addition, the Licensing Agreement ~~with~~was ~~regards~~amended to ~~its~~delete ~~exclusivity,~~the ~~its~~Company’s ~~territorial application~~exclusive ~~and~~rights ~~restrictions~~under onthe ~~its application~~agreement.

~~Licensor~~Investment ~~may terminate the~~ Agreement if Licensee is in breach or default of the terms or conditions contained in this Agreement and does not rectify or remedy that breach or default within 90 days from the date of receipt of notice by Licensor requiring that default or breach to be remedied, then Licensor, may alter License granted by this Agreement with ~~regards~~Lambert toPrivate ~~its exclusivity~~Equity, ~~its territorial applications and restrictions on its application.~~LLC

On ~~May~~October 74, ~~2015~~2013, the Company ~~and~~entered ~~Synergistic~~into ~~agreed~~a tostandby ~~amend~~equity ~~the~~purchase ~~Synergistic~~agreement ~~Licensing~~(the “Investment Agreement”) towith ~~eliminate~~Lambert Private ~~the~~Equity, ~~Company’s $29~~LLC,~~414,819~~ ~~funding~~a ~~requirements~~Delaware ~~under~~limited ~~Article~~liability 3company ~~and~~(the ~~replace~~“Investor”). itPursuant ~~with a requirement~~ to ~~pay~~the aInvestment ~~license fee in~~ Agreement, the ~~amount~~Investor ofcommitted 10to purchase,~~000 common~~ ~~shares~~subject ~~upon~~to ~~completion~~certain restrictions and ~~acceptance~~conditions, ofup ~~each~~to ~~installation~~$100,000,000 of(which ~~the~~can ~~software~~be atextended to a$200,000,000 ~~location~~under ~~for~~the ~~each~~same ~~affiliate~~terms) ~~or subsidiary~~ of the Company’s ~~and~~common ~~the~~stock, ~~sum~~over ofa ~~$10,000~~period onof ~~each~~36 ~~anniversary~~months ~~after~~from ~~each~~the ~~such~~first ~~installation~~trading ~~during~~day following the ~~period~~effectiveness of ~~time in which~~ the ~~Software~~ isregistration ~~used~~statement atregistering ~~such location. In addition,~~ the ~~Company~~resale ~~will~~of beshares ~~responsible~~purchased ~~for~~by the ~~reasonable~~Investor ~~installation costs incurred~~pursuant byto ~~Synergistic in connection with~~ the ~~installation~~Investment ~~and~~Agreement. ~~setup~~As of the ~~software~~date asof ~~required~~this byreport, ~~the~~no ~~Company.~~shares ~~The~~had ~~license~~been ~~fee~~issued ~~may~~by ~~be paid in cash or~~ the Company’s ~~common~~or ~~stock.~~purchased Inby ~~addition,~~ the ~~Synergistic Licensing Agreement was amended to delete the Company’s~~Investor ~~exclusive rights~~ under ~~such~~the ~~agreement~~Investment Agreement.

OnThe ~~October~~Company 4,may ~~2013,~~draw on the ~~Company~~facility ~~entered~~from ~~into~~time ato ~~Standby~~time, ~~Equity~~as ~~Purchase~~and ~~Agreement~~when ~~with~~it ~~Lambert~~determines ~~Private~~appropriate ~~Equity,~~in ~~LLC,~~accordance awith ~~Delaware limited liability company (~~the ~~“Investor”).~~terms ~~Pursuant~~and toconditions of the Investment Agreement,. The maximum amount that the ~~Investor~~Company ~~committed~~is entitled to ~~purchase,~~ ~~subject~~put to ~~certain~~the ~~restrictions~~Investor ~~and~~in ~~conditions,~~any upone todraw down notice is no more than $~~100~~2,000,000 ~~(which~~and ~~can~~not exceeding 285,710 shares. The purchase price shall be ~~extended~~set toat ~~$200,000,000~~ninety ~~under~~percent (90%) of the lowest ~~same~~daily ~~terms~~volume weighted average price (VWAP) of the Company’s common stock during the fifteen (15) consecutive trading day period beginning on the date of delivery of the applicable draw down notice. The Company has the right to withdraw all or any portion of any put, ~~over~~except that portion of the put that has already been sold to a ~~period~~third party, including any portion of 36a ~~months~~put that ~~from~~is below the ~~first~~minimum ~~trading~~acceptable ~~day~~price ~~following~~set forth on the ~~effectiveness~~put notice, before the closing. There are put restrictions applied ofon days between the ~~registration~~draw ~~statement~~down ~~registering~~notice date and the ~~resale~~closing ofdate ~~shares~~with ~~purchased~~respect byto that particular put. During such time, the Company shall not be entitled to deliver another draw down notice. In addition, the Investor ~~pursuant~~will not be obligated to purchase shares if the ~~Investment~~Investor’s ~~Agreement~~total number of shares beneficially held at that time would exceed 4.99% of the number of shares of the Company’s common stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended (the “~~Equity~~Exchange ~~Line~~Act”). In addition, the Company is not permitted to draw on the facility unless there is an effective registration statement (as further explained below) to cover the resale of the shares.

The Company may draw on the facility from time to time, as and when it determines appropriate in accordance with the terms and conditions of the Investment Agreement. The maximum amount that the Company is entitled to put to the Investor in any one draw down notice is no more than $2,000,000 and not exceeding 285,710 shares. The purchase price shall be set at ninety percent (90%) of the lowest daily volume weighted average price (VWAP) of the Company’s common stock during the fifteen (15) consecutive trading day period beginning on the date of delivery of the applicable draw down notice. The Company has the right to withdraw all or any portion of any put, except that portion of the put that has already been sold to a third party, including any portion of a put that is below the minimum acceptable price set forth on the put notice, before the closing. There are put restrictions applied on days between the draw down notice date and the closing date with respect to that particular put. During such time, the Company shall not be entitled to deliver another draw down notice. In addition, the Investor will not be obligated to purchase shares if the Investor’s total number of shares beneficially held at that time would exceed 4.99% of the number of shares of the Company’s common stock as determined in accordance with Rule 13d-1(j) of the Securities Exchange Act of 1934, as amended. In addition, the Company is not permitted to draw on the facility unless there is an effective registration statement (as further explained below) to cover the resale of the shares.

The Investment Agreement further provides that the Company and the Investor are each entitled to customary indemnification from the other for, among other things, any losses or liabilities they may suffer as a result of any breach by the other party of any provisions of the Investment Agreement or Registration Rights Agreement (as defined below), or as a result of any lawsuit brought by a third-party arising out of or resulting from the other party’s execution, delivery, performance or enforcement of the Investment Agreement.

- 10 6-

The Investment Agreement also contains customary representations and warranties of each of the parties. The assertions embodied in those representations and warranties were made for purposes of the Investment Agreement and are subject to qualifications and limitations agreed to by the parties in connection with negotiating the terms of the Investment Agreement. In addition, certain representations and warranties were made as of a specific date, may be subject or a contractual standard of materiality different from what a shareholder or investor might view as material, or may have been used for purposes of allocating risk between the respective parties rather than establishing matters as facts. Investors should read the Investment Agreement together with the other information concerning the Company that the Company publicly files in reports and statements with the Securities and Exchange Commission (the “SEC”).

Pursuant to the terms of a ~~Registration~~registration ~~Rights~~rights agreement between the Company and the Investor (the “Registration Rights Agreement”), the Company is obligated to file one or more registrations statements with the SEC to register the resale by Investor of the shares of common stock issued or issuable under the Investment Agreement. In addition, the Company is obligated to use all commercially reasonable efforts to have the registration statement declared effective by the SEC within 180 days after the registration statement is filed.

As an inducement to Investor to enter in to the Investment Agreement and as consideration for the Investor making the investment the Investor received 285,710 shares of common stock and 100% warrant/option coverage. The option to purchase shares certified that ~~for good and valuable consideration,~~ the ~~receipt~~Investor ~~and sufficiency of which~~ was ~~acknowledged~~entitled, ~~Lambert Private Equity, LLC is entitled~~ effective as of October 4, 2013, and subject to the terms and conditions of the ~~Option~~option, to purchase from the Company up to a total of 14,287,710 shares of the Company’s common ~~shares~~stock at ~~the~~a price of the lesser of (a) $7.00 or (b) 110% of the lowest daily VWAP for the common stock as reported by Bloomberg during the thirty (30) trading days prior to the date the Investor exercised the ~~Warrant~~warrant, prior to 5:00pm (New York time) on September 3, 2018, the expiration date.

Acquisition of Behavioral Health Care Associates, Ltd.

On November 20, 2013, ~~our~~we ~~wholly~~entered ~~owned~~into ~~subsidiary, Accelera Healthcare Management Service Organization LLC, (“Accelera HMSO”) executed~~ a ~~Stock~~stock ~~Purchase~~purchase ~~Agreement,~~agreement ~~as amended~~ (the “SPA”) with Behavioral Health Care Associates, Ltd. (“BHCA”), an Illinois company, and its owner, Blaise J. Wolfrum, M.D., to acquire 100% of the issued and outstanding shares of BHCA from Dr. Wolfrum. The SPA was amended as of May 30, 2014.

Pursuant the SPA, we agreed to pay to Dr. Wolfrum a purchase price of $4,550,000 for his shares of BHCA, of which $1,000,000 iswas payable on May 31, 2015, $750,000 iswas payable on July 30, 2015, and $2,800,000 iswas payable on December 31, 2015. Prior to Dr. Wolfram’s receipt of the initial $1,000,000 payment, he ~~has~~had the right to cancel and terminate the SPA. In addition, as consideration for entering into various amendments to the SPA, we agreed to issue Dr. Wolfrum a total of 50,000 shares of our common stock which we agreed to register for resale upon completion of a public offering of our securities. We originally recorded the purchase of BHCA on November 11, 2013 and began consolidating the operating results of BHCA from that date. We never made any of the required installment payments in accordance with the SPA and the stock of BHCA was never transferred to us. As a result, we have determined that the financial statements of BHCA should have never been consolidated with our financial statements since we was never able to take control of BHCA due to non-payment of the purchase price. The 2015 financial statements included elsewhere in this Form 10K have been restated to remove BHCA from our consolidated financial statements.

**On November 20, 2013, the Company entered into an employment agreement with ~~Blaise J~~Dr. Wolfrum, ~~M.D.,~~ as the President of the Accelera ~~business~~ business unit “Behavioral Health Care Associates” ~~reporting to John Wallin, CEO of Accelera~~. In consideration of the services, the Company agreed to issue a stock option to purchase 600,000 shares of the Company’s Common Stock under the terms of the Company’s 2011 Stock Option Plan at an exercise price of $.0001 per share. The 600,000 shares shall vest over the course of the three years, earned annually, at 200,000 shares each year; after the commencement of employment so long as he remain an employee of the Company. Furthermore, the shares are subject to a six month lock-up agreement and a 27 month leak-out agreement limiting the sale of shares over the period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options from the agreement shall immediately vest and become fully exercisable. The employment agreement with Dr. Wolfrum provides that the Company shall pay Blaise a base salary of $300,000 per year to be paid at the times and subject to the Company’s standard payroll practices, subject to applicable withholding. Mr. Wolfrum will begin receiving compensation at the time Accelera completes the Due Diligence, Valuation and Audited Financials of the Behavioral Health Care Associates business performed by an Accelera appointed audit firm. The Board of Directors will implement a bonus structure based on goals, objectives and performance.

~~TerminationAgreement~~On ~~with~~March ~~Blaise~~31, J2016, the Company, Dr. Wolfrum and BHCA entered into a termination agreement (the “Termination Agreement”) pursuant to which the various agreements between the parties were terminated effective January 1, MD2016 except for certain surviving obligations as set forth in the Termination Agreement.

Accelera Innovations, Inc. (the “Company”), Blaise J. Wolfrum, M.D. (the “Seller”), and Behavioral Health Care Associates, Ltd., an Illinois corporation (the “Behavioral”) (collectively the “Parties”), entered into a Stock Purchase Agreement dated on or about November 20, 2013, First Amendment to the Stock Purchase Agreement dated February 24, 2014, Second Amendment to the Stock Purchase Agreement dated March 18, 2014, Third Amendment to the Stock Purchase Agreement dated May 30, 2014, Fourth Amendment to the Stock Purchase Agreement dated May 31, 2015, Employment Agreement and Employee Confidentiality, Non-~~Circumvention and Non~~7-Solicitation Agreement dated on or about November 20, 2013, Stock Pledge and Escrow Agreement dated on or about November 20, 2013, Stock Power Certificate dated on or about November 20, 2013, Bill of Sale dated on or about November 20, 2013, Assignment of Stock dated on or about November 20, 2013, and other written and oral agreements or understandings relating to the aforementioned agreements (hereinafter collectively referred to as the “Stock Sale Agreement”).

OnIn ~~March~~conjunction ~~31,~~with ~~2016~~the Termination Agreement, the ~~Parties~~Company, Dr. Wolfrum and Accelera Healthcare Management Service Organization, LLC (“Accelera Healthcare”) executed a ~~Termination~~resignation ~~Agreement~~and release agreement effective as of January 1, 2016 pursuant to which Dr. Wolfrum resigned as manager and from any and all positions with Accelera Healthcare. Further, the Company and Accelera Healthcare, and any of their affiliates or other parties claiming by or through the Company or Accelera Healthcare, agreed to release and discharge Dr. Wolfrum from any and all claims, actions, lawsuits, obligations, or liability, monetary or otherwise arising from or related to the operating agreement between Accelera Healthcare and Dr. Wolfrum dated November 11, 2013 (the “~~Termination~~ Operating Agreement”), his performance and actions as Manager of Accelera Healthcare, or any other issue or matter arising prior to or on the date of full execution of the resignation and release agreement. In addition, the Company and Accelera Healthcare, and any of their affiliates or other parties claiming by ~~which~~or through the ~~Stock~~Company ~~Sale~~or Accelera Healthcare, agreed not to make, commence, file, or assert against Dr. Wolfrum any claim, lawsuit, action, or other request for relief arising from or related to the Operating Agreement, ~~was~~his ~~terminated~~performance ~~effect~~and actions as Manager of ~~January~~Accelera 1Healthcare, ~~2016~~or ~~except~~any ~~for~~other issue or matter arising prior to or on the ~~following~~date ~~Surviving~~of ~~Obligations:~~full execution of the resignation and release agreement.

-The Behavioral 11Health -Care Associates Ltd agreement was signed in 2013 and as noted numerous extensions were signed; the Company never officially made a first payment therefore we are restating our 2015 consolidated financials.

A. The Parties agree and reaffirm their previous agreement that the Company has conveyed and transferred or shall convey or transfer Seventy Thousand (70,000) Shares of Stock in the Company. The Seller shall be fully vested in the Seventy Thousand (70,000) Shares of Stock upon the execution of this Agreement by all Parties. The Seventy Thousand (70,000) Shares of Stock shall be unrestricted and free trading stock and free and clear of all liens, security interests, pledges, restrictions, encumbrances, equities, claims, charges, voting agreements, voting trusts, proxies and rights of any kind, nature or description, except for restrictions imposed under federal securities laws.

B. The Company, at its sole cost and expense, shall immediately take any and all actions required to remove all restrictions on the Seventy Thousand (70,000) Shares of Stock in the Company, including, without limitation, the provision of an attorney opinion letter satisfactory to the Company to the extent legally permissible under federal securities laws.

C. The Parties agree that the Company has transferred or conveyed or shall transfer and convey Six Hundred Thousand (600,000) Shares of Stock in the Company. The Seller shall be fully vested the Six Hundred Thousand (600,000) Shares of Stock upon the execution of this Agreement by all Parties. The Six Hundred Thousand (600,000) Shares of Stock shall be free and clear of all liens, security interests, pledges, restrictions, encumbrances, equities, claims, charges, voting agreements, voting trusts, proxies and rights of any kind, nature or description, except for the terms and conditions of the Lock-Up and Leak-Out Agreement dated November 20, 2013 and restrictions imposed under federal securities laws.

D. The Company, at its sole cost and expense, shall take any and all actions required to remove all restrictions on the Six Hundred Thousand (600,000) Shares of Stock, including, without limitation, the provision of an attorney opinion letter satisfactory to the Company to the extent legally permissible under federal securities laws, subject to the terms and conditions of the Lock-Up and Leak-Out Agreement dated November 20, 2013.

E. The transfer of Shares from the Company to Seller is irrevocable and non-refundable under any circumstance. The Parties agree that the transfer of Shares from the Company to Seller shall not be deemed to be consideration under or pursuant to the Stock Sale Agreement.

In addition, the Seller agreed to permit the Company, at its sole cost and expense, to conduct a commercially reasonable audit of Behavioral consistent with the nature and scope of previous audits performed by the Company of Behavioral. Further, the Company agreed to file a Form 8-K with the U.S. Securities and Exchange Commission disclosing the terms of the Termination Agreement.

Resignation and Release Agreement with Blaise J. Wolfrum, MD

In conjunction with the Termination Agreement, the Company, Blaise J. Wolfrum, M.D., and Accelera Healthcare Management Service Organization, LLC (“Accelera Healthcare”) executed a Resignation and Release Agreement effective as of January 1, 2016 pursuant to which Blaise J. Wolfrum, M.D. resigned as manager and from any and all positions with Accelera Healthcare. Further, the Company and Accelera Healthcare, and any of their affiliates or other parties claiming by or through the Company or Accelera Healthcare, agreed to release and discharge Blaise J. Wolfrum, M.D., from any and all claims, actions, lawsuits, obligations, or liability, monetary or otherwise arising from or related to the Operating Agreement of Accelera Healthcare, his performance and actions as Manager of Accelera Healthcare, or any other issue or matter arising prior to or on the date of full execution of the resignation and Release Agreement. In addition, the Company and Accelera Healthcare, and any of their affiliates or other parties claiming by or through the Company or Accelera Healthcare, agreed not to make, commence, file, or assert against Blaise J. Wolfrum, M.D., any claim, lawsuit, action, or other request for relief arising from or related to the Operating Agreement of Accelera Healthcare, his performance and actions as Manager Accelera Healthcare, or any other issue or matter arising prior to or on the date of full execution of this Agreement.

Termination of Planned Acquisition of At Home Health Services LLC

On December 13, 2013, we entered into a ~~Purchase~~purchase ~~Agreement~~agreement with At Home Health Services LLC, All Staffing Services, LLC (together, the “Subject LLCs”) and Rose Gallagher, individually and as Trustee of the Rose M. Gallagher Revocable Trust dated November 30, 1994 (“Gallagher”), pursuant to which we agreed to purchase and Gallagher agreed to sell, all of Gallagher’s interests in the Subject LLCs. We terminated this agreement effective ~~as of~~ December 31, 2014.

Acquisition of with SCI Home Health, Inc. (d/b/a Advance Lifecare Home Health)

On August 25, 2014, we entered into a ~~Stock~~stock ~~Purchase~~purchase ~~Agreement~~agreement (the “Stock Purchase Agreement”) with SCI Home Health, Inc. (d/b/a Advance Lifecare Home Health) (“SCI”), Ethel dela Cruz, Virgilia Avila, Ma Lourdes Reyes Celicious, Cristina Soriano, Michelle Cartas and Jimmy Lacaba (collectively, the “Sellers”), pursuant to which we agreed to purchase, and the Sellers agreed to sell, all their SCI shares, collectively representing all of the outstanding shares of common stock of SCI, for an aggregate purchase price of $450,000 (the “Stock Purchase”). This transaction closed in October 2104, at which time SCI became our wholly owned subsidiary.

- 12 8-

ITEM 1A. RISK FACTORS

~~Before~~Not ~~you invest in our securities, you should be aware that there are various risks~~required. You should consider carefully these risk factors, together with all of the other information included in this Current Report on Form 8-K, as well as elsewhere in our SEC filings before you decide to purchase our securities. Independent of the risk factors we list, you should further be aware that none of the Company’s securities are registered for resale with the Securities and Exchange Commission, so they can only be purchased under an applicable exemption from registration or if the Company registers the securities under the Securities Act of 1933. If any of the following risks and uncertainties develop into actual events, our business, financial condition or results of operations could be materially adversely affected.

Events giving rise to the restatement of our financial statements included in our Annual Reports for the years ended December 31, 2013 and 2014 may lead to additional risks and uncertainties, including shareholder litigation, governmental investigations, rescission, events of default, loss of investor confidence, and negative impacts on our stock price.

As previously disclosed in Company’s Current Report on Form 8-K filed with the SEC on July 21, 2015, the Company’s Board of Directors determined that the Company’s financial statements included in: (i) its quarterly reports on Form 10-Q for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013, (ii) its annual report on Form 10-K for the year ended December 31, 2013, (iii) its quarterly reports on Form 10-Q for the periods ended March 31, 2014, June 30, 2014 and September 30, 2014, and (iv) its annual report on Form 10-K for the year ended December 31, 2014 (collectively, the “Financial Statements”) could not be relied on. The Financial Statements contained errors related to (i) failure to record issuances of the Company’s common and preferred stock, the receipt of funds related to these issuances and the accounting for the use of the proceeds from these sales, (ii) disclosure of a related party transactions, and (iii) the valuation of shares of the Company’s common stock issued as compensation. In addition, as described later in this report in Part I, Item 3. Legal Proceedings, the Securities and Exchange Commission issued subpoenas to our company, our Chief Executive Officer and the Chairman of the Board of Directors for our company in connection with a formal investigation of our company (Case No. C-08191). As a result of these events, we have become subject to a number of additional risks and uncertainties, including substantial unanticipated costs for accounting and legal fees in connection with or related to the restatement and potential shareholder litigation, governmental investigations, disgorgement, civil monetary penalties and rescission by the investors who purchased our securities in 2013 and 2014. We will incur additional substantial defense and investigation costs regardless of the outcome of any such litigation or governmental investigation. Likewise, such events may cause a diversion of our management’s time and attention. If we do not prevail in any such litigation or governmental investigation, we could be required to pay substantial damages or settlement costs. In addition, the fact that we have determined that our Financial Statements must be restated may lead to the triggering of events of default under existing agreements, a loss of investor confidence and have negative impacts on the trading price of our common stock.

Our independent auditors have expressed substantial doubt about our ability to continue as a going concern, which may hinder our ability to continue as a going concern and our ability to obtain future financing.

In their report dated August 3, 2016, our independent auditors stated that our financial statements for the period ended December 31, 2015 were prepared assuming that we would continue as a going concern. Our ability to continue as a going concern is an issue raised as a result of recurring losses from operations and cash flow deficiencies since our inception. We continue to experience net losses. Our ability to continue as a going concern is subject to our ability to generate a profit and/or obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, increasing sales or obtaining loans and grants from various financial institutions where possible. If we are unable to continue as a going concern, you may lose your entire investment.

We may not be able to raise the funds necessary to pay the purchase price of BHCA and the Seller may terminate the acquisition at any time prior to receipt of a substantial payment

We presently do not have the cash or commitments for financing to pay Dr. Wolfrum the purchase price of $4,550,000 for his shares of BHCA, of which $1,000,000 is payable on May 31, 2015, $750,000 is payable on July 30, 2015, and $2,800,000 is payable on December 31, 2015. Furthermore, prior to Dr. Wolfram’s receipt of the $1,000,000 payment, he has the right to cancel and terminate his agreement with us. If we are unable to raise the cash needed to complete this acquisition or if Dr. Wolfrum elects terminate the agreement to sell BHCA to us or we are unable to raise additional funds to finance this purchase we will lose a significant asset from which we derive primarily all of our revenues. The loss of our ownership of BHCA will have a material adverse effect on our business, our financial condition, including liquidity and profitability, and our results of operations.

We were formed April 29, 2008 and have a limited operating history and, accordingly, you will not have any basis on which to evaluate our ability to achieve our business objectives.

We were formed in April 2008 with limited operating results to date. Since we do not have an established operating history and have limited sales, you will have no basis upon which to evaluate our ability to achieve our business objectives.

- 13 -

The absence of any significant operating history for us makes forecasting our revenue and expenses difficult, and we may be unable to adjust our spending in a timely manner to compensate for unexpected revenue shortfalls or unexpected expenses.

As a result of the absence of any operating history for us, it is difficult to accurately forecast our future revenue. In addition, we have limited meaningful historical financial data upon which to base planned operating expenses. Current and future expense levels are based on our operating plans and estimates of future revenue. Revenue and operating results are difficult to forecast because they generally depend on our ability to promote and sell our services. As a result, we may be unable to adjust our spending in a timely manner to compensate for any unexpected revenue shortfall, which would result in further substantial losses. We may also be unable to expand our operations in a timely manner to adequately meet demand to the extent it exceeds expectations.

Our limited operating history does not afford investors a sufficient history on which to base an investment decision.

We are currently in the early stages of developing our business. There can be no assurance that at this time that we will operate profitably or that we will have adequate working capital to meet our obligations as they become due.

Investors must consider the risks and difficulties frequently encountered by early stage companies, particularly in rapidly evolving markets. Such risks include the following:

● Competition ● Ability to anticipate and adapt to a competitive market; ● Ability to effectively manage expanding operations; amount and timing of operating costs and capital expenditures relating to expansion of our business, operations, and infrastructure; and ● Dependence upon key personnel to market and sell our services and the loss of one of our key managers may adversely affect the marketing of our services.

Our business strategy may not be successful and we may not successfully address these risks. In the event that we do not successfully address these risks, our business, prospects, financial condition, and results of operations could be materially and adversely affected and we may not have the resources to continue or expand our business operations.

Conflicts of interest between the Company and its officers and directors may impede the operational ability of the Company.

Our directors including our Chairman Mr. Geoff Thompson and our CEO, Mr. John Wallin are engaged in outside business activities, Mr. Thompson is the founder and director of Synergistic Holdings, LLC and Mr. Wallin has been the CEO and director of Synergistic Holdings, LLC since 2009, the Company’s majority shareholder and Licensor of the Company’s technology, which may result in a conflict of interest in allocating his time between our operations and his other business activities. Although Mr. Wallin has a full time employment agreement with the Company his other business affairs may require him to devote more substantial amounts of time to such affairs, it could limit his ability to devote time to our affairs and could have a negative impact on our ability efficiently operate the Company as a result, Mr. Thompson and Mr. Wallin will be in a position to make business decisions adverse to Accelera Innovations to the benefit of Synergistic Holdings.

We are substantially dependent on a third party

The Company is currently dependent upon technology licensed from Synergistic Holdings, LLC. The Company will be required to pay a license fee in the amount of 10,000 common shares upon completion and acceptance of each installation of the software at a location for each affiliate or subsidiary of the Company and the sum of $10,000 on each anniversary after each such installation during the period of time in which the Software is used at such location.

We have no profitable operating history and May Never Achieve Profitability

From inception (April 29, 2008) through December 31, 2015, the Company has an accumulated deficit of $63,927,121. We are an early stage company and have a limited history of operations and have only started generated revenues since November 2013 from operations. We are faced with all of the risks associated with a company in the early stages of development. Our business is subject to numerous risks associated with a relatively new, low-capitalized company engaged in our business sector. Such risks include, but are not limited to, competition from well-established and well-capitalized companies, and unanticipated difficulties regarding the marketing and sale of our services. We may not ever generate significant commercial sales or achieve profitability. Should this be the case, our common stock could become worthless and investors in our common stock or other securities could lose their entire investment.

We have a need to raise additional capital

The Company will not be able to complete additional acquisitions and commercialize its technology without additional capital, if we do not raise substantial additional funds. The Company will require significant additional financing in order to meet the milestones and requirements of its Business Plan and avoid discontinuation of the License. Funding would be required for staffing, marketing, public relations and the necessary research precedent to expanding the scope of its offering. The Company intends to seek an aggregate of $35,000,000 in an offering through the sale of equity or convertible debt securities, the issuance of these securities could dilute existing shareholders. The Company’s funding plans include selling additional capital stock and/or borrowing to fund the aforementioned expenses. The Company intends to approach Hedge Funds, Venture Capital Groups, Private Investment Groups and other Institutional Investment Groups in its efforts to achieve future funding. It is estimated that $9,874,940 will be used for management, engineering, sales and marketing, $18,000,000 will be used for acquisitions, infrastructure, and an estimated $4,000,000 will be spent on legal, accounting, rent and other payables leaving $3,125,050 in reserve for increased working capital.

- 14 -

It’s estimated the minimum amount of capital the company needs to raise over the next twelve months is $30,000,000 to continue operations. There is no guarantee that the Company will be able to raise this or any amount of additional capital and a failure to do so would have a significant adverse effect on the Company’s ability, or would cause significant delays in its ability to address the market for content delivery and achieve its Business Plan. Neither the Company nor any of its advisors or consultants has significant experience in raising funds similar to the $30,000,000 estimated to be required.

Dependence on our Management, without whose services Company business operations could cease.

At this time, our management is wholly responsible for the development and execution of our business plan. Our management is under no contractual obligation to remain employed by us. If our management should choose to leave us for any reason before we have hired additional personnel our operations may fail. Even if we are able to find additional personnel, it is uncertain whether we could find qualified management who could develop our business along the lines described herein or would be willing to work for compensation the Company could afford. Without such management, the Company could be forced to cease operations and investors in our common stock or other securities could lose their entire investment.

Lack of additional working capital may cause curtailment of any expansion plans while raising capital through sale of equity securities would dilute existing shareholders’ percentage of ownership.

Our available capital resources will not be adequate to fund our working capital requirements based upon our present level of operations for the 12-month period subsequent to December 31, 2015. A shortage of capital would affect our ability to fund our working capital requirements. If we require additional capital, funds may not be available on acceptable terms, if at all. In addition, if we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could dilute existing shareholders. If funds are not available, we could be placed in the position of having to cease all operations.

Our success is substantially dependent on general economic conditions and business trends, particularly in healthcare, a downturn of which could adversely affect our operations

The success of our operations depends to a significant extent upon a number of factors relating to business spending. These factors include economic conditions, activity in the financial markets, general business conditions, personnel cost, inflation, interest rates and taxation. Our business is affected by the general condition and economic stability of our customers and their continued willingness to work with us in the future. An overall decline in the demand for technology could cause a reduction in our sales and the Company could face a situation where it never achieves sales and thereby be forced to cease operations.

We are subject to compliance with securities law, which exposes us to potential liabilities, including potential rescission rights.

We have offered and sold our common stock to investors pursuant to certain exemptions from the registration requirements of the Securities Act of 1933, as well as those of various state securities laws. The basis for relying on such exemptions is factual; that is, the applicability of such exemptions depends upon our conduct and that of those persons contacting prospective investors and making the offering. We have not received a legal opinion to the effect that any of our prior offerings were exempt from registration under any federal or state law. Instead, we have relied upon the operative facts as the basis for such exemptions, including information provided by investors themselves. If any prior offering did not qualify for such exemption, an investor would have the right to rescind its purchase of the securities if it so desired. It is possible that if an investor should seek rescission, such investor would succeed. A similar situation prevails under state law in those states where the securities may be offered without registration in reliance on the partial preemption from the registration or qualification provisions of such state statutes under the National Securities Markets Improvement Act of 1996. If investors were successful in seeking rescission, we would face severe financial demands that could adversely affect our business and operations. Additionally, if we did not in fact qualify for the exemptions upon which it has relied, we may become subject to significant fines and penalties imposed by the SEC and state securities agencies.

- 15 -

Anti-takeover effects of certain provisions of Delaware State law hinder a potential takeover of Accelera Innovations, Inc.

We may be subject to Section 203 of the DGCL, an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation’s voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.

For purposes of Delaware law, an “interested stockholder” is any person who that (i) is the owner of 15% or more of the outstanding voting stock of the corporation, or (ii) is an affiliate or associate of the corporation and was the owner of 15% or more of the outstanding voting stock of the corporation at any time within the 3-year period immediately prior to the date on which it is sought to be determined whether such person is an interested stockholder, and the affiliates and associates of such person; provided, however, that the term “interested stockholder” shall not include (x) any person who (A) owned shares in excess of the 15% limitation set forth herein as of, or acquired such shares pursuant to a tender offer commenced prior to, December 23, 1987, or pursuant to an exchange offer announced prior to the aforesaid date and commenced within 90 days thereafter and either (I) continued to own shares in excess of such 15% limitation or would have but for action by the corporation or (II) is an affiliate or associate of the corporation and so continued (or so would have continued but for action by the corporation) to be the owner of 15% or more of the outstanding voting stock of the corporation at any time within the 3-year period immediately prior to the date on which it is sought to be determined whether such a person is an interested stockholder or (B) acquired said shares from a person described in item (A) of this paragraph by gift, inheritance or in a transaction in which no consideration was exchanged; or (y) any person whose ownership of shares in excess of the 15% limitation set forth herein is the result of action taken solely by the corporation; provided that such person shall be an interested stockholder if thereafter such person acquires additional shares of voting stock of the corporation, except as a result of further corporate action not caused, directly or indirectly, by such person. For the purpose of determining whether a person is an interested stockholder, the voting stock of the corporation deemed to be outstanding shall include stock deemed to be owned by the person through (i) Beneficially owns such stock, directly or indirectly; or (ii) Has (A) the right to acquire such stock (whether such right is exercisable immediately or only after the passage of time) pursuant to any agreement, arrangement or understanding, or upon the exercise of conversion rights, exchange rights, warrants or options, or otherwise; provided, however, that a person shall not be deemed the owner of stock tendered pursuant to a tender or exchange offer made by such person or any of such person’s affiliates or associates until such tendered stock is accepted for purchase or exchange; or (B) the right to vote such stock pursuant to any agreement, arrangement or understanding; provided, however, that a person shall not be deemed the owner of any stock because of such person’s right to vote such stock if the agreement, arrangement or understanding to vote such stock arises solely from a revocable proxy or consent given in response to a proxy or consent solicitation made to 10 or more persons; or (iii) Has any agreement, arrangement or understanding for the purpose of acquiring, holding, voting, or disposing of such stock with any other person that beneficially owns, or whose affiliates or associates beneficially own, directly or indirectly, such stock.

The definition of the term “business combination” is sufficiently broad to cover virtually any kind of transaction that would allow a potential acquiror to use the corporation’s assets to finance the acquisition or otherwise to benefit its own interests rather than the interests of the corporation and its other stockholders.

The effect of Delaware’s business combination law is to potentially discourage parties interested in taking control of our company from doing so if it cannot obtain the approval of our board of directors.

We may need additional capital that could dilute the ownership interest of investors.

We require substantial working capital to fund our business. If we raise additional funds through the issuance of equity, equity-related or convertible debt securities, these securities may have rights, preferences or privileges senior to those of the rights of holders of our common stock and they may experience additional dilution. There may not be additional financing available to us on favorable terms when required, or at all. Since our inception, we have experienced negative cash flow from operations and expect to experience significant negative cash flow from operations in the future. The issuance of additional common stock by the Company may have the effect of further diluting the proportionate equity interest and voting power of holders of our common stock.

Because we do not intend to pay any cash dividends on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.

We intend to retain any future earnings to finance the expansion of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. Stockholders may never be able to sell shares when desired. Before you invest in our securities, you should be aware that there are various risks. You should consider carefully these risk factors, together with all of the other information included in this annual report before you decide to purchase our securities. If any of the following risks and uncertainties develop into actual events, our business, financial condition or results of operations could be materially adversely affected.

Our common stock is subject to the Penny Stock Regulations

Once it commences trading (if ever) our common stock could be subject to the SEC’s “penny stock” rules to the extent that the price remains less than $5.00. Those rules, which require delivery of a schedule explaining the penny stock market and the associated risks before any sale, may further limit your ability to sell your shares.

- 16 -

The SEC has adopted regulations, which generally define “penny stock” to be an equity security that has a market price of less than $5.00 per share. Our common stock currently has no “market price” and when and if a trading market develops, may fall within the definition of penny stock and subject to rules that impose additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000, or annual incomes exceeding $200,000 or $300,000, together with their spouse).

For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser’s prior written consent to the transaction. Additionally, for any transaction, other than exempt transactions, involving a penny stock, the rules require the delivery, prior to the transaction, of a risk disclosure document mandated by the Commission relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer’s presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. Consequently, the `penny stock` rules may restrict the ability of broker-dealers to sell our common stock and may affect the ability of investors to sell their common stock in the secondary market.

Our common stock is illiquid and may in the future be subject to price volatility unrelated to our operations

Our common stock is thinly traded and the market price could fluctuate substantially due to a variety of factors, including market perception of our ability to achieve our planned growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting our competitors or us. In addition, the stock market is subject to extreme price and volume fluctuations. This volatility has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock. Sales of substantial amounts of common stock, or the perception that such sales could occur, could adversely affect the market price of our common stock (if and when a market price is established) and could impair our ability to raise capital through the sale of our equity securities.

We have not voluntarily implemented various corporate governance measures, in the absence of which, shareholders may have more limited protections against interested director transactions, conflicts of interest and similar matters.

Recent Federal legislation, including the Sarbanes-Oxley Act of 2002, has resulted in the adoption of various corporate governance measures designed to promote the integrity of the corporate management and the securities markets. Some of these measures have been adopted in response to legal requirements. Others have been adopted by companies in response to the requirements of national securities exchanges, such as the NYSE or the Nasdaq Stock Market, on which their securities are listed. Among the corporate governance measures that are required under the rules of national securities exchanges are those that address board of directors’ independence, audit committee oversight, and the adoption of a code of ethics. We have not yet adopted any of these corporate governance measures and, since our securities are not yet listed on a national securities exchange, we are not required to do so. It is possible that if we were to adopt some or all of these corporate governance measures, stockholders would benefit from somewhat greater assurances that internal corporate decisions were being made by disinterested directors and that policies had been implemented to define responsible conduct. Prospective investors should bear in mind our current lack of corporate governance measures in formulating their investment decisions.

RISKS RELATED TO OUR INDUSTRY

If physicians and hospitals do not accept our products and services, or delay in deciding whether to purchase our products and services, our business, financial condition and results of operations will be adversely affected.

Our business model depends on our ability to sell our products and services. Acceptance of our products and services requires physicians and hospitals to adopt different behavior patterns and new methods of conducting business and exchanging information. Physicians and hospitals may not integrate our products and services into their workflow and other participants in the healthcare market may not accept our products and services as a replacement for traditional methods of conducting healthcare transactions. Achieving market acceptance for our products and services will require substantial sales and marketing efforts and the expenditure of significant financial and other resources to create awareness and demand by participants in the healthcare industry. If we fail to achieve broad acceptance of our products and services by physicians, hospitals and other healthcare industry participants or if we fail to position our services as a preferred method for information management and healthcare delivery, our business, financial condition and results of operations will be adversely affected.

We may not see the benefits of government programs initiated to accelerate the adoption and utilization of health information technology and to counter the effects of the current economic situation.

While government programs have been initiated to improve the efficiency and quality of the healthcare sector and also counter the effects of the current economic situation, including expenditures to stimulate business and accelerate the adoption and utilization of health care technology, we may not receive any of those funds. For example, the passage of the Health Information Technology for Economic and Clinical Health Act, or HITECH, under the American Recovery and Reinvestment Act of 2009 (ARRA) authorizes what is expected to be up to almost $30 billion in expenditures, including discretionary funding, to further adoption of electronic health records. Although we believe that our service offerings will meet the requirements of the HITECH Act in order for our clients to qualify for financial incentives for implementing and using our services, there can be no certainty that any of the planned financial incentives, if made, will be made in regard to our services. We also cannot predict the speed at which physicians will adopt electronic health record systems in response to such government incentives, whether physicians will select our products and services or whether physicians will implement an electronic health record system at all. Any delay in the purchase and implementation of electronic health records systems by physicians in response to government programs, or the failure of physicians to purchase an electronic health record system, could have an adverse effect on our business, financial condition and results of operations. It is also possible that Congress will repeal or not fund HITECH or otherwise amend it in a manner that would be unfavorable to our business.

- 17 -

Our failure to compete successfully could cause our revenue or market share to decline.

The market for our products and services is intensely competitive and is characterized by rapidly evolving technology and product standards, technology and user needs and the frequent introduction of new products and services. Some of our competitors may be more established, benefit from greater name recognition and have substantially greater financial, technical and marketing resources than us. Moreover, we expect that competition will continue to increase as a result of potential incentives provided by the Stimulus and consolidation in both the information technology and healthcare industries. If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could adversely affect our ability to compete effectively. We compete on the basis of several factors, including:

● Breadth and depth of services; ● Reputation; ● Reliability, accuracy and security; ● Client service; ● Price; and ● Industry expertise and experience

Our principal existing competitors in the physician healthcare information systems and services market include Aprima Medical Software (formerly iMedica Corporation), athenahealth Inc., Cerner Corporation, eClinicalWorks Inc., Emdeon Business Services LLC, Epic Systems Corporation, General Electric Company, McKesson Corporation, Quality Systems, Inc., Sage Software, Inc., The Trizetto Group, Inc., and Wellsoft Corporation.

Our principal existing competitors in the hospital and post-acute healthcare information systems and services market include Cerner Corporation, eDischarge, Epic Systems Corporation, General Electric Company, Maxsys Ltd., McKesson Corporation, MedHost, Meditech, Midas+, Picis, ProviderLink, Quadramed, Siemens AG and WellSoft. We may not be able to compete successfully against current and future competitors or with the competitive pressures that we face and this could materially adversely affect our business, financial condition and results of operations.

It is difficult to predict the sales cycle and implementation schedule for our software solutions.

The duration of the sales cycle and implementation schedule for our software solutions depends on a number of factors, including the nature and size of the potential customer and the extent of the commitment being made by the potential customer, which is difficult to predict. Our sales and marketing efforts with respect to hospitals and large health organizations generally involve a lengthy sales cycle due to these organizations’ complex decision-making processes. Additionally, in light of increased government involvement in healthcare, and related changes in the operating environment for healthcare organizations, our potential customers may react by curtailing or deferring investments, including those for our services. If potential customers take longer than we expect to decide whether to purchase our solutions, our selling expenses could increase and our revenues could decrease, which could harm our business, financial condition and results of operations. If customers take longer than we expect to implement our solutions, our recognition of related revenue would be delayed, which would adversely affect our business, financial condition and results of operations.

Our future success depends upon our ability to grow, and if we are unable to manage our growth effectively, we may incur unexpected expenses and be unable to meet our customers’ requirements.

We will need to expand our operations if we successfully achieve market acceptance for our products and services. We may not be able to expend our systems, procedures, controls and existing space will be adequate to support expansion of our operations. Our future operating results will depend on the ability of our officers and key employees to manage changing business conditions and to implement and improve our technical, administrative, financial control and reporting systems. We may not be able to expand and upgrade our systems and infrastructure to accommodate these increases. Difficulties in managing any future growth could have a significant negative impact on our business, financial condition and results of operations because we may incur unexpected expenses and be unable to meet our customers’ requirements.

- 18 -

Competition for our employees could be intense, and we may not be able to attract and retain the highly skilled employees we need to support our business.

Our ability to provide high-quality services to our clients depends in large part upon our employees’ experience and expertise. We must attract and retain highly qualified personnel with a deep understanding of the healthcare and health information technology industries. We compete with a number of companies for experienced personnel and many of these companies, including clients and competitors, have greater resources than we have and may be able to offer more attractive terms of employment. In addition, we intend to invest significant time and expense in training our employees, which increases their value to clients and competitors who may seek to recruit them and increases the costs of replacing them. If we fail to retain our employees, the quality of our services could diminish, which could have a material adverse effect on our business, financial condition and results of operations.

If we are unable to successfully introduce new products or services or fail to keep pace with advances in technology, our business, financial condition and results of operations will be adversely affected.

The successful implementation of our business model depends on our ability to adapt to evolving technologies and increasingly aggressive industry standards and introduce new products and services accordingly. We may not be able to introduce new products on schedule, or at all, or that such products will achieve market acceptance. Moreover, competitors may develop competitive products that could adversely affect our results of operations. A failure by us to introduce planned products or other new products or to introduce these products on schedule could have an adverse effect on our business, financial condition and results of operations.

If we cannot adapt to changing technologies, our products and services may become obsolete, and our business could suffer. Because the health information technology market is characterized by rapid technological change, we may be unable to anticipate changes in our current and potential customers’ requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing products and services, develop new technology that addresses the increasingly sophisticated and varied needs of our prospective customers, license leading technologies and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using new technologies effectively or adapting our proprietary technology to evolving customer requirements or emerging industry standards, and, as a result, our business could suffer.

Our business depends in part on and will continue to depend in part on our ability to establish and maintain additional strategic relationships.

To be successful, we must establish strategic relationships with leaders in a number of healthcare and health information technology industry segments. This is critical to our success because we believe that these relationships contribute towards our ability to:

● Extend the reach of our products and services to a larger number of physicians and hospitals and to other participants in the Healthcare industry; ● Develop and deploy new products and services; ● Further enhance the Accelera Innovations brand; and ● Generate additional revenue and cash flows.

Entering into strategic relationships is complicated because strategic partners may decide to compete with us in some or all of our markets. In addition, we may not be able to maintain or establish relationships with key participants in the healthcare industry if we conduct business with their competitors. We will depend, in part, on our strategic partners’ ability to generate increased acceptance and use of our products and services. If we fail to establish additional relationships, or if our strategic relationships fail to benefit us as expected, we may not be able to execute our business plan, and our business, financial condition and results of operations may suffer.

Future acquisitions may result in potentially dilutive issuances of equity securities, the incurrence of indebtedness and increased amortization expense.

Future acquisitions may result in dilutive issuances of equity securities, the incurrence of debt, the assumption of known and unknown liabilities, the write off of software development costs and the amortization of expenses related to intangible assets, all of which could have an adverse effect on our business, financial condition and results of operations.

If our products fail to perform properly due to errors or similar problems, our business could suffer.

Complex software, such as ours, often contains defects or errors, some of which may remain undetected for a period of time. It is possible that such errors may be found after the introduction of new software or enhancements to existing software. We continually introduce new solutions and enhancements to our solutions, and, despite testing by us, it is possible that errors may occur in our software. If we detect any errors before we introduce a solution, we might have to delay deployment for an extended period of time while we address the problem. If we do not discover software errors that affect our new or current solutions or enhancements until after they are deployed, we would need to provide enhancements to correct such errors. Errors in our software could result in:

● Harm to our reputation; ● Lost sales; ● Delays in commercial releases; ● Product liability claims;

- 19 -

● Delays in or loss of market acceptance of our solutions; ● License terminations or renegotiations; and ● Unexpected expenses and diversion of resources to remedy errors.

Furthermore, our customers might use our software together with products from other companies or those that they have developed internally. As a result, when problems occur, it might be difficult to identify the source of the problem. Even when our software does not cause these problems, the existence of these errors might cause us to incur significant costs, divert the attention of our technical personnel from our solution development efforts, impact our reputation and cause significant customer relations problems.

Our business depends on our intellectual property rights, and if we are unable to protect them, our competitive position may suffer.

Our business plan is predicated on our proprietary systems and technology products. Accordingly, protecting our intellectual property rights is critical to our continued success and our ability to maintain our competitive position. In addition to existing trademark, trade secret and copyright law, we protect our proprietary rights through confidentiality agreements and technical measures. We do not have any patents on our technology. We generally enter into non-disclosure agreements with our employees and consultants and limit access to our trade secrets and technology. Nonetheless, in some instances, third parties may have access to source-code versions of software. Furthermore, our use and distribution of open source software and modules in connection with our business also presents risks. Open source commonly refers to software whose source code is subject to a license allowing it to be modified, combined with other software and redistributed, subject to restrictions set forth in the license. We cannot be certain that, under the terms of those licenses, our software will not become publicly available or that we will be found to be in material compliance with such agreements. The steps we have taken may not have and may not continue to prevent misappropriation of our technology and misappropriations of our intellectual property have occurred in the past. Misappropriation of our intellectual property could have an adverse effect on our competitive position. In addition, we may have to engage in litigation in the future to enforce or protect our intellectual property rights or to defend against claims of infringement, misappropriation or other violations of third-party intellectual property rights. We may incur substantial costs and the diversion of management’s time and attention as a result and an adverse decision could have a negative impact on our business.

If we are deemed to infringe, misappropriate or violate the proprietary rights of third parties, we could incur unanticipated expense and be prevented from providing our products and services.

We are and may continue to be subject to intellectual property infringement, misappropriation or other intellectual property violation claims as our applications’ functionality overlaps with competitive products and third parties may claim that we do not own or have rights to use all intellectual property rights used in the conduct of our business. Claims may be occasionally asserted against us, and may have infringements, misappropriation or claims alleging intellectual property violations asserted against us in the future. We could incur substantial costs and diversion of management resources defending any such claims. Furthermore, a party making a claim against us could secure a judgment awarding substantial damages, as well as injunctive or other equitable relief that could effectively block our ability to provide products or services. In addition, our licenses for any intellectual property of third parties that might be required for our products or services may not be available on commercially reasonable terms, or at all. Such claims also might require indemnification of our clients at significant expense.

If our content and service providers fail to perform adequately, or to comply with laws, regulations or contractual covenants, our reputation and our business, financial condition and results of operations could be adversely affected.

We will depend on independent content and service providers for communications and information services and for many of the benefits we provide through our software applications and services, including the maintenance of managed care pharmacy guidelines, drug interaction reviews, the routing of transaction data to third-party payers and the hosting of our applications. Our ability to rely on these services could be impaired as a result of the failure of such providers to comply with applicable laws, regulations and contractual covenants, or as a result of events affecting such providers, such as power loss, telecommunication failures, software or hardware errors, computer viruses and similar disruptive problems, fire, flood and natural disasters. Any such failure or event could adversely affect our relationships with our customers and damage our reputation. This would adversely affect our business, financial condition and results of operations. In addition, we may have no means of replacing content or services on a timely basis or at all if they are inadequate or in the event of a service interruption or failure. We also rely on independent content providers for the majority of the clinical, educational and other healthcare information that we provide. In addition, we depend on our content providers to deliver high quality content from reliable sources and to continually upgrade their content in response to demand and evolving healthcare industry trends. If these parties fail to develop and maintain high quality, attractive content, the value of our brand and our business, financial condition and results of operations could be impaired.

We may be liable for use of content we provide.

We will provide content for use by healthcare providers in treating patients. Third-party contractors provide us with most of this content. If this content is incorrect or incomplete, adverse consequences, including death, may occur and give rise to product liability and other claims against us. In addition, certain of our solutions provide applications that relate to patient clinical information, and a court or government agency may take the position that our delivery of health information directly, including through licensed practitioners, or delivery of information by a third party site that a consumer accesses through our websites, exposes us to personal injury liability, or other liability for wrongful delivery or handling of healthcare services or erroneous health information. While we intend to have product liability insurance coverage in an amount that we believe is sufficient for our business, we cannot assure you that this coverage will prove to be adequate or will continue to be available on acceptable terms, if at all. A claim brought against us that is uninsured or under-insured could harm our business, financial condition and results of operations. Even unsuccessful claims could result in substantial costs and diversion of management resources.

- 20 -

If our security is breached, we could be subject to liability, and customers could be deterred from using our services.

Our business relies on electronic transmission of confidential patient and other information. We believe that any well-publicized compromise of our network security or a misappropriation of patient information or other data would adversely affect our reputation and would require us to devote significant financial and other resources to alleviate such problems. In addition, our existing or potential customers could be deterred from using our products and services, and we could be subject to liability and regulatory action. We could face financial loss, litigation and other liabilities to the extent that our activities or the activities of third-party contractors involve the storage and transmission of U.S. healthcare system reform at both the federal and state level, could increase government involvement in healthcare, lower reimbursement rates and otherwise change the business environment of our potential customers and the other entities with which we have a business relationship. We cannot predict whether or when future healthcare reform initiatives at the federal or state level or other initiatives affecting our business will be proposed, enacted or implemented or what impact those initiatives may have on our business, financial condition or results of operations. Our potential customers and the other entities with which we have a business relationship could react to these initiatives and the uncertainty surrounding these proposals by curtailing or deferring investments, including those for our products and services. Additionally, the government has signaled increased enforcement activity targeting healthcare fraud and abuse, which could adversely impact our business, either directly or indirectly. To the extent that our potential customers, most of whom are providers, may be affected by this increased enforcement environment, our business could correspondingly be affected. Additionally, government regulation could alter the clinical workflow of physicians, hospitals and other healthcare participants, thereby limiting the utility of our products and services to potential customers and curtailing broad acceptance of our products and services. Further examples of government involvement could include requiring the standardization of technology relating to electronic health records, providing potential customers with incentives to adopt electronic health record solutions or developing a low-cost government sponsored electronic health record solution, such as the VistA-Office electronic health record. Additionally, certain safe harbors to the federal Anti-Kickback Statute and corresponding exceptions to the federal Stark law may alter the competitive landscape. These safe harbors and exceptions are intended to accelerate the adoption of electronic prescription systems and electronic health records systems, and therefore provide new and attractive opportunities for us to work with hospitals and other donors who wish to provide our solutions to physicians. At the same time, such safe harbors and exceptions may result in increased competition from providers of acute electronic health record solutions, whose hospital customers may seek to donate their existing acute electronic health record solutions to physicians for use in ambulatory settings.

If the electronic healthcare information market fails to develop as quickly as expected, our business, financial condition and results of operations will be adversely affected.

The electronic healthcare information market is in the early stages of development and is rapidly evolving. A number of market entrants have introduced or developed products and services that are competitive with one or more components of the solutions we offer. We expect that additional companies will continue to enter this market, especially in response to recent government subsidies. In new and rapidly evolving industries, there is significant uncertainty and risk as to the demand for, and market acceptance of, recently introduced products and services. Because the markets for our products and services are new and evolving, we are not able to predict the size and growth rate of the markets with any certainty. There may not be a market for our products and services that will develop and, if they do, they will be strong and continue to grow at a sufficient pace. If markets fail to develop, develop more slowly than expected or become saturated with competitors, our business, financial condition and results of operations will be adversely affected.

Consolidation in the healthcare industry could adversely affect our business, financial condition and results of operations.

Many healthcare industry participants are consolidating to create integrated healthcare delivery systems with greater market power. As provider networks and managed care organizations consolidate, thus decreasing the number of market participants, competition to provide products and services like ours will become more intense, and the importance of establishing relationships with key industry participants will become greater. These industry participants may try to use their market power to negotiate price reductions for our products and services. Further, consolidation of management and billing services through integrated delivery systems may decrease demand for our products. If we were forced to reduce our prices, our business would become less profitable unless we were able to achieve corresponding reductions in our expenses.

ITEM 1B. UNRESOLVED STAFF COMMENTS

~~Not applicable~~None.

ITEM 2. PROPERTIES

We maintain our corporate office at 20511 Abbey Drive, Frankfort, Illinois 60423. ~~Advance~~SCI ~~Lifecare~~formerly ~~operates~~operated from a 1,900 square foot ~~leased~~ facility located at 3590 Hobson RdRoad, Woodridge, ILIllinois 60517 ~~which expires on September 15~~, ~~2016. Behavioral Health operates from a 5,988 leased facility located at 1375 E. Schaumburg Rd Suite 230, Schaumburg IL 60194~~ which ~~expires~~has onsince ~~October~~closed ~~31, 2016~~ and ~~another~~the ~~2,000~~lease ~~square foot facility located at 484 N~~expired. ~~Lee St., Des Plaines, IL 60016 which is on a month to month basis.~~

- 21 9-

ITEM 3. LEGAL PROCEEDINGS

In 2015, the Securities and Exchange Commission (the “SEC”) issued subpoenas to ~~our company~~us, our Chief Executive Officer and ~~the~~ our Chairman of the Board ~~of Directors for our company~~ in connection with a formal investigation of our ~~company~~affairs (Case No. C-08191). We have responded to the subpoenas and no further action has been taken by the SEC as of the date of this report.

In addition, in November and December 2016, certain of our officers and employees received subpoenas from the SEC requesting certain information regarding a separate formal investigation.

On May 5, 2016, LG Capital Funding LLC provided the Company with a $52,500.00 convertible note. On March 28, 2017 a complaint was filed by LG Capital to settle the convertible note.

Other than as described above, we do not know of any material, active or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholders are an adverse party or have a material interest adverse to us.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock is quoted on the ~~OTCPK~~OTCQB under the symbol “ACNV”. On ~~August~~April 313, ~~2016~~2017, the closing price for our common stock was $0.~~05 on the OTCPK~~0077.

As of ~~August~~April 314, ~~2016~~2017 there were approximately 239 holders of record ~~holders~~of our common stock, an unknown number of additional holders whose stock is held in “street name” and 4578,~~713~~158,~~716~~673 shares of common stock issued and outstanding.

We have not declared or paid dividends on our common stock since our formation, and we do not anticipate paying dividends in the foreseeable future. Declaration or payment of dividends, if any, in the future, will be at the discretion of our Board of Directors and will depend on our then current financial condition, results of operations, capital requirements and other factors deemed relevant by the Board of Directors. There are no contractual restrictions on our ability to declare or pay dividends.Dividends

~~STOCKHOLDERS’~~We ~~DEFICIT~~have not declared or paid dividends on our common stock since our formation, and we do not anticipate paying dividends in the foreseeable future. Declaration or payment of dividends, if any, in the future, will be at the discretion of our board of directors and will depend on our then current financial condition, results of operations, capital requirements and other factors deemed relevant by the board. There are no contractual restrictions on our ability to declare or pay dividends.

~~The Company has two classes of stock, preferred stock and common stock. There are~~ -10~~,000,000 shares of $.0001 par value preferred shares authorized, 500,000 of which have been designated as 8% Convertible Preferred Stock as of May 7, 2015.~~-

Preferred Stock

The Company has two classes of stock, preferred stock and common stock. There are 10,000,000 shares of $0.0001 par value preferred stock authorized, 500,000 of which were designated as 8% Convertible Preferred Stock on May 7, 2015.

The 500,000 shares of 8% Convertible Preferred Stock have the following the designations, rights, and preferences:

● The state value of each share is $4.00, ● Holders of shares ~~of 8% Convertible Preferred Stock~~ do not have any voting rights, ● The shares pay quarterly dividends in arrears at the rate of 8% per annum and on each conversion date. Subject to certain conditions, the dividends are payable at our option in cash or such dividends shall be accreted to, and increase, the outstanding ~~Stated~~stated ~~Value~~value, ● Each share is convertible into shares of our common stock at a conversion price of $4.00 per share, subject to adjustment discussed below, and ● The conversion price of the 8%shares ~~Convertible Preferred~~ is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.

There were 198,473 shares of 8% Convertible Preferred Stock issued and outstanding as of December 31, ~~2015~~2016.

ITEM 6. SELECTED FINANCIAL DATA

~~Smaller~~Not ~~companies do not compete this Item~~required.

- 22 11-

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

~~Management’s~~Plan ~~Discussion and Analysis~~ of ~~Financial Condition and Results of~~ Operations

~~Plan~~We are a healthcare service company focused on acquiring companies primarily in the post-acute care patient services and information technology services industries. In October 2014, we acquired SCI Home Health, Inc. (d/b/a Advance Lifecare Home Health), an Illinois corporation (“SCI”) that offers home health services to patients in the Chicago, Illinois area. In addition, we planned to acquire an interest in several other home health care service providers; however, each of ~~Operation~~those transactions was abandoned by mutual agreements of the parties in January 2016.

~~Accelera~~In ~~Innovations~~January 2017, ~~Inc. (“~~we,” ~~“us,”~~began ~~the~~to ~~“Company,”~~consider ortransitioning ~~“Accelera”),~~from abeing ~~Delaware corporation, is~~ a ~~healthcare~~home service company which is focused on acquiring companies primarily in the post-acute care patient services and information technology services industries. The Company acquired Behavioral Health Care Associates, Ltd. (“BHCA”) in November 2013 which offers full treatment services for mental health ~~conditions~~agency ~~and~~acquirer ~~addictions~~to ~~and SCI Home Health, Inc. (d/b/~~a ~~Advance~~ ~~Lifecare~~company ~~Home~~involved ~~Health) (“SCI”)~~ in ~~October~~assisted ~~2014 which offers home health services to patients in the Chicago,~~living ~~Illinois~~real ~~area.~~estate ~~In addition, the Company has entered into agreements to acquire home health care service providers Grace Home Health Care, Inc~~transactions. ~~(“Grace”), the assets of Watson Health Care, Inc. and Affordable Nursing, Inc. and Traditions Home Care, Inc., each of which is subject to completion of financing.~~

As a result of our plans to focus our business efforts on the acquisition of health care services companies and utilize the Synergistic Technology we license from an affiliate, we agreed to amend the Synergistic Licensing Agreement to eliminate the $29,414,819 funding requirements we were obligated to make and replace it with a requirement to pay a license fee in the amount of 10,000 upon completion and acceptance of each installation of the software at a location for each affiliate or subsidiary of the Company and the sum of $10,000.00 on each anniversary after each such installation during the period of time in which the Software is used at such location (the “License Fee”). In addition, the Company will be responsible for the reasonable installation costs incurred by Synergistic in connection with the installation and setup of the software as required by the Company. The license fee may be paid in cash or the Company’s common stock. In addition, the Synergistic Licensing Agreement was amended to delete the Company’s exclusive rights under such agreement. In addition, the Synergistic Licensing Agreement was amended to delete the Company’s exclusive rights under such agreement. We believe that use of any future working capital we raise will be better utilized by us to acquire additional health care services companies.-12-

~~We,~~Recent Blaise J. Wolfrum, M.D., and Behavioral (the “Parties) entered into a Stock Purchase Agreement dated on or about November 20, 2013, as amended. On March 31, 2016, the Parties executed a Termination Agreement by which the Stock Sale Agreement was terminated effect as of January 1, 2016. Behavioral will be accounted for as a discontinued operation in all future financial statements issued by the Company.Developments

~~Management’s~~On ~~Discussion~~April 1, ~~Analysis~~2017, ofJames ~~Financial~~Millikan ~~Condition~~retired ~~and~~as ~~Results~~our ofChief ~~Operations~~Operating Officer.

The Company’s ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations, which include several new acquisitions. Management’s plan includes obtaining additional funds by equity financing and/or debt using the acquisitions cash flow and/or assets as collateral, however there is no assurance of additional funding being available. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might arise as a result of this uncertainty.

In order to meet our need for cash we are attempting to raise money from the various investor groups which include institutions and high net worth individuals. In January of 2014, the Company was listed on the OTCQB tier of the OTC Markets. If we do not raise all of the money we need from the public exchange, we will have to find alternative sources, such as a second public offering, a private placement of securities, or loans from third party sources.

Our current plans, predicated on raising $30,000,000 from the sale of shares of common stock will allow the Company to meet the milestones and requirements of its proposed acquisitions. The use of proceeds from the planned capital raise will be to fund the closings of BHCA, SCI, Grace, Watson, Affordable and Traditions. In addition, the Company will use excess funds to cover general corporate expenses, as well as the implementation of its technology into the operations of the acquired companies.

The Company has contacted several debt providers for both asset backed lending and cash flow lending. These include commercial banks as well as Hedge Funds which specialize in lower middle market lending. There is no assurance that the Company will be successful in raising debt and/or the cost of debt may be detrimental to the operations of the acquisitions and/or the Company.

Going Concern

Because we had $474,564 in cash at December 31, 2015, which is insufficient to fund our operations, the report of our independent registered public accounting firm on our financial statements for the year ended December 31, 2015 contains an explanatory paragraph regarding their substantial doubt about our ability to continue as a going concern. Our auditors’ opinion is based upon our operating losses and our need to obtain additional financing to sustain operations. Our ability to continue as a going concern will be dependent upon our ability to obtain the necessary financing to meet our obligations and repay our liabilities when they become due, and to generate sufficient revenues from our operations to pay our operating expenses.

- 23 -

Results of Operations

The following comparative analysis on results of operations was based primarily on the comparative financial statements, footnotes and related information for the periods identified below and should be read in conjunction with the financial statements and the notes to those statements that are included elsewhere in this report. The results related to the operation of At Home Health Services, LLC and All Staffing Services, LLC, discontinued operations (see Note 5 to our financial statements included in this report), are excluded from the following ~~discussion. The following~~ is a summary of the Company’s operational results for the ~~three and~~years ~~year~~ ended December 31, ~~2015~~2016 and ~~2014~~2015:

Year ended December 31, 2015 compared to year ended December 31, 2014

	Years Ended
	December 31,			December 31,			Dollar			Percentage
	2016			2015			Change			Change
Revenue	$	2,750		$	1,133,715		$	(1,130,965	)		-99.8	%
Cost of revenue		-			157,711			(157,711	)		-100.0	%
Gross profit		2,750			976,004			(973,254	)		-99.7	%
Total operating expenses		1,900,962			13,992,521			(12,091,559	)		-86.4	%
Other expense		(27,082	)		(1,799,158	)		1,772,076			-98.5	%
Net loss		(1,925,294)			(14,815,675	)		12,890,381			-87.0	%

	Years Ended
	December 31, 2015			December 31, 2014			Dollar Change			Percentage Change
Revenue	$	3,623,131		$	2,715,523		$	907,608			33.4	%
Cost of revenue		1,856,401			1,685,740			170,661			10.1	%
Gross profit		1,766,730			1,029,783			736,947			71.6	%
Total operating expenses		14,892,236			32,806,136			(17,913,900	)		-54.6	%
Other expense		(1,799,158	)		(4,312,057	)		2,512,899			-58.3	%
Discontinued operations		-			(221,766	)		221,766			-100.0	%
Net loss		(14,924,664	)		(36,310,176	)		21,385,512			-58.9	%

Revenue

Total revenue ~~increased~~ decreased by $~~907~~1,~~608~~130,965 to $32,~~623,131~~750 for the year ended December 31, ~~2015~~2016 compared to $21,~~715~~133,~~523~~715 in the same period in ~~2014~~2015. This ~~increase~~ decrease in total revenue is primarily due to ~~revenues~~the ~~generated~~sudden ~~from~~departure of the ~~Behavioral~~administrator ~~Health~~of ~~Care~~SCI. ~~Associates,~~We ~~Ltd.~~have transitioned this position to a new administrator and ~~SCI~~filed ~~Home~~these ~~Health, Inc.~~changes with IDPH (~~d/b/a~~Illinois ~~Advance~~Department ~~Lifecare~~of ~~Home~~Public Health). ~~acquisitions~~There are claims to be processed and invoiced when IDPH approves, through the uniform process, the new administrator, we expect this to be resolved in the near future.

-13-

Gross Profit

Gross profit ~~increased~~decreased by $~~736~~973,~~947~~254 to $12,~~766,730~~750 for the year ended December 31, ~~2015~~2016 compared to $1976,~~029,783~~004 in the same period in ~~2014~~2015. This decrease ~~increase~~ in ~~total~~ gross profit is primarily due to anthe ~~increase~~sudden indeparture ~~revenues~~of ~~generated from~~ the ~~Behavioral~~administrator ~~Health~~of ~~Care Associates, Ltd. and~~ SCI ~~Home~~as ~~Health,~~described ~~Inc~~above. ~~(d/b/a Advance Lifecare Home Health) acquisitions.~~

Operating Expenses

Total operating expenses for the year ended December 31, ~~2015~~2016 decreased by $1712,~~913~~091,~~900~~559 to $141,~~892~~900,~~236~~962, compared to $3213,~~806~~992,~~136~~521 during the same period in ~~2014~~2015. ~~primarily~~The asdecrease is principally a result of ~~shares~~lower ofstock ~~our~~option expense and common stock issued for services ~~in 2015 was significantly less~~, ~~than in 2014~~ and welower ~~took~~operating acost ~~writedown~~for ~~of intangible assets in 2014~~SCI.

Other Expenses

Total other expenses for the year ended December 31, ~~2015~~2016 decreased by $21,~~512~~772,~~899~~076 to $127,~~799~~082,~~158,~~ compared to $41,~~312~~799,~~057~~158 during the same period in ~~2014~~2015. The decrease is due to ~~fewer~~lower ~~penalties (additional~~ interest expense) and financing costs for ~~not~~the ~~repaying~~year ended December 31, 2016 as a result of penalty interest incurred in 2015 offset by a gain related to the change in the value of our derivative liability all in connection with the issuance of convertible notes payable ~~when~~during ~~they became~~the ~~due~~2016 year.

Net ~~Loss~~loss

The net loss for the year ended December 31, ~~2015~~2016 was $141,~~924~~925,~~664~~294, a decrease of $2112,~~385~~890,~~512~~381 compared to $3614,~~310~~815,~~176~~675 during the same period in ~~2014~~2015, as a result of factors described above.

-14-

Liquidity and Capital Resources

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs for cash requirements. As of December 31, ~~2015~~2016, our working capital deficit amounted to $62,~~395~~389,~~817~~904, an increase of $5233,~~217,977~~673 as compared to working capital deficit of $12,~~177~~156,~~840~~ 231 as of December 31, ~~2014~~2015. This increase is primarily a result of ~~the~~add ~~classification~~notes ofpayables ~~the~~issued ~~$4,550,000~~in ~~subordinated~~2016. ~~unsecured note~~Our ~~payable~~working from long-term to current based on the required principal payments offset by the reclassification of preferred stock subscription payable into equity as a result of us obtaining the certificate of designation so we could issue the preferred shares. Working capital deficit at December 31, ~~2015~~2016 included ~~primarily~~current ~~cash~~assets of $~~474~~2,~~564~~750 offset by current liabilities of $62,~~900~~392,~~174~~654.

-Net cash 24used -in operating activities was $214,814 during the year ended December 31, 2016 compared to $443,860 in the same period in 2015. The decrease in cash used in operating activities is primarily attributable the lack of revenue generated from operations in 2016.

Net cash used ~~operating~~in investing activities ~~was $29,219~~ during the year ended December 31, ~~2015~~2016 was $0 compared to ~~net cash used in operating activities of~~ $23,~~105,150~~767 in the same period in ~~2014~~2015. ~~The decrease in cash used in operating activities is primarily attributable to our increase in accounts payable and accrued expenses.~~

Net cash ~~used~~provided inby ~~investing~~financing activities during the year ended December 31, ~~2015~~2016 was $3214,~~767~~814 compared to $1447,~~221~~627 in the same period in ~~2014~~in 2015. The ~~increase~~decrease ~~was~~is primarily a result of ~~payment~~a ofdecrease ~~purchase~~in ofthe ~~property~~proceeds from notes payable and ~~equipment~~advances from related parties in 2016.

Net cash provided by financing activities during the year ended December 31, 2015 was $452,688 compared to $1,975,489 in the same period in 2014. The decrease is primarily a result of a reduction of the proceeds from sale of stock offset by a reduction of payment to stockholder.

Cash Requirements

Our future capital requirements will depend on numerous factors, including the extent we continue to make acquisitions and our ability to control costs. ~~It’s~~We ~~estimated~~estimate ~~the~~that ~~minimum~~we ~~amount~~will ofneed ~~capital the company needs~~ to raise ~~over~~a ~~the~~minimum ~~next~~amount ~~twelve~~of ~~months is~~ $305,000,000 toover ~~pay debts incurred in connection with~~ the ~~Company’s~~next ~~acquisition~~12 ofmonths ~~BHCA,~~to ~~SCI~~pay ~~and~~debts ~~Grace~~incurred, ~~Watson, Affordable~~ ~~and~~fund ~~Traditions~~future acquisitions and continue operations. We will be reliant upon shareholder loans, private placements or public offerings of debt and equity to fund our planned acquisitions and systems ~~roll-out~~rollout. There can be no assurance that additional capital will be available to us. Other than the Standby Equity Purchase Agreement we entered into with Lambert Private Equity, LLC to sell, subject to certain restrictions and conditions, up to $100,000,000 (which can be extended to $200,000,000 under the same terms) of our common stock, we currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. We are not currently eligible to sell all of the securities under the Standby Equity Purchase Agreement and cannot determine when we will meet all the requirements necessary in order to begin selling securities under ~~this~~that agreement. Consequently, we have no arrangements or plans currently in effect that would allow us to immediately raise capital and our inability to raise funds for the above purposes will have a severe negative impact on our ability to carry out our plans to complete acquisitions and fund our operations.

We do not currently have any contractual restrictions on our ability to incur debt and, accordingly we could incur significant amounts of indebtedness to finance operations. Any such indebtedness could contain covenants which would restrict our operations.

Going Concern

As reflected in the consolidated financial statements of the Company included in this report, we reported a net loss from continuing operations of $141,~~924~~925,~~664~~ 294 for the year ended December 31, 2016 and at December 31, ~~2015~~2016, a working capital deficit, stockholders’ deficit and accumulated deficit of $62,~~395~~389,~~817~~904, $2,383,015 and $6361,~~927~~612,~~121~~829, respectively. These matters raise substantial doubt about our ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on our ability to further implement our business plan, raise additional capital, and generate positive cash flow. The unaudited consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Critical Accounting Policies

We have identified the following policies below as critical to our business and results of operations. Our reported results are impacted by the application of the following accounting policies, certain of which require management to make subjective or complex judgments. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact quarterly or annual results of operations. For all of these policies, management cautions that future events rarely develop exactly as expected, and the best estimates routinely require adjustment. Specific risks associated with these critical accounting policies are described in the following paragraphs.

~~Use of Estimates in the Preparation of Financial Statements~~-15-

~~The~~Principles ~~preparation~~ of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.Consolidation

-The Company 25operates -companies in the personal health care industry. The Company operates out of one service center serving the Chicago, Illinois area. The consolidated financial statements for the year ended December 31, 2016 include the accounts of the Company and its 100% owned subsidiary SCI., Significant intercompany accounts and transactions have been eliminated in consolidation

Derivative Financial Instruments

We evaluate all of our agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, we use the Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Our only derivative financial instrument was an embedded conversion feature associated with convertible notes due to the conversion price being a percentage of the market price of our common stock.

Stock-based Compensation

ASC 718, “Compensation-Stock Compensation” requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). We measure the cost of employee services received in exchange for an award based on the grant-date fair value of the award. We account for non-employee share-based awards based upon ASC 505-50, “Equity-Based Payments to Non-Employees.” ASC 505-50 requires the costs of goods and services received in exchange for an award of equity instruments to be recognized using the fair value of the goods and services or the fair value of the equity award, whichever is more reliably measurable. The fair value of the equity award is determined on the measurement date, which is the earlier of the date that a performance commitment is reached or the date that performance is complete. Generally, our awards do not entail performance commitments. When an award vests over time such that performance occurs over multiple reporting periods, we estimate the fair value of the award as of the end of each reporting period and recognize an appropriate portion of the cost based on the fair value on that date. When the award vests, we adjust the cost previously recognized so that the cost ultimately recognized is equivalent to the fair value on the vesting date, which is presumed to be the date performance is complete.

Inflation

In the opinion of management, inflation has not and will not have a material effect on our operations in the immediate future. Management will continue to monitor inflation and evaluate the possible future effects of inflation on our business and operations.

Off-Balance Sheet Arrangements

~~Under~~We ~~SEC~~do ~~regulations,~~not wehave ~~are~~any ~~required to disclose our~~ off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, ~~such as~~ changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. ~~As of December 31, 2015 we have no off-balance sheet arrangements~~

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not ~~applicable~~required.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

See the Index to Financial Statements and Financial Statement Schedules beginning on page F - 1 of this ~~Form 10-K~~report.

- 26 16-

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Exchange Act, we carried out an evaluation of the effectiveness of the design and operation of our disclosure controls as of the end of the period covered by this report, December 31, ~~2014~~2016. This evaluation was carried out under the supervision and with the participation of our principal executive officer and our principal financial officer (the “Certifying Officers”). Based upon that evaluation, our Certifying Officers concluded that as of the end of the period covered by this report, December 31, ~~2014~~2016, our disclosure controls and procedures were ineffective.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control, as defined in the Exchange Act. These internal controls are designed to provide reasonable assurance that the reported financial information is presented fairly, that disclosures are adequate and that the judgments inherent in the preparation of financial statements are reasonable. There are inherent limitations in the effectiveness of any system of internal controls including the possibility of human error and overriding of controls. Consequently, an ineffective internal control system can only provide reasonable, not absolute, assurance with respect to reporting financial information.

Our internal control over financial reporting includes policies and procedures that: (i) pertain to maintaining records that, in reasonable detail, accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements in accordance with generally accepted accounting principles and that the receipts and expenditures of company assets are made in accordance with our management and directors authorization; and (iii) provide reasonable assurance regarding the prevention of or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.

Management has undertaken an assessment of the effectiveness of our internal control over financial reporting based on the framework and criteria established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based upon this evaluation, our management concluded that, due to the material weaknesses described below, our internal control over financial reporting was ineffective as of December 31, ~~2015~~2016.

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements would not be prevented or detected on a timely basis.

The specific material weaknesses identified by our management relate to limited resources and our inadequate number of personnel to allow for proper segregation of duties and the requisite internal controls and application of ~~GAAP~~accounting principles generally accepted in the United States of America. John F. Wallin functions as our Chief Executive Officer and Chief Financial Officer and as such, has not established adequate processes and channels of communication to provide the timely and accurate flow of information to others. This weakness in internal controls has prevented the timely recording of company transactions and execution of reliable financial closing procedures. Management has determined that our internal audit function is also significantly deficient due to insufficient resources to perform internal audit functions. Finally, management determined that the lack of an ~~Audit~~audit ~~Committee~~ committee of our Board of Directors also contributes to insufficient oversight of our accounting and audit functions. Also, certain aspects of the financial reporting process were materially deficient because itwe ~~lacked~~lack a sufficient complement of personnel with a level of accounting expertise and an adequate supervisory review structure that is commensurate with ~~the~~our ~~Company’s~~ financial reporting requirements.

- 27 17-

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in ~~U.S.~~ GAAP, there are no assurances that the ~~material~~ material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Our management, including our principal executive officer and our principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.

This ~~annual~~ report ~~on Form 10-K~~ does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to SEC rules that permit the Company to provide only management’s report in this ~~annual~~ report ~~on Form 10-K~~.

Changes in Internal Control

There were no changes in our internal control over financial reporting during the quarter ended December 31, ~~2015~~2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

- 28 18-

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Set forth below are the names and ages of our directors and executive officers and their principal occupations at present and for at least the past five years.

Name	Age	Position(s) with the Company
Geoffrey Thompson	4849	Chairman of the Board
John F. Wallin	6667	Chief Executive Officer, Chief Financial Officer* and Chief Marketing Officer
James R. Millikan	64	Chief Operating Officer
Cynthia Boerum	63	Chief Strategic Officer
Daniel Freeman	60	Former Chief Financial Officer*
Patrick Custardo	65	Chief Acquisitions Officer
Cynthia Boerum	62	Chief Strategic Officer
Patrick Custardo	64	Chief Acquisitions Officer
Blaise J. Wolfrum M.D.	56	President of Behavioral Health Care

*Geoffrey ~~Mr. Wallin took over the role as our interim Chief Financial Officer on March 20~~Thompson, ~~2015~~Chairman ~~upon~~of the ~~resignation of Mr. Freeman on that date. Blaise Wolfrum resigned as of January 1, 2016~~Board

~~Geoff~~Mr. Thompson, founded Accelera in 2008 as serves as the Chairman of the Board. In 2008, Mr. Thompson transitioned Global Wealth Solutions into GWS Financial Services which started to create unique financial products which included Private Placement Memorandums with principal protection, Private Placed Life Insurance, Private Placed Variable Annuities, Premium Financed estate transfers and Supplemental Employee Retirement Plans. In 2005, he launched Global Wealth Solutions, a client consulting firm with a heavy focus on strategic investing and advanced finance strategies.

~~Mr. Thompson is the Chairman of the Board and founder of Accelera Innovations, since 2008, his experience with IPO’s and Mergers and Acquisitions has positioned the company for eminent success.~~ In ~~2008 Mr. Thompson transitioned Global Wealth Solutions into~~ GWS Financial Services which started to create unique financial products which included Private Placement Memorandums with principal protection, Private Placed Life Insurance, Private Placed Variable Annuities, Premium Financed estate transfers and Supplemental Employee Retirement Plans. In 2005 Mr. Thompson launched Global Wealth Solutions a client consulting firm with a heavy focus on strategic investing and advanced finance strategies. In 2001 Mr. Thompson launched Stremline Mortgage company after relocating to Minneapolis, MNMinnesota. As Streamline grew into a multi-state company ~~the~~he ~~Thompsons~~ opened Streamline Title and started acquiring properties under Streamline Real Estate investments. The companies then ~~grew into a real estate development company under the~~ ~~banner of Presidium. In 2001 Mr. Thompson launched Stremline Mortgage company after relocating to Minneapolis, MN. As Streamline~~ grew into a ~~multi-state company the Thompsons opened Streamline Title and started acquiring properties under Streamline Real Estate investments. The companies then grew into a~~ real estate development company under the banner of Presidium. Mr. ~~Thompsons~~Thompson’s professional career started in 1993 when he took on the role of finance and insurance manager for Bergstrom Automotive Group in Neenah, Wisconsin.

Mr. Thompson brings our board his considerable experience in the strategic planning and growth of companies and qualifies him to continue to serve as the Chairman of the board of directors of our company.

John Wallin, Chief Executive Officer, Chief Financial Officer and Chief Marketing Officer

Mr. Wallin is our Chief Executive Officer, and Chief Marketing Officer, and since March 2420, 2015 ~~our~~has ~~Interim~~also ~~Chief~~acted ~~Financial~~as ~~Officer~~our ~~and has been~~ Chief ~~Executive~~ Financial Officer~~, Chief Marketing Officer and Director of Synergistic Holdings, LLC since 2009~~. Mr. Wallin has ~~over 30~~been ~~years of experience in the financial services industry. Prior to Synergistic Holdings, LLC, Mr. Wallin was President and~~ Chief ~~Marketing~~ ~~Officer at GWG Advantage in Minneapolis from 2007 to 2009. Previously, Mr. Wallin held positions of~~ Executive ~~Director of Medicare Advantage-PFFS at American Insurance Marketing Corporation from 2005 to 2007~~Officer, ~~Senior Sales Executive/ National Sales and~~ Chief Marketing Officer at RNA-Rock Island from 2002 to 2005, Senior Vice President/Regional Financial Services Manager at Allstate Financial Services from 2000 to 2002, Senior Vice President, National Key Account Manager at Federated Investors from 1998 to 2000, Vice President BISYS Funds from 1995 to 1998, Senior Vice President of Marketing and ~~National~~Director ~~Accounts at Putnam Mutual Funds and Senior Vice President~~ of ~~Marketing~~Synergistic ~~and~~since ~~National Accounts at Kemper Financial Services from 1989 to 1992~~2009. ~~Mr. Walling received his B.S. in 1976 and Masters in Education in 1982 from Chicago State University.~~

Mr. Wallin has over 30 years of experience in the financial services industry. Prior to his involvement with Synergistic, Mr. Wallin was President and Chief Marketing Officer at GWG Advantage in Minneapolis from 2007 to 2009. Previously, Mr. Wallin held the positions of Executive Director of Medicare Advantage-PFFS 29at American Insurance Marketing Corporation from 2005 to 2007, Senior Sales Executive/ National Sales and Chief Marketing Officer at RNA-Rock Island from 2002 to 2005, Senior Vice President/Regional Financial Services Manager at Allstate Financial Services from 2000 to 2002, Senior Vice President, National Key Account Manager at Federated Investors from 1998 to 2000, Vice President BISYS Funds from 1995 to 1998, Senior Vice President of Marketing and National Accounts at Putnam Mutual Funds and Senior Vice President of Marketing and National Accounts at Kemper Financial Services from 1989 to 1992. Mr. Wallin received his B.Sc. in 1976 and Masters in Education in 1982 from Chicago State University.

~~Daniel Freeman, Former Chief Financial Officer~~-19-

Prior to joining the Company, Mr. Freeman was Vice President and Principle with DS&B, Ltd, Certified Public Accountants in Minneapolis, Minnesota from 2008 to 2014. He has been the lead on audits and reviews of companies ranging from startup entrepreneurs to companies with revenues in excess of $250 million. He has led many strategic planning sessions in addition to providing accounting, audit and tax guidance with companies of all sizes. Previously, Mr. Freeman held positions of President and Managing Partner of Freeman Wehmhoff and Gatlin PLLC a Certified Public Accounting firm in Minneapolis, Minnesota from 2002 to 2008 and as the founder he grew the practice by offering auditing, accounting and tax services to a wide variety of clients in a vast cross section of industries. He also held the positions of Vice President and Principle of Blanski Peter Kronlage & Zoch, PA, Certified Public Accountants in Minneapolis Minnesota from 1995 to 2002. Prior to joining Blanski Peter Kronlage & Zoch, P.A. he gained a wide range of experience working for local certified public accounting firms and private companies. Mr. Freeman is Certified Public Accountant, Chartered Global Management Accountant and a Certified Information Technology Professional. He has also attained his yellow belt in lean six sigma in the health care industry. Mr. Freeman received a Bachelor of Science in Business Administration degree from Drake University in Des Moines, Iowa in 1979 and his Masters of Business Administration at the University of St. Thomas in Saint Paul, Minnesota in 1989.

Cynthia Boerum, Chief Strategic Officer

Ms. Boerum became the Chief Strategic Officer of the Company in April 2012. Prior to joining the Company, Ms. Boerum was Vice President of Sales and Consultant for Accentia International Outsourcing ~~company~~ in Hyberdad, India, from 2009 to 2011. The leadership included national and international sales teams. Previously, Ms. Boerum held positions of Vice President of Sales for Opus Healthcare in Austin, Texas from 2004 to 2007 and positioned the company for acquisition by NextGen. She also held the positions of Enterprise Vice President of National Accounts and Sales Manager for the top 32 health organizations nationally at McKesson from 1989 to 2003. During this time she received various top performer awards, not only from McKesson, but also the state of Minnesota. Ms. Boerum received her clinical experience at Shady Grove Adventist Hospital, in Maryland, from 1979 to 1989. Ms. Boerum attended the ADN program at Frederick Community College in Maryland.

Previously, Ms. Boerum held the positions of Vice President of Sales for Opus Healthcare in Austin, Texas from 2004 to 2007 and positioned the company for acquisition by NextGen. She also held the positions of Enterprise Vice President of National Accounts and Sales Manager for the top 32 health organizations nationally at McKesson from 1989 to 2003. During this time she received various top performer awards, not only from McKesson, but also the state of Minnesota. Ms. Boerum received her clinical experience at Shady Grove Adventist Hospital, in Maryland, from 1979 to 1989. Ms. Boerum attended the ADN program at Frederick Community College in Maryland.

Patrick Custardo, Chief Acquisitions Officer

Mr. Custardo joined Accelera ~~Innovations, Inc.,~~ in December 2012. He started his career as Vice President of Mergers and Acquisitions with Northern Continent Capital Funds, in Chicago, Illinois. He left that position to create Sentry Financial Corporation, an investment banking firm specializing in ~~Acquisitions~~acquisitions and ~~Divestitures~~divestitures. In 2006, he acquired a small third - party medical billing company and through personal investment, transformed it into a regional Revenue Cycle Management (RCM) firm. In conjunction with other health care professionals, he has been instrumental in the founding of an Accountable Care Organization. He has been published in Health Care journals and is regarded as a Medicare expert in the industry.

Blaise J. Wolfrum, M.D., President of Behavioral Health Care

Dr. Wolfrum became the President of Accelera’s President of Behavioral Health Care in November 2013, Dr. Wolfrum is the founder and CEO of Behavioral Health Care Associates in Schaumburg, IL, created in 1994. Dr. Wolfrum is Board Certified in psychiatry and addictions by the American Board of Psychiatry and Neurology and is a fellow of the American Psychiatric Association. Dr. Wolfrum created Behavioral Health Care to bring to Chicago a comprehensive and innovative healing approach that combines the best of evaluation and diagnosis with patient focused therapy. Dr. Wolfrum brings 27 years of experience as a MD, he attended Loyola University Medical School and did his internship and residency at Hayden Donahue Mental Health Institute. On November 20, 2013, Behavioral Health Care Associates was acquired by Accelera Innovation Inc. and Dr. Wolfrum will continue to operate and lead the company through an Operating Agreement with Accelera Healthcare Management Service Organization, LLC.

Board Committees

Our securities are not quoted on an exchange that has requirements that a majority of our board members be independent and we are not currently otherwise subject to any law, rule or regulation requiring that all or any portion of our board of directors include “independent” directors, nor are we required to establish or maintain an audit committee or other committee of our board of directors.

The board does not have standing audit, compensation or nominating committees. The board does not believe these committees are necessary based on the size of our company, and the current levels of compensation paid to corporate officers ~~and the beneficial ownership by one shareholder of more than [0]% of our outstanding common stock~~. The board will consider establishing audit, compensation and nominating committees at the appropriate time.

The entire board of directors participates in the consideration of compensation issues and of director nominees. Candidates for director nominees are reviewed in the context of the current composition of the board and the Company’s operating requirements and the long-term interests of its stockholders. In conducting this assessment, the ~~Board~~board ~~of Directors~~ considers skills, diversity, age, and such other factors as it deems appropriate given the current needs of the board and the Company, to maintain a balance of knowledge, experience and capability.

The board’s process for identifying and evaluating nominees for director, including nominees recommended by stockholders, will involve compiling names of potentially eligible candidates, conducting background and reference checks, conducting interviews with the candidate and others (as schedules permit), meeting to consider and approve the final candidates and, as appropriate, preparing an analysis with regard to particular recommended candidates.

Through their own business activities and experiences each of our directors ~~have~~has come to understand that in today’s business environment, development of useful products and identification of undervalued medical providers, along with other related efforts, are the keys to building our company. The directors will seek out individuals with relevant experience to operate and build our current and proposed business activities.

- 30 20-

Director Compensation

~~Typically,~~Our ~~our~~ directors do not receive any compensation in consideration for their services as directors and there is no other compensation being considered at this time.

Compliance with Section 16(a) of the ~~Securities~~ Exchange Act ~~of 1934~~

Section 16(a) of the ~~Securities~~ Exchange Act ~~of 1934, as amended,~~ requires our executive officers and directors, and persons who beneficially own more than 10% of a registered class of our equity securities to file with the ~~Securities~~SEC ~~and Exchange Commission~~ initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our common ~~shares~~stock and other equity securities, on Forms 3, 4 and 5, respectively. Executive officers, directors and greater than 10% shareholders are required by ~~the~~SEC ~~Securities and Exchange Commission~~ regulations to furnish us with copies of all Section 16(a) reports they file. Based on our review of the copies of such forms received by us, and to the best of our knowledge, all executive officers, directors and persons holding greater than 10% of our issued and outstanding stock have filed the required reports in a timely manner during ~~2015~~ 2016.

ITEM 11. EXECUTIVE COMPENSATION

The following table summarizes all compensation recorded by us induring the years ended December 31, 2016 and 2015 for our principal executive officers, each other executive officer serving as such whose annual compensation exceeded $100,000, and additional individual for whom disclosure would have been made in this table but for the fact that the individual was not serving as an executive officer of our Company at December 31, ~~2015:~~2016. Pursuant to Item 402(a)(5) of Regulation S-K we have omitted certain columns from the table since there was no compensation awarded to, earned by or paid to these individuals required to be reported in such columns in either year.

~~2015~~ SUMMARY COMPENSATION TABLE

Name and Principal Position	Year		Salary ($)		~~Bonus~~Option ~~($) Stock~~ Awards ($)		~~Option Awards ($)~~		Total ($)		~~Non-Equity Incentive Plan Compensation ($)~~		~~Nonqualified Deferred Compensation ($)~~		~~All Other Compensation ($)~~		~~Total ($)~~
John Wallin (1)		~~2015~~2016		0	~~0 0~~	131,144		~~786,720~~		131,144		0		0		0		~~786,720~~
		2014		0	0 0			1,955,420				0		0		0		1,955,420
		2015		0		786,720				786,720
James Millikan (2)		~~2015~~2016		0	~~0 0~~	75,000		~~450,000~~		75,000		0		0		0		~~450,000~~
		2014		0	0 0			1,116,668				0		0		0		1,116,668
		2015		0		450,000				450,000
Daniel Freeman (3)		~~2014~~2016		0N/A	~~0 0~~	N/A		~~1,125,332~~		N/A		0		0		0		~~1,125,332~~
		2015		0		30,000				30,000

	(1)	Chief Executive Officer. In addition, Mr. Wallin ~~was~~has ~~appointed~~acted ~~interim~~as our Chief Financial Officer assince of March 20, 2015.
	(2)	Chief Operating Officer (retired on April 1, 2017).
	(3)	Former Chief Financial Officer – (resigned on March 20, 2015).

~~Our~~None ~~director~~of ~~has~~our ~~not~~directors has received any monetary compensation ~~since~~from our inception to the date of this ~~Form~~annual ~~10-K~~report. We currently do not pay any compensation to our ~~director~~directors ~~or officer~~ for serving on our board of directors ~~or as management~~.

- 31 21-

~~STOCK~~Stock ~~OPTION~~Option ~~GRANTS~~Grants

We currently have 5,803,250 options outstanding under our 2011 Stock Option Plan which have been granted to key employees, . John Wallin has 1,049,000 options, James Millikan has 600,000, Cynthia Boerum and Patrick Custardo each have 800,000 ~~options~~, ~~the~~and ~~options~~the options awarded will vest in equal annual installments over a four-year period. Also, ~~Blaise Wolfrum has 600,000 options; Rose Gallagher has 154,583 options;~~ Daniel ~~Gallagher has 825,000 options and Daniel~~ Freeman has 914,667 and Jimmy LaCaba has 60,000 ~~options~~.

~~EMPLOYMENT~~Employment ~~AGREEMENTS WITH EXECUTIVE OFFICERS~~Agreements

Effective April 26, 2012, the Company entered into an employment agreement with John F. Wallin, as the President and Chief Executive Officer ~~“CEO”~~ of the Company. The employment agreement with Mr. Wallin provides that, upon completion of $2,000,000 in financing, the Company shall ~~begin to~~ pay ~~John~~him a base salary of $250,000 per year, ~~to be paid~~ at the times and subject to the Company’s standard payroll practices, subject to applicable withholding. ~~Base~~The base salary shall be reviewed at least annually, and increased as determined by the ~~Board~~board. So long as Mr. Wallin has not been terminated for cause, as defined in the employment agreement, he will be eligible for bonus compensation, payable immediately following completion of the Company’s financial statements for each full fiscal year, commencing ~~with the~~ in 2013 ~~fiscal year~~. Mr. Wallin’s annual bonus targets are still being developed by the Company and will be adjusted from time to time, based upon the Company’s achieving 100% of certain financial metrics plan targets to be determined by the ~~Board~~board.

In further consideration offor ~~the~~Mr. Wallin’s services, the Company agreed to ~~issue~~grant aoptions ~~stock option~~ to purchase 1,750,000 shares of the Company’s common stock at an exercise price of $0.0001 per share, vesting over a four year period. The ~~stock~~options ~~option shall~~ vest with ~~respect~~ respect to 20% of the total number ~~of shares which are the subject of the option~~ (350,000 ~~shares~~) immediately after the effective date of the agreement, and thereafter the remaining options ~~shares granted under the option shall~~ vest ratably on a monthly basis (29,166 ~~shares~~ per month) at the end of each month over a 48-month period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options ~~from this agreement and others shall~~ immediately vest and become fully exercisable.

Effective April 26, 2012, the Company entered into an employment agreement with James R. Millikan, as the Chief Operating Officer ~~“COO”~~ of the Company ~~reporting to the President and CEO~~. The employment agreement with Mr. Millikan provides that, upon completion of ~~two~~ ~~million~~$2,000,000 ~~dollars~~ in financing, the Company shall ~~begin to~~ pay ~~Jim~~him a base salary of $175,000 per year, ~~to be paid~~ at the times and subject to the Company’s standard payroll practices, subject to applicable withholding. ~~Base~~The base salary shall be reviewed at least annually, and increased as determined by the ~~Board~~board. So long as Mr. Millikan has not been terminated for cause, as defined in the employment agreement, he will be eligible for bonus compensation, payable immediately following completion of the Company’s financial statements for each full fiscal year, commencing ~~with the~~ in 2013 ~~fiscal year~~. Mr. Millikan’s annual bonus targets are still being developed by the Company and will be adjusted from time to time, based upon the Company’s achieving 100% of certain financial metrics plan ~~Targets~~targets to be determined by the ~~Board~~board.

In further consideration offor ~~the~~Mr. Millikan’s services, the Company agreed to ~~issue~~grant aoptions ~~stock option~~ to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.0001 per share, vesting over a four year period. The ~~stock~~options ~~option shall~~ vest with ~~respect~~ respect to 20% of the total number ~~of shares which are the subject of the option~~ (200,000 ~~shares~~) immediately after the effective date of the agreement, and thereafter the remaining options ~~shares granted under the option shall~~ vest ratably on a monthly basis (16,666 ~~shares~~ per month) at the end of each month over a 48-month period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options ~~from this agreement and others shall~~ immediately vest and become fully exercisable.

Effective April 26, 2012, the Company entered into an employment agreement with Cynthia Boerum, as the Chief Strategic Officer ~~“CSO”~~ of the Company ~~reporting to the President and CEO~~. The employment agreement with Ms. Boerum provides that, upon completion of ~~two million~~$2,000,000 ~~dollars~~ in financing, the Company shall ~~begin to~~ pay ~~Cynthia~~ her a base salary of $150,000 per year, ~~to be paid~~ at the times and subject to the Company’s standard payroll practices, subject to applicable withholding. ~~Base~~The base salary shall be reviewed at least annually, and increased as determined by the ~~Board~~board. So long as Ms. Boerum has not been terminated for cause, as defined in the employment agreement, she will be eligible for bonus compensation, payable immediately following completion of the Company’s financial statements for each full fiscal year, commencing ~~with~~in ~~the~~ 2013 ~~fiscal year~~. Ms . Boerum’s annual bonus targets are still being developed by the Company and will be adjusted from time to time, based upon the Company’s achieving 100% of certain financial metrics plan ~~Targets~~targets to be determined by the ~~Board~~board.

In further consideration of ~~the~~Ms. Boerum’s services, the Company agreed to ~~issue~~grant aoptions ~~stock option~~ to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.0001 per share, vesting over a four year period. The ~~stock~~options ~~option shall~~ vest with ~~respect~~ respect to 20% of the total number ~~of shares which are the subject of the option~~ (200,000 ~~shares~~) immediately after the effective date of the agreement, and thereafter the remaining options ~~shares granted under the option shall~~ vest ratably on a monthly basis (16,666 ~~shares~~ per month) at the end of each month over a 48-month period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options ~~from this agreement and others shall~~ immediately vest and become fully exercisable.

Effective January 1, 2013, the Company entered into an employment agreement with Patrick Custardo, as the Chief Acquisitions Officer ~~“CAO”~~ of the ~~Company reporting to the President and CEO. In consideration of the services, the Company agreed to issue a stock option~~ ~~to purchase 1,000,000 shares of the~~ Company~~’s common stock at an exercise price of $~~.~~0001~~ ~~per share, vesting over a four-year period.~~ The stock option shall vest with respect to 20% of the total number of shares which are the subject of the option (200,000 shares) immediately after the effective date of the agreement, thereafter the remaining shares granted under the option shall vest ratably on a monthly basis (16,666 shares per month) at the end of each month over a 48-month period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options from this agreement and others shall immediately vest and become fully exercisable. The employment agreement with Mr. Custardo provides that, upon completion of ~~two~~$2,000,000 ~~million dollars~~ in financing, the Company shall ~~begin to~~ pay ~~Patrick~~him a base salary of $150,000 per year, ~~to be paid~~ at the times and subject to the Company’s standard payroll practices, subject to applicable withholding. ~~Base~~The base salary shall be reviewed at least annually, and increased as determined by the ~~Board~~board. So long as Mr. Custardo has not been terminated for cause, as defined in the employment agreement, ~~she~~he will be eligible for bonus compensation, payable immediately following completion of the Company’s financial statements for each full fiscal year, commencing ~~with the~~ in 2013 ~~fiscal year~~. Mr. Custardo’s annual bonus targets are still being developed by the Company and will be adjusted from time to time, based upon the Company’s achieving 100% of certain financial metrics plan ~~Targets~~targets to be determined by the Board.

In further consideration of Mr. Custardo’s services, the Company agreed to grant options to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.0001 per share, vesting over a four-year 32period. The options vest with respect to 20% of the total number (200,000) immediately after the effective date of the agreement, and thereafter the remaining options vest ratably on a monthly basis (16,666 per month) at the end of each month over a 48-month period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options immediately vest and become fully exercisable.

Effective November 20, 2013, the Company entered into an employment agreement with Blaise J. Wolfrum, M.D., as the President of the Accelera business unit “Behavioral Health Care Associates” reporting to John Wallin, CEO of Accelera. In consideration of the services, the Company agreed to issue a stock option to purchase Six Hundred Thousand (600,000) shares of the Company’s Common Stock under the terms of the Company’s 2011 Stock Option Plan at an exercise price of $.0001 per share. The Six Hundred Thousand (600,000) shares shall vest over the course of the Three (3) years, earned annually, at Two Hundred Thousand (200,000) shares each year; after the commencement of employment so long as he remain an employee of the Company. Furthermore, the shares are subject to a Six (6) month lock-~~up agreement and a Twenty Seven (27) month leak~~22-out agreement limiting the sale of shares over the period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options from the agreement shall immediately vest and become fully exercisable. The employment agreement with Dr. Wolfrum provides that the Company shall pay Blaise a base salary of $300,000 per year to be paid at the times and subject to the Company’s standard payroll practices, subject to applicable withholding. Mr. Wolfrum will begin receiving compensation at the time Accelera completes the Due Diligence, Valuation and Audited Financials of the Behavioral Health Care Associates business performed by an Accelera appointed audit firm. The Board of Directors will implement a bonus structure based on goals, objectives and performance.

Effective ~~December~~November 1320, 2013, ~~Accelera~~the Company entered into aan ~~three-year~~employment ~~Employment~~agreement ~~Agreement~~ with ~~Rose~~Blaise MJ. ~~Gallagher as the President of Accelera’s At Home Health Care business unit reporting to John Wallin~~Wolfrum, ~~Accelera’s CEO~~M. ~~In consideration of the services, Accelera agreed to immediately grant Ms~~D. ~~Gallagher 585~~,~~000~~ ~~common~~as ~~shares~~the atPresident ~~a price~~ of $0BHCA.~~0001~~ ~~per share, and an option to purchase 1,000,000~~The ~~common~~employment ~~shares~~agreement atwith ~~a price of $0~~Dr.~~0001~~ ~~per~~Wolfrum ~~share,~~provides tothat ~~be vested Two Hundred and Fifty Thousand (250,000) shares annually for 4 years, beginning March 12, 2014; with final vested shares on March 12, 2017, all~~ the ~~shares~~Company ~~will~~shall bepay ~~issued~~him ~~in accordance with the terms of the Accelera’s 2011 Stock Option Plan. Furthermore, the shares are subject to~~ a ~~Six~~base ~~(6)~~salary ~~month lock-up agreement and a Twenty Seven (27) month leak-out agreement limiting the sale~~ of ~~shares over the period. Additionally, Accelera agreed to compensate Ms. Gallagher~~ $~~150~~300,000 per ~~annum,~~year ~~which~~at ~~shall~~the betimes and ~~paid~~subject ~~bi-weekly~~to ~~in accordance with~~ the Company’s ~~customary~~standard payroll practices., ~~Ms.~~subject ~~Gallagher~~to ~~will~~applicable ~~begin receiving compensation at the time Accelera completes the Due Diligence~~withholding, ~~Valuation~~ and ~~Audited Financials of the At Home Health Care business~~ that ~~includes~~ the ~~Subject~~board ~~LLC’s~~will ~~performed by an Accelera’s appointed accounting firm, approximately ninety (90) days from the employment offer. The Board of Directors intends to~~ implement a bonus structure based on goals, objectives and performance.

~~Outstanding~~In ~~Equity~~further ~~Awards~~consideration of Dr. Wolfrum’s services, the Company agreed to grant options to purchase 600,000 shares of the Company’s common stock at ~~2015~~an ~~Fiscal~~exercise ~~Year~~price of $0.0001 per share, vesting over the course of three years at a rate of 200,000 each year so long as he remain an employee of the Company. The shares of common stock underlying the options are subject to a six month lock-~~End~~up agreement and a 27 month leak-out agreement limiting the sale of shares over the period. Notwithstanding the foregoing, in the event of a closing of a Change of Control transaction, all options immediately vest and become fully exercisable.

~~The~~Dr. ~~following~~Wolfrum’s ~~table~~employment ~~provides~~agreement ~~information~~was ~~regarding~~terminated ~~all~~pursuant ~~restricted~~to ~~stock, stock options and SAR awards (if any) held by our officers listed in~~ the ~~summary~~Termination ~~compensation table above as of December 31, 2015~~Agreement.

Name	Number of Securities Underlying Unexercised Options Exercisable		Number of Securities Underlying Unexercised Options Unexercisable				Weighted Average Exercise Price	Expiration Date
John Wallin		983,428		65,572	-	$	.0001-	2022-	-	-	-	-
James Millikan		562,500		37,500		- $	.0001-	2022-	-	-	-	-
Daniel Freeman		489,000		-		- $	.0001-	2024-	-	-	-	-

Effective December 13, 2013, the Company entered into a three-year employment agreement with Rose M. Gallagher as the President of Accelera’s At Home Health Care business unit. The employment agreement with Ms. Gallagher provides that that Company shall pay her a base salary of $150,000 per annum on a bi-weekly basis in accordance with the Company’s customary payroll practices. Ms. Gallagher will begin receiving compensation at the time Accelera completes the Due Diligence, Valuation and Audited Financials of the At Home Health Care business that includes the Subject LLC’s performed by an Accelera’s appointed accounting firm, approximately ninety (90) days from the employment offer. The Board of Directors intends to implement a bonus structure based on goals, objectives and performance.

In further consideration for Ms. Gallagher’s services, the Company agreed to grant options to purchase 585,000 shares of the Company’s common stock at an exercise price of $0.0001 per share, and options to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.0001 per share, vesting as to 250,000 shares annually for four years beginning on March 12, 2014. The shares of common stock underlying the options are subject to a six month lock-up 33agreement and a 27 month leak-out agreement limiting the sale of shares over the period.

Ms. Gallagher’s employment agreement was terminated pursuant to a termination agreement effective December 31, 2014.

Outstanding Equity Awards at Fiscal Year-End

The following table provides information regarding all restricted stock, stock options and SAR awards (if any) held by our officers listed in the summary compensation table above as of December 31, 2016.

Name	Number of Securities Underlying Unexercised Options Exercisable		Number of Securities Underlying Unexercised Options Unexercisable		Weighted Average Exercise Price		Expiration Date
John Wallin		1,049,000		-	$	0.0001		2022
James Millikan		600,000		-	$	0.0001		2022
Daniel Freeman		914,667		-	$	0.0001		2024

-23-

ITEM 12. OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table lists, as of ~~August~~April 314, ~~2016~~2017, the number of shares of common stock of ~~our~~the Company that are beneficially owned by (i) each person or entity known to ~~our~~the Company to be the beneficial owner of more than 5% of the outstanding common stock; (ii) each officer and director of ~~our~~the Company; and (iii) all officers and directors as a group. Information relating to beneficial ownership of common stock by our principal shareholders and management is based upon information furnished by each person using “beneficial ownership” concepts under the rules of the ~~Securities and Exchange Commission~~SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to vote or direct the voting of the security. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days. Under the ~~Securities and Exchange Commission~~ SEC’s rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary beneficial interest. Except as noted below, each person has sole voting and investment power. The percentages below are calculated based on 4578,~~713~~158,~~716~~673 shares of our common stock issued and outstanding as of ~~August~~the 3,date ~~2016~~of this report.

	Name and Address	Number of Shares			Beneficial Ownership		Percent of
Title of Class	of Beneficial Owner	Owned Beneficially			within 60 days		Class Owned
Common Stock:	Synergistic Holdings, LLC (1)		5,489,561					12.009	%
Common Stock	Synergistic Holdings, LLC (1)		5,489,561					7.02	%
	0511 Abbey Drive, Frankfort, Illinois 60423
	20511 Abbey Drive Frankfort, IL 60423
Common Stock	~~Accelerated~~Victory ~~Venture~~Investment ~~Partners~~Management LLC (1) 20511 Abbey Drive Frankfort, IL 60423		35,~~500~~000,000					~~14.219~~6,40	%
	1840 Gateway Dr. Suite 200
Common Stock	NGT Holdings LLC (1) 20511 Abbey Drive Frankfort, IL 60423		8,250,000					10.56	%
	Foster City, CA 94404
Common Stock	Geoffrey Thompson, Chairman of Board (2)		3,169					*
Common Stock:	Victory Investment Management LLC (1) 20511 Abbey Dr. Frankfort, IL 60423		5,000,000					10.938	%
Common Stock	John Wallin, Chief Executive Officer, Chief Financial Officer (2)		1,752,050	(3)				2.21	%
Common Stock:	NGT Holdings LLC (1) 20511 Abbey Dr. Frankfort, IL 60423		8,250,000					18.047	%
All executive officers and directors as a group			20,494,780					25.87	%
Common Stock:	Geoffrey Thompson, Chairman of Board (2)		3169
Common Stock	John Wallin, Chief Executive Officer, Chief Financial Officer (2) (3)		1,662,502			58,332		*
Common Stock	James Millikan, Chief Operating Officer (2)		950,002			33,333		*
Common Stock	Daniel Freeman, Chief Financial Officer (3) (4)		329,333
All executive officers and directors as a group			25,184,567			91,665

(1.	Mr Thompson is deemed to be the beneficial holder of Synergistic Holdings LLC, Victory Investment Management LLC and NGT Holdings LLC. Of Mr. Thompson’s shares 18,739,561 are held with Synergistic Holdings LLC, Victory Investment Management LLC and NGT Holdings LLC and 3169 shares are held jointly with his spouse. Mr. Thompson has voting and dispositive control over the shares held by Synergistic Holdings LLC, Victory Investment Management LC and NGT Holdings LLC.
(1)	Mr Thompson is deemed to be the beneficial holder of Synergistic Holdings LLC, Victory Investment Management LLC and NGT Holdings LLC. Of Mr. Thompson’s shares, 18,739,561 are held with Synergistic Holdings LLC, Victory Investment Management LLC and NGT Holdings LLC and 3,169 shares are held jointly with his spouse. Mr. Thompson has voting and dispositive control over the shares held by Synergistic Holdings LLC, Victory Investment Management LC and NGT Holdings LLC.
(2.	The beneficial holders address is c/o Accelera Innovations Inc 20511 Abbey Dr. Frankfort, IL 60423.
(2)	The beneficial holders address is c/o Accelera Innovations, Inc., 20511 Abbey Drive, Frankfort, IL 60423.
(3.	Of these shares, Mr. Wallin holds 3,525 jointly with his spouse.
(3)	Includes 1,050 shares held jointly by Mr. Wallin and his spouse, and 1,049,000 options exercisable at a price of $0.0001 per share.
(4.	Mr. Freeman ceased to be an executive officer as of March 20, 2015
(5.	Of these shares, 500 shares are held jointly with Mr. Freeman’s spouse, 1,000 shares are held by Freeman Farms, LLC, 1,000 shares are held by DVN Freeman Family Farms, LLC, 1,000 shares are held by Deer River Farms, LLC, 1,000 shares are held by Freeman Ag Enterprises, LLC, and 1,000 shares are held by Freeman Spring Valley Farms, LLC. Each of the limited liability companies is owned by Mr. Freeman, and Mr. Freeman has voting and dispositive control over the shares held by the limited liability companies.

*less than 51 %.

- 34 24-

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

On ~~April~~December 135, ~~2012~~2014, the Company ~~entered~~and ~~into~~Synergistic, ana ~~amended~~major ~~Licensing~~shareholder ~~Agreement~~of ~~(“Agreement”)~~the ~~with~~Company, agreed to cancel 796,671 shares of the Company’s common stock owned by Synergistic ~~Holdings~~and ~~LLC~~forgive certain indebtedness owed by the Company to Synergistic in the amount of $1,018,618. ~~(Licensor)~~In ~~whereas~~addition, the Company ~~and~~entered ~~Licensor~~into ~~agreed~~an oral agreement to amend the ~~August~~Licensing 22Agreement to reduce the total amount of reimbursable distribution and commercialization expenses due under the Licensing Agreement by $585,181 ~~2011~~to $29,414,819 and defer the date of certain payment obligations by the Company under the Licensing Agreement. as follows:

[to be updated upon completion of financial statements.]

The Company and Synergistic Holdings, LLC (“Synergistic”), a controlling shareholder of the Company, agreed to cancel 796,671 shares of the Company’s common stock owned by Synergistic and forgive certain indebtedness owed by the Company to Synergistic in the amount of $1,018,618. In addition, the Company entered into an oral agreement to amend the license agreement entered into between the Company and Synergistic to reduce the total amount of reimbursable distribution and commercialization expenses due under the license agreement by $585,181 to $29,414,819 and defer the commencement date of the agreement until the payment dates for the following amounts:

(a) $5,000,000 no later than December 31, 2015;

(b) An additional $7,500,000 no later than December 31, 2016;

(d) An additional $6,914,819 no later than December 31, 2018.

~~Tec~~On ~~Explorer~~May is7, a2015, ~~related~~the ~~party~~Company ~~through~~and ~~common~~Synergistic ~~ownership.~~agreed ~~Tec~~to ~~Explorer~~amend ~~supplied~~the ~~working~~Licensing ~~capital~~Agreement to eliminate the Company’s $29,414,819 funding requirement under Article 3 and replace it with a requirement to ~~fund~~pay ~~primarily~~a license fee in the amount of $10,000 upon completion and acceptance of each installation of the software at a location for each affiliate or subsidiary of the Company and the sum ~~acquisition~~of ~~costs~~$10,000 ~~accounting~~on ~~services,~~each ~~commissions~~anniversary ~~and~~after ~~subcontract~~each ~~costs~~such installation during ~~2010~~the ~~through~~period ~~2013~~of time in which the software is used at such location. In addition, the Company will be responsible for the reasonable installation costs incurred by Synergistic ~~Holdings,~~in ~~LLC~~connection with ~~assumed~~the ~~all~~installation ~~obligations~~and tosetup ~~Tec~~of ~~Explorer~~the ~~during~~software ~~2014~~as ~~and~~required ~~2013~~by onthe ~~behalf~~Company. ofThe license fee may be paid in cash or the Company’s common stock. ~~This~~In ~~verbal~~addition, ~~agreement~~the Licensing Agreement was ~~agreed~~amended to ~~by all~~delete ~~three~~the ~~companies~~Company’s exclusive rights under such agreement.

OnAt ~~May~~December 731, ~~2015,~~2016 ~~the Company~~ and ~~Synergistic~~2015, ~~agreed~~advances tofrom ~~amend~~related ~~the~~party ~~Synergistic~~were ~~Licensing Agreement to eliminate the Company’s~~ $29403,~~414,819~~092 ~~funding requirements under Article 3~~ and replace it with a requirement to pay a license fee in the amount of 10,000 common shares upon completion and acceptance of each installation of the software at a location for each affiliate or subsidiary of the Company and the sum of $10243,~~000~~799, ~~on each anniversary after each such installation during the period of time in which the Software is used at such location~~respectively. InThese ~~addition,~~advances ~~the~~are ~~Company will be responsible for the reasonable installation costs incurred~~non-interest bybearing ~~Synergistic in connection with the installation~~ and ~~setup~~payable ofupon ~~the software as required by the Company~~demand. ~~The license fee may be paid in cash or the Company’s common stock. In addition, the Synergistic Licensing Agreement was amended to delete the Company’s exclusive rights under such agreement.~~

Other than as described above, we have not entered into any transactions with our officers, directors, persons nominated for these positions, beneficial owners of 5% or more of our common stock, or family members of those persons wherein the amount involved in the transaction or a series of similar transactions exceeded the lesser of $120,000 or 1% of the average of our total assets for the last two fiscal years.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The following table shows the fees that were billed for the audit and other services provided by AJ Robbins CPA and Anton & Chia, LLP for the fiscal years ended December 31, ~~2015~~2016 and ~~2014~~2015.

	2015		2014
	2016		2015
Audit Fees	$	42110,~~000~~357	$	66,860
Audit-Related Fees		~~3043.52~~3,044		9282
Tax Fees		-		-
All Other Fees		-		-
Total	$	45113,~~043.52~~401	$	~~76142~~76,142

- 35 25-

Audit Fees—This category includes the audit of our annual financial statements, review of financial statements included in our Quarterly Reports on Form 10-Q and services that are normally provided by the independent registered public accounting firm in connection with engagements for those fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.

Audit-Related Fees—This category consists of assurance and related services by the independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the Commission and other accounting consulting.

Tax Fees—This category consists of professional services rendered by our independent registered public accounting firm for tax compliance and tax advice. The services for the fees disclosed under this category include tax return preparation and technical tax advice.

All Other Fees—This category consists of fees for other miscellaneous items.

Our board of directors has adopted a procedure for pre-approval of all fees charged by our independent registered public accounting firm. Under the procedure, the board approves the engagement letter with respect to audit, tax and review services. Other fees are subject to pre-approval by the board, or, in the period between meetings, by a designated member of board. Any such approval by the designated member is disclosed to the entire board at the next meeting.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a)	Financial Statements and Schedules:

The consolidated financial statements and Report of Independent Registered Public Accounting Firm are listed in the “Index to Financial Statements and Schedules” on page F-1 and begin with page F-1. All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

(b)	Exhibits:

			Exhibit Number	Date of
Exhibit No.	Description	Form	in form	Filing
3.1	Certificate of Incorporation	10	3.1	08/28/2008
3.2	Certificate of Amendment of Certificate of Incorporation	S-1	3.1.2	05/22/2012
3.3	Bylaws ~~of the Company~~	10	3.2	08/28/2008
3.4	Certificate of Designations of 8% Convertible Preferred Stock	8-K	3.4	05/13/2015
10.1	Subscription Agreement by and among the Company and Synergistic Holdings, LLC, dated as of June 13, 2011	8-K	10.1	06/17/2011
10.2	Consulting Agreement by and among the Company and Accelerated Venture Partners, LLC, dated as of June 16, 2011	8-K	10.4	06/17/2011
10.3	Licensing ~~internet~~Agreement ~~based software (CareNav)~~ by and among the ~~company~~Company and Synergistic Holdings, LLC, dated as of August 22, 2011	8-K	10.1	08/29/2011
10.4	~~Amend~~First ~~the~~Amendment ~~license~~and ~~agreement~~Modification ~~between~~to ~~Synergistic~~Licensing ~~Holdings~~Agreement by and among the Company toand ~~include~~Synergistic ~~additional~~Holdings, ~~technology~~LLC, todated ~~enhance~~as ~~product~~of ~~offering~~April 13, 2012	8-K	10.1	04/16/2012
10.5	~~Company creates~~ 2011 Employee, Director and Consultant Stock Plan	10-K	10.6	04/16/2012
10.6+	Employment Agreement by and among the Company and John Wallin dated as ~~CEO~~of April 26, 2012	8-K	10.1	04/30/2012
10.7+	Employment Agreement by and among the Company and James Millikan dated as ~~COO~~of April 26, 2012	8-K	10.2	04/30/2012
10.8+	Employment Agreement by and among the Company and Cindy Boerum dated as ~~CSO~~of April 26, 2012	8-K	10.3	04/30/2012

- 36 26-

10.9	Form of Lock-up and ~~Leek-out~~Leak Out Agreement between the Company and holder of common stock of the Company	S-1	10.59	05/22/2012
10.11	Operating Agreement by and among the Company and Accelera Healthcare Management Service Organization LLC	8-K	10-2	12/02/2013
10.10	Stock Purchase Agreement by and among the Company and Blaise J. Wolfrum, M.D., dated as of November 11, 2013	8-K	10.1	12/02/2013
10.12	Security Agreement by and among Company and Blaise J. Wolfrum MD for Behavioral Health Care Associates Ltd	8-K	10-3	12/02/2013
10.11	Operating Agreement by and among Accelera Healthcare Management Service Organization LLC and Blaise J. Wolfrum, M.D., dated as of November 11, 2013	8-K	10-2	12/02/2013
10.13	Secured Promissory Note in reference to Stock Purchase Agreement by and among Company and Blaise Wolfrum MD for Behavioral Health Care	8-K	10-4	12/02/2013
10.12	Security Agreement by and among Company and Blaise J. Wolfrum, M.D., dated as of November 11, 2013	8-K	10-3	12/02/2013
10.14	Assignment of Stock in reference to Stock Purchase Agreement by and among Company and Blaise Wolfrum for Behavioral Health Care Associates Ltd	8-K	10-5	12/02/2013
10.13	Secured Promissory Note issued by the Company to Blaise J. Wolfrum, M.D. dated as of November 11, 2013	8-K	10-4	12/02/2013
10.15+	Employment Agreement by and among the Company and Blaise Wolfrum MD as President of the Accelera business unit Behavioral Health Care Associates Ltd,	8-K	10-6	12/02/2013
10.14	Assignment of Stock in by and among the Company and Blaise J. Wolfrum, M.D., dated as of November 11, 2013	8-K	10-5	12/02/2013
10.16	Lock-up and Leak-Out Agreement between Company and Blaise Wolfrum MD	8-K	10-7	12/02/2013
10.15+	Employment Agreement by and among the Company and Blaise J. Wolfrum, M.D., dated as of November 20, 2013	8-K	10-6	12/02/2013
10.17	Purchase Agreement by and among the Company and At Home Health Services LLC and All Staffing Services LLC	8-K	10-1	12/16/2013
10.16	Lock-up and Leak-Out Agreement by and among the Company and Blaise J. Wolfrum M.D., dated as of November 11, 2013	8-K	10-7	12/02/2013
10.18	Operating Agreement by and among the Company and At Home Health Management LLC	8-K	10-2	12/16/2013
10.17	Purchase Agreement by and among the Company, At Home Health Services LLC, All Staffing Services, LLC, Rose Gallagher and the Rose M. Gallagher Revocable Trust dated November 30, 1994, dated as of December 13, 2013	8-K	10-1	12/16/2013
10.19+	Employment Agreement by and among the Company and Rose M. Gallagher as President of Accelera business unit At Home Health	8-K	10-3	12/16/2013
10.18	Operating Agreement by and among the Company and At Home Health Management LLC dated as of December 13, 2013	8-K	10-2	12/16/2013
10.20+	Employment Agreement by and among the Company and Daniel P. Gallagher as Director of Marketing and Business Development at At Home Health	8-K	10-4	12/16/2013
10.19+	Employment Agreement by and among the Company and Rose M. Gallagher dated as of December 13, 2013	8-K	10-3	12/16/2013
10.21	Second Amendment and Modification to Software Technology agreement payment dates by and among the Company and Synergistic Holdings LLC	10-K	10.20	04/15/2014
10.20+	Employment Agreement by and among the Company and Daniel P. Gallagher dated as of December 13, 2013	8-K	10-4	12/16/2013
10.22+	Employment Agreement by and among the Company and Daniel Freeman as CFO	8-K	10.1	10/08/2014
10.21	Second Amendment and Modification to Licensing Agreement by and among the Company and Synergistic Holdings, LLC, dated as of April 12, 2014	10-K	10.20	04/15/2014
10.23	Stock Purchase Agreement by and among the Company and SCI Home Health Inc.	8-K	10-1	10/14/2014
10.22+	Employment Agreement by and among the Company and Daniel Freeman dated as of October 6, 2014	8-K	10.1	10/08/2014
10.24	Promissory Note by and among the Company and AOK Property Investments LLC to purchase SCI Home Health Inc.	8-K	10-2	10/14/2014
10.23	Stock Purchase Agreement by and among the Company, Ethel dela Cruz, Virgilia Avila, Ma Lourdes Reyes Celicious, Cristina Soriano, Michelle Cartas and Jimmy Lacaba ated as of August 25, 2014	8-K	10-1	10/14/2014
10.25	Stock Purchase Agreement by and among the Company and Grace Home Health Care. Employment Agreement by and among the Company and Angelo L. Cadiente as CEO of the Accelera business unit Grace Home Health	8-K	10.1	12/04/2014
10.24	Promissory Note issued by the Company to AOK Property Investments LLC dated as of October 1, 2014	8-K	10-2	10/14/2014
10.26	Asset Purchase Agreement by and among the Company and Watson Health Care Inc.	8-K	10.2	12/04/2014
10.25	Stock Purchase Agreement by and among the Company and Grace Home Health Care, Inc. dated as of November 25, 2014	8-K	10.1	12/04/2014
10.27	Stock Purchase Agreement by and among the Company and Traditions Home Care Inc. Employment by and among the Company and Sonny Nix as CEO	8-K	10.1	01/09/2015
10.26	Asset Purchase Agreement by and among the Company and Watson Health Care, Inc. dated as of November 25, 2014	8-K	10.2	12/04/2014
31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer and Principal Financial Officer			X

32.1	Section 1350 Certification of Principal Executive Officer and Principal Financial Officer	X
101.INS**	XBRL Instance	X
101.SCH**	XBRL Taxonomy Extension Schema	X
101.CAL**	XBRL Taxonomy Extension Calculation Linkbase	X
101.DEF**	XBRL Taxonomy Extension Definition Linkbase	X
101.LAB**	XBRL Taxonomy Extension Labels Linkbase	X
101.PRE**	XBRL Taxonomy Extension Presentation Linkbase	X

-27-


10.27	Stock Purchase Agreement by and among the Company, Sonny Nix and John Noah dated as of January 5, 2015	8-K	10.1	01/09/2015

10.28	Amendment to Purchase Agreement by and among the Company and Traditions Home Health, Inc. dated as of January 5, 2015	10-Q	10.28	05/20/2015

10.29	Second Amendment to Licensing Agreement by and among the Company and Synergistic Holdings, LLC dated as of May 7, 2015	10-Q	10.29	05/20/2015

10.30	Separation Agreement by and among the Company and Daniel Freeman dated as of May 8, 2015	10-Q	10.30	05/20/2015

10.31	Amendment to Stock Purchase Agreement by and among the Company and Grace Home Health Care dated as of May 7, 2015	10.Q	10.31	05/20/2015

10.32	Amendment to Asset Purchase Agreement by and among the Company, Watson Health Care Inc. and Affordable Nursing Inc. dated May 20, 2015		10.32	05/20/2015

10.33	Settlement Agreement and Release by and among the Company, Geoffrey J. Thompson, Nancy Thompson, GWS Financial Services, Inc., Synergistic Holdings, LLC, Earl Kopriva and Robert C. Acri dated as of July 1, 2015	8-K	10.1	07/07/2015

10.34	Termination Agreement by and among the Company and Blaise J. Wolfrum, M,D,, dated as of March 31, 2016	8-K	10.1	04/06/2016

10.35	Resignation and Release Agreement by and among the Company, Blaise J. Wolfrum, M.D., and Accelera Healthcare Management Service Organization LLC dated as of January 1, 2016	8-K	10.2	04/06/2016

31.1	Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer and Principal Financial Officer			X

32.1	Section 1350 Certification of Principal Executive Officer and Principal Financial Officer			X

101.INS**	XBRL Instance			X

101.SCH**	XBRL Taxonomy Extension Schema			X

101.CAL**	XBRL Taxonomy Extension Calculation Linkbase			X

101.DEF**	XBRL Taxonomy Extension Definition Linkbase			X

101.LAB**	XBRL Taxonomy Extension Labels Linkbase			X

101.PRE**	XBRL Taxonomy Extension Presentation Linkbase			X

+ Management compensation plan or arrangement.

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of this annual report on Form 10-K for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

- 37 28-

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Accelera Innovations, Inc.
	By:	/S/ John Wallin
Dated: August 12, 2016		John Wallin
Dated: April 17, 2017		John Wallin
		Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date
	Chief Executive Officer and	~~August~~April 1214, ~~2016~~2017
	Chief Financial Officer
	(Principal Executive Officer and
	Principal Financial and
/S/ John Wallin	Accounting Officer)
John Wallin
/S/ Geoffrey Thompson	Chairman of the Board	~~August~~April 1214, ~~2016~~2017
Geoffrey Thompson

- 38 29-

Accelera Innovations, Inc. and Subsidiaries

Consolidated Financial Statements

For The Years Ended December 31, ~~2015~~2016 and ~~2014~~2015

Contents

	Page
Reports of Independent Registered Public Accounting Firm	F-12
Report of Anton & Chia, LLP	F-1
Report of AJ Robbins CPA LLC	F-2
Consolidated Financial Statements:
Consolidated Balance Sheets as of December 31, 2015 and 2014	F-2
Consolidated Balance Sheets as of December 31, 2016 and 2015	F-3
Consolidated Statements of Operations for the years ended December 31, 2015 and 2014	F-3
Consolidated Statements of Operations for the years ended December 31, 2016 and 2015	F-4
Consolidated Statement of Changes in Stockholder Deficit for the years ended December 31, 2015 and 2014	F-4
Consolidated Statement of Changes in Stockholder Deficit for the years ended December 31, 2016 and 2015	F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2015 and 2014	F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2016 and 2015	F-6
Notes to Consolidated Financial Statements	F-67

F- ~~39 -~~1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

AJ Robbins CPA, LLC

Certified Public Accountant

To the Board of Directors and

Stockholders of Accelera Innovations, Inc.

We have audited the accompanying consolidated balance sheets of Accelera Innovations, Inc and Subsidiaries (collectively “the Company”) as of December 31, ~~2015~~2016 and ~~2014~~2015, and the related consolidated statements of operations, changes in stockholders’ deficit, and cash flows for the years then ended. The Company’s management is responsible for these consolidated financial statements. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Accelera Innovations, Inc. as of December 31, ~~2015~~2016 and ~~2014~~2015, and the consolidated results of their operations and their cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.

~~The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern.~~ As discussed in ~~Note~~Note12 4 to the ~~consolidated~~ financial statements, ~~has had minimal revenue since inception and has experienced recurring operating losses. These conditions, among others, raise substantial doubt about~~ the ~~Company’s~~2015 ~~ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 4 to the consolidated~~ financial statements~~. The~~ ~~consolidated~~have ~~financial~~been ~~statements~~restated doto ~~not~~correct ~~include~~a ~~any adjustments that might result from the outcome of this uncertainty~~misstatement.

~~/s/~~The accompanying ~~Anton~~consolidated &financial ~~Chia~~statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 4 to the consolidated financial statements, ~~LLP~~the ~~Newport~~Company ~~Beach~~has ~~August~~had 12minimal revenue since inception and has experienced recurring operating losses. These conditions, ~~2016~~among others, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 4 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~F-1~~/s/AJ Robbins CPA LLC Denver, Colorado

April 17, 2017

aj@ajrobbins.com

3773 Cherry Creek North Drive, Suite 575 East, Denver, Colorado 80209

(B)303-331-6190 (M)720-339-5566 (F)303-845-9078

F-2

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	December 31, 2015			December 31, 2014
	December 31, 2016			December 31, 2015
				(restated)
ASSETS
Current Assets:
Cash	$	~~474,564~~-		$	~~54,862~~-
Accounts receivable, net		-2,750			~~605,796~~-
Due from stockholder		-			109,620
Prepaid expenses and other current assets		-			29,793
Prepaid expenses and other current assets		29,793			6,026
Total current assets		2,750			29,793
Total current assets		504,357			776,304
Property and equipment, net		6,889			8,889
Property and equipment, net		8,889			6,381
Security deposit		-			1,805
Security deposit		1,805			1,805
TOTAL ASSETS	$	9,639		$	40,487
TOTAL ASSETS	$	515,051		$	784,490
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Short-term notes payable	$	901,521		$	844,507
Cash overdraft	$	-		$	6,624
Subordinated unsecured note payable		4,550,000			-
Short-term notes payable		886,166			901,521
Advances from related party		~~243~~403,~~799~~092			-243,799
Accounts payable		~~474~~465,~~510~~379			88408,~~689~~919
Preferred stock subscription payable		-			793,892
Accrued expenses		333,471			322,581
Accrued expenses		427,764			227,056
Convertible note, net of discount of $19,395 and $0		155,277			-
Derivative liability		~~302~~149,~~580~~269			-302,580
Total current liabilities		62,~~900~~392,~~174~~654			12,~~954~~186,~~144~~024
Long-term subordinated unsecured note payable		-			4,550,000
Convertible note, net of discount of $0 and $158,806		-			15,434
Convertible note, net of discount of 158,806		15,434			-
TOTAL LIABILITIES		2,392,654			2,201,458
TOTAL LIABILITIES		6,915,608			6,504,144
Commitment and contingencies		-			-
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding		-			-
8% convertible preferred stock, 500,000 shares authorized 198,473 shares issued and outstanding; $4.00 stated value		20			-20
Common stock, $0.0001 par value, 100,000,000 shares authorized, 45,011,216 and 40,445,926 shares issued and outstanding at December 31, 2015 and 2014		4,501			4,046
Common stock, $0.0001 par value, 100,000,000 shares authorized, 69,569,444 and 45,011,216 shares issued and outstanding at December 31, 2016 and 2015		6,957			4,501
Additional paid-in capital		5559,~~955~~222,~~631~~837			4157,~~712~~522,~~345~~043
Common stock issuable		1,566,412			1,566,412
Accumulated deficit		(61,612,829	)		(59,687,535	)
Accumulated deficit		(63,927,121	)		(49,002,457	)
Total stockholders’ deficit		(2,383,015	)		(2,160,971	)
Total stockholders’ deficit		(6,400,557	)		(5,719,654	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	9,639		$	40,487
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	515,051		$	784,490

The accompanying notes are an integral part of these consolidated financial statements.

F-23

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

	Years Ended December 31,
	2015			2014
	2016			2015
Revenues	$	3,623,131		$	2,715,523
				(restated)
Cost of revenues		1,856,401			1,685,740
Revenues	$	2,750		$	1,133,715
Gross profit		1,766,730			1,029,783
Cost of revenues		-			157,711
Gross profit		2,750			976,004
Operating expenses:
General and administrative expenses		141,~~892~~900,~~236~~962			3213,~~806~~992,~~136~~521
Total operating expenses		141,~~892~~900,~~236~~962			3213,~~806~~992,~~136~~521
Loss from operations		(131,~~125~~898,~~506~~212	)		(3113,~~776~~016,~~353~~517	)
Other expense
Other income (expense)
Interest expense and financing costs		(1445,~~801,903~~926	)		(41,~~217~~801,~~062~~903	)
Loss on disposal of subsidiaries		-			(94,995	)
Change in fair value of derivative liability		418,844			2,745
Change in fair value of derivative liability		2,745			-
Total other income (expenses)		(27,082	)		(1,799,158	)
Total operating expenses		(1,799,158	)		(4,312,057	)
Loss before provision for taxes		(1,925,294	)		(14,815,675	)
Loss before provision for taxes		(14,924,664	)		(36,088,410	)
Provision for income taxes		-			-
Net loss from continuing operations		(14,924,664	)		(36,088,410	)
Net loss	$	(1,925,294	)	$	(14,857,675	)
Net loss from discontinued operations, net of tax		-			(221,766	)
Preferred stock dividend		47,503			41,413
Net loss	$	(14,924,664	)	$	(36,310,176	)
Net loss attributed to common stockholders	$	(1,972,797)		$	(14,857,088	)
Preferred stock dividend		41,413			-
Weighted average shares outstanding - basic and diluted		48,727,220			42,919,132
Net loss attributed to common stockholders	$	(14,966,077	)	$	(36,310,176	)
Loss per share - basic and diluted	$	(0.04	)	$	(0.35	)
Weighted average shares outstanding - basic and diluted		42,919,132			32,229,831
Loss per share - basic and diluted
Continuing operations	$	(0.35	)	$	(1.12	)
Discontinued operations	$	-		$	(0.01	)

The accompanying notes are an integral part of these consolidated financial statements.

F-34

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

	8% Convertible Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital			Deficit			Equity
Balance, December 31, 2013		-	$	-		22,382,522	$	2,239	$	12,227,526		$	(12,692,281	)	$	(462,516	)
Balance, December 31, 2014 (restated)		-		-		40,445,926		4,046		43,278,757			(44,871,860	)		(1,589,057	)
Issuance of common stock										1,566,412						1,566,412
Issuance of common stock to founders						12,000,000		1,200		(1,200	)					-
Shares issued for services						4,553,404		456		22,728,092						22,728,548
Shares issued for loan consideration						510,000		51		237,549						237,600
Shares for termination of agreement						1,000,000		100								100
Fair value of options vested										6,520,378						6,520,378
Net loss													(36,310,176	)		(36,310,176	)
Balance, December 31, 2014		-		-		40,445,926		4,046		43,278,757			(49,002,457	)		(5,719,654	)
Issuance of 8% convertible preferred stock		198,473		20						793,872						793,892
Shares issued for services						3,810,290		380		7,731,113						7,731,493
Shares issued for cash						255,000		25		14,975						15,000
Shares issued for extension of loan payment terms						500,000		50		1,437,437						1,437,487
Fair value of options vested										4,265,889						4,265,889
Net loss													(14,924,664	)		(14,924,664	)
Net loss (restated)													(14,815,675	)		(14,815,675	)
Balance, December 31, 2015		198,473	$	20		45,011,216	$	4,501	$	57,522,043		$	(63,927,121	)	$	(6,400,557	)
Balance, December 31, 2015 (restated)		198,473		20		45,011,216		4,501		57,522,043			(59,687,535	)		(2,160,971	)
Shares issued for convertible debt						24,558,228		2,456		84,650						87,106
Fair value of options vested										1,616,144						1,616,144
Net loss													(1,925,294)			(1,925,294)
Balance, December 31, 2016		198,473	$	20		69,569,444	$	6,957	$	59,222,837		$	(61,612,829	)	$	(2,383,015	)

The accompanying notes are an integral part of these consolidated financial statements.

F-45

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

	Years Ended December 31,
	2015			2014
	2016			2015
				(restated)
OPERATING ACTIVITIES:
Net loss	$	(141,~~924~~925,~~664~~294)	)	$	(3614,~~310~~815,~~176~~675	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		12,~~259~~000			~~593~~1,259
Stock options expense		41,~~265~~616,~~889~~144			64,~~520~~265,~~378~~889
Shares issued for services		~~7,731,493~~-			227,~~728~~731,~~548~~493
Shares issued for loan consideration and termination agreement		-			37,700
Shares issued for extending loan payment terms					1,437,487
Shares issued for extending loan payment terms		1,437,487			200,000
Amortization of debt discount		277,439			15,434
Expenses to terminate financing		-			30,649
Change in fair value of derivative liability		(418,844	)		(2,745	)
Impairment of intangible assets		-			4,151,151
Financing costs associated with convertible note		135,533			136,640
Loss on disposal of subsidiary		-			94,995
Offering cost for preferred stock subscription		-			141,430
Amortization of debt discount		15,434			-
Change in fair value of derivative liability		(2,745	)		-
Financing costs associated with convertible note		136,640			-
Offering cost for preferred stock subscription		141,430			-
Change in current assets and liabilities:
Accounts receivable		~~605~~(2,~~796~~750	)		~~166~~153,~~711~~478
Prepaid expenses and other current assets		(23,767	)		(6,026	)
Prepaid expenses and current assets		31,598			(23,767	)
Accounts payable		~~385~~56,~~821~~460			~~280~~320,~~327~~230
Accrued expenses		~~200~~12,~~708~~900			-194,987
Net cash used in operating activities		(29214,~~219~~814	)		(2443,~~105,150~~860	)
INVESTING ACTIVITIES:
Purchase of property and equipment		~~(3,767~~-	)		-(3,767	)
Cash acquired upon acquisition of SCI Home Health, Inc.		-			584
Net cash used in investing activities		-			(3,767	)
Payment of security deposit		-			(1,805	)
Advances to related parties		-			-
Net cash used in investing activities		(3,767	)		(1,221	)
FINANCING ACTIVITIES:
Proceeds from the sale of stock		~~15,000~~-			115,~~566,412~~000
Proceeds from convertible note		50,000			-
Proceeds from convertible notes		77,500			50,000
Proceeds from notes payable		~~250,000~~-			~~151~~250,~~930~~000
Payment on notes payable		(7415,~~301~~355	)		(874,~~041~~301	)
Advances from (payments to) related parties		211,989			31,810
Cash overdraft		(6,624	)		(5,061	)
Payments of due to stockholder		-			(419,084	)
Advances from (payments to) related parties		159,293			211,989
Proceeds from preferred stock subscriptions		-			652,462
Net cash provided by financing activities		214,814			447,627
Net cash provided by financing activities		452,688			1,975,489
NET INCREASE (DECREASE) IN CASH		-			-
NET INCREASE IN CASH		419,702			(130,882	)
CASH, BEGINNING BALANCE		-			-
CASH, BEGINNING BALANCE		54,862			185,744
CASH, ENDING BALANCE	$	-		$	-
CASH, ENDING BALANCE	$	474,564		$	54,862
CASH PAID FOR:
Interest	$	-		$	~~29,177~~-
Income taxes	$	-		$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Note payable to finance acquisition	$	-		$	431,070
Convertible notes and accrued interest converted to common stock	$	87,106		$	-
Note payable forgiven	$	-		$	1,420,000
Convertible note issued for liabilities	$	-		$	118,685
Convertible note issued for liabilities	$	118,685		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-56

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

Accelera Innovations, Inc., formerly Accelerated Acquisitions IV, Inc. (~~“Accelera” or~~ the “Company”) was incorporated in the State of Delaware on April 29, 2008 for the purpose of raising capital intended to be used in connection with its business plan which may include a possible merger, acquisition or other business combination with an operating business.

On June 13, 2011, Synergistic Holdings, LLC (“~~Purchaser~~Synergistic”) agreed to acquire 17,000,000 shares of the Company’s common stock, par value $0.0001 per share. At the same time, Accelerated Venture Partners, LLC agreed to tender 3,750,000 of ~~their~~its 5,000,000 shares of the Company’s common stock, par value $0.0001 per share, for cancellation. Following these transactions, ~~Synergistic~~ ~~Holdings,~~Synergistic ~~LLC~~ owned 93.15% of the Company’s 18,250,000 issued and outstanding shares of common stock, par value $0.0001 ~~and~~per share, and the interest of Accelerated Venture Partners, LLC was reduced to approximately 6.85% of the total issued and outstanding shares. ~~Simultaneously~~ Concurrent with the share purchase, Timothy Neher resigned from the Company’s Board of Directors and John Wallin ~~was~~ ~~simultaneously~~was appointed to the Company’s Board of Directors. Such action represented a change of control of the Company.

On October 18, 2011, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of Delaware and changed its name from Accelerated Acquisition IV, Inc. to Accelera Innovations, Inc.

~~Accelera~~The Company is a healthcare service company which is focused on acquiring companies primarily in the post-acute care patient services ~~and~~ and information technology services industries. The Company ~~has~~currently ~~acquired~~owns ~~Behavioral Health Care Associates, Ltd. (“BHCA”) (See Note 18) and~~ SCI Home Health, Inc. (d/b/a Advance Lifecare Home Health) (“SCI”), which offers personal care to patients in the Chicago, Illinois area.

The accompanying consolidated financial statements and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION - ~~Accelera~~The Company operates companies in the personal health care industry. ~~Accelera~~The Company operates out of ~~three~~one service ~~centers~~ center serving ~~counties in~~ the Chicago, Illinois area. The consolidated financial statements ~~include~~for the year ended December 31, 2016 include the accounts of ~~Accelera~~the Company and its 100% owned ~~subsidiaries,~~subsidiary ~~Behavioral Health and~~ SCI, ~~Home Health.~~ Significant intercompany accounts and transactions have been eliminated in consolidation.

USE OF ESTIMATES –- The preparation of ~~unaudited condensed~~ consolidated ~~interim~~ financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Significant estimates in these financial statements include allowance for doubtful accounts, the valuation of intangibles, valuation allowance for deferred taxes, estimated useful life of property and equipment and the fair value of stock and options issues for services and interest.

CASH - All cash is maintained with a major financial institution in the United States. Deposits with this bank may exceed the amount of insurance provided on such deposits. Temporary cash investments with an original maturity of three months or less are considered to be cash equivalents. The Company had no cash equivalents as of December 31, ~~2015~~2016 and ~~2014~~2015, respectively. The Company has not suffered any credit issues when deposits have exceeded the amount of insurance provided for such deposits.

ACCOUNTS RECEIVABLE – Accounts receivable are recorded at estimated value, net of allowance for doubtful accounts. Accounts receivable are not interest bearing. The allowance for doubtful accounts is based upon management’s best estimate and past collection experience. Uncollectible accounts are charged off when all reasonable efforts to collect the accounts have been exhausted.F-7

F-6

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

~~PROPERTY~~ACCOUNTS ~~AND~~RECEIVABLE ~~EQUIPMENT~~- –Accounts ~~Property~~receivable ~~and~~are ~~equipment~~recorded ~~is stated~~ at ~~cost.~~estimated ~~Depreciation~~value, isnet ~~provided~~of onallowance afor ~~straight~~doubtful ~~line~~accounts. ~~basis~~Accounts ~~over the estimated~~receivable ~~useful~~are ~~lives~~not ofinterest ~~the assets~~bearing. ~~Maintenance~~The ~~and~~allowance ~~repairs~~for ~~are~~doubtful ~~charged~~accounts tois ~~expense~~based asupon ~~incurred;~~management’s ~~major~~best ~~renewals~~estimate and ~~betterments~~past ~~are capitalized.~~collection ~~When~~experience. ~~items~~For ofaccounts ~~property~~greater ~~and~~than ~~equipment~~180 ~~are sold or retired~~days, the ~~related~~Company ~~cost~~carries ~~and~~a ~~accumulated~~100% ~~depreciation~~allowance. ~~are~~Uncollectible ~~removed~~accounts ~~from~~are ~~the~~charged ~~accounts,~~off when ~~and~~all ~~any~~reasonable ~~gain~~efforts orto ~~loss~~collect isthe ~~included~~accounts inhave ~~income~~been exhausted.

~~DERIVATIVE~~PROPERTY ~~FINANCIAL~~AND ~~INSTRUMENTS~~EQUIPMENT –- ~~The~~Property ~~Company~~and ~~evaluates~~equipment ~~all~~is ofstated ~~its~~at ~~agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives~~cost. ~~For~~Depreciation ~~derivative financial instruments that are accounted for as liabilities, the derivative instrument~~ is ~~initially~~provided ~~recorded~~on ata ~~its fair value and is then re~~straight-~~valued~~line atbasis ~~each~~over ~~reporting~~the ~~date, with changes in~~estimated ~~the~~useful ~~fair~~lives ~~value~~of ~~reported in~~ the ~~statements of operations~~assets. ~~For~~Maintenance ~~stock-based~~and ~~derivative~~repairs ~~financial~~are ~~instruments,~~charged ~~the Company uses the Black-Scholes-Merton option pricing model~~ to ~~value~~expense ~~the~~as ~~derivative~~incurred; ~~instruments~~major atrenewals ~~inception~~ and onbetterments ~~subsequent~~are ~~valuation dates~~capitalized. ~~The~~When ~~classification~~items of ~~derivative~~property ~~instruments,~~and ~~including~~equipment ~~whether~~are ~~such~~sold ~~instruments should be recorded as liabilities~~ or ~~as equity~~retired, is ~~evaluated at~~ the ~~end~~related ofcost ~~each~~and ~~reporting~~accumulated ~~period.~~depreciation ~~Derivative instrument liabilities~~ are ~~classified~~removed infrom the ~~balance sheet as current~~accounts, orand ~~non-current~~any ~~based~~gain ~~on whether~~ or ~~not~~loss ~~net-cash~~is ~~settlement~~included ofin ~~the derivative instrument could be required within 12 months of the balance sheet date~~income. As of December 31, 2015, the Company’s only derivative financial instrument was an embedded conversion feature associated with convertible notes due to the conversion price being a percentage of the market price of the Company’s common.

~~PREFERRED~~DERIVATIVE ~~STOCK~~FINANCIAL ~~SUBSCRIPTION~~INSTRUMENTS ~~PAYABLE~~- –The ~~During~~Company ~~the~~evaluates ~~years~~all ~~ended~~of ~~December~~its ~~31,~~agreements ~~2014~~to ~~and~~determine ~~2013,~~if ansuch ~~affiliate~~instruments ofhave ~~the~~derivatives ~~Company~~or ~~entered into~~contain ~~subscription~~features ~~agreements~~that ~~with~~qualify 13as ~~investors~~embedded derivatives. ~~Pursuant~~For toderivative ~~the~~financial ~~terms~~instruments ofthat ~~the~~are ~~subscription~~accounted ~~agreements,~~for ~~the~~as ~~affiliate~~liabilities, ~~agreed to issue~~the ~~shares~~derivative ofinstrument ~~the~~is ~~Company’s~~initially 8%recorded ~~Convertible~~at ~~Preferred~~its ~~Stock~~fair ~~that~~value itand ~~was~~is ~~authorized~~then tore-valued ~~issue~~at aseach ofreporting ~~May 7~~date, ~~2015.~~with Inchanges ~~exchange,~~in the ~~Company~~fair ~~received~~value ~~aggregate~~reported ~~proceeds~~in ~~from~~ the ~~investors~~statements of ~~$652,462~~operations. ~~Accordingly~~For stock-based derivative financial instruments, the Company isuses ~~obligated~~the Black-Scholes-Merton option pricing model to ~~issue~~value anthe ~~aggregate of~~derivative ~~198,473~~instruments ~~shares~~at ofinception 8%and ~~Convertible~~on ~~Preferred~~subsequent ~~Stock~~valuation todates. ~~the~~The ~~investors~~classification ~~with~~of derivative ainstruments, ~~stated~~including ~~value~~whether ofsuch ~~$4.00~~instruments ~~per~~should ~~share~~be orrecorded anas ~~aggregate~~liabilities ~~of $793~~or as equity,~~892.~~ ~~The~~is ~~net~~evaluated ~~proceeds~~at the end of ~~$652,462~~each ~~have~~reporting ~~been~~period. ~~received~~Derivative byinstrument orliabilities onare ~~behalf~~classified ofin the ~~Company~~balance ~~and~~sheet ~~recorded~~ as ~~preferred~~current ~~stock~~or ~~subscription~~non-current ~~payable~~based ~~net~~on ofwhether ~~$141,430~~or ofnot ~~original~~net-cash ~~issue~~settlement ~~discount~~of ~~related~~the toderivative ~~such~~instrument ~~offering~~could ~~which~~be ~~amount~~required ~~was~~within ~~expensed.~~12 ~~Upon~~months ~~obtaining the Certificate~~ of ~~Designation for~~ the 8%balance ~~Convertible~~sheet date. ~~Preferred~~As ~~Stock~~of onDecember ~~May 7~~31, 2016 and 2015, the Company’s ~~has~~only ~~included~~derivative ~~the~~financial ~~aggregate~~instrument ~~amount~~was ofan ~~$793,892~~embedded conversion feature ofassociated ~~preferred~~with ~~stock~~convertible asnotes ~~part~~due ofto ~~stockholders’~~the ~~equity.~~conversion ~~Prior~~price tobeing ~~May~~a 7,percentage ~~2015,~~of the ~~preferred~~market ~~stock~~price ~~subscription~~of ~~payable~~the ~~was~~Company’s ~~included~~common ~~as a current liability~~stock.

PREFERRED STOCK SUBSCRIPTION PAYABLE - During the years ended December 31, 2014 and 2013, an affiliate of the Company entered into subscription agreements with 13 investors. Pursuant to the terms of the subscription agreements, the affiliate agreed to issue shares of the Company’s 8% Convertible Preferred Stock that it was authorized to issue as of May 7, 2015. In exchange, the Company received aggregate proceeds from the investors of $652,462. Accordingly, the Company is obligated to issue an aggregate of 198,473 shares of 8% Convertible Preferred Stock to the investors with a stated value of $4.00 per share or an aggregate of $793,892. The net proceeds of $652,462 have been received by or on behalf of the Company and recorded as preferred stock subscription payable net of $141,430 of original issue discount related to such offering which amount was expensed. Upon obtaining the Certificate of Designation for the 8% Convertible Preferred Stock on May 7, 2015, the Company has included the aggregate amount of $793,892 of preferred stock as part of stockholders’ equity. Prior to May 7, 2015, the preferred stock subscription payable was included as a current liability.

COMMON STOCK - The Company records common stock issuances when all of the legal requirements for the issuance of such common stock have been satisfied.

REVENUE RECOGNITION - Revenue related to services and administrative support services is recognized ratably at the time services have been performed and pre-approved by payer. Gross service revenue is recorded in the accounting records on an accrual basis at the provider’s established rates, regardless of whether the health care entity expects to collect that amount. The Company will reserve a provision for contractual adjustment and discounts and deduct from gross service revenue. The Company believes that recognizing revenue at the time the services have been performed because the Company’s revenue policies meet the following four criteria in accordance with ~~ASC~~Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-10-S25, Revenue Recognition: Overall, (i) persuasive evidence that arrangement exists, (ii) services has occurred, (iii) the price is fixed and determinable and (iv) collectability is reasonably assured. The Company reports revenues net of any sales, use and value added taxes.

COST OF REVENUES - Costs of revenues are comprised of fees paid to members of the Company’s medical staff, other direct costs including transcription, film and medical record obtainment and transportation; and other indirect costs including labor and overhead related to the generation of revenues.

~~ADVERTISING COSTS~~ F- ~~The Company’s policy regarding advertising is to expense advertising when incurred.~~8

F-7

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

ADVERTISING COSTS - The Company’s policy regarding advertising is to expense advertising when incurred.

INCOME TAXES - The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The adoption had no effect on the Company’s consolidated financial statements.

STOCK BASED COMPENSATION - The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of the Company’s common stock at the fair market value at the time of grant. Stock-based compensation cost to employees is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718., Compensation – Stock Compensation. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock to non-employees and other parties are accounted for in accordance with ~~the~~ ASC 505, Equity, at the measurement date. For awards with service or performance conditions, the Company generally ~~recognize~~recognizes expense over the service period or when the performance condition is met.

LOSS PER SHARE - Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted loss per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and the conversion of notes payable to common stock. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation.

FINANCIAL INSTRUMENTS - ~~FASB Accounting Standards Codification (~~ASC) 820, Fair Value Measurements and Disclosures, ~~(ASC 820)~~ defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

●	Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

●	Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

●	Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2015. These financial instruments include stock options granted to the officers in 2015 and 2014.F-9

F-8

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2016. These financial instruments include stock options granted to the officers in 2016 and 2015.

The Company uses Level 2 inputs for its valuation methodology for its derivative liability as its fair value was determined by using the Black-Scholes-Merton pricing model based on various assumptions. The Company’s derivative liability is adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives.

At December 31, 2016 and 2015, the Company identified the following liability that is required to be presented on the balance sheet at fair value (see Note 117):

	Fair Value		Fair Value Measurements at
	As of		December 31, 2016
Description	December 31, 2016		Using Fair Value Hierarchy
			Level 1		Level 2		Level 3
Derivative liability - conversion feature	$	149,269		-		149,269		-

Total	$	149,269		-		149,269		-

	Fair Value		Fair Value Measurements at
	As of		December 31, 2015
Description	December 31, 2015		Using Fair Value Hierarchy
			Level 1		Level 2		Level 3
Derivative liability - conversion feature	$	302,580		-		302,580		-

Total	$	302,580		-		302,580		-

RECENT ACCOUNTING PRONOUNCEMENTS

In January ~~2015~~2017, the FASB issued Accounting Standards Update (“ASU”) ~~No. 2015~~2017-01, Business Combinations (~~Subtopic~~Topic ~~225-20~~805) -Clarifying the ~~Income~~Definition ~~Statement~~of -a ~~Extraordinary and~~Business. ~~Unusual~~The ~~Items.~~amendments ~~ASU~~in ~~2015-01~~this ~~eliminates~~update clarify the ~~concept~~definition of ~~an extraordinary item from GAAP. As~~ a ~~result,~~business anwith ~~entity~~the ~~will~~objective noof ~~longer~~adding beguidance ~~required~~ to ~~segregate~~assist ~~extraordinary~~entities ~~items~~with ~~from~~evaluating ~~the~~whether ~~results~~transactions ofshould ~~ordinary~~be ~~operations,~~accounted tofor ~~separately~~as ~~present~~acquisitions anor ~~extraordinary~~disposals ~~item~~of assets onor ~~its~~businesses. ~~income~~The ~~statement,~~definition ~~net~~ of ~~tax,~~a ~~after~~business ~~income~~affects ~~from~~many ~~continuing~~areas ~~operations~~of oraccounting toincluding ~~disclose~~acquisitions, ~~income~~disposals, ~~taxes~~goodwill, and ~~earnings-per-share~~ ~~data~~consolidation. ~~applicable~~The toguidance anis ~~extraordinary~~effective ~~item.~~for ~~However,~~interim ~~ASU~~and ~~2015-01~~annual ~~will~~periods ~~still~~beginning ~~retain~~after ~~the~~December ~~presentation~~15, 2017 and ~~disclosure~~should ~~guidance~~be ~~for~~applied ~~items~~prospectively ~~that~~on ~~are~~or ~~unusual~~after inthe ~~nature~~effective ~~and occur infrequently~~date. ~~ASU~~The ~~2015-01~~Company is ~~effective~~in ~~for~~the ~~periods~~process ~~beginning~~of ~~after~~evaluating ~~December~~the ~~15,~~impact ~~2015. The adoption~~ of ASU ~~2015~~2017-01 ~~is not expected to have a material effect~~ on ~~the~~its ~~Company’s consolidated~~ financial statements. ~~Early adoption is permitted.~~

In ~~February,~~November ~~2015~~2016, the FASB issued ~~Accounting Standards Update (~~ASU) ~~No. 2015~~2016-0218, ~~Consolidation~~Statement of Cash Flows (Topic ~~810~~230): ~~Amendments~~Restricted toCash, ~~the~~which requires restricted ~~Consolidation~~cash ~~Analysis.~~to ~~ASU~~be ~~2015-02~~presented ~~provides~~with ~~guidance~~cash onand ~~the~~cash ~~consolidation~~equivalents ~~evaluation~~on ~~for~~the ~~reporting~~statement ~~organizations~~of ~~that~~cash ~~are required~~flows toand ~~evaluate~~disclosure ~~whether~~of ~~they~~how ~~should~~the ~~consolidate~~statement ~~certain~~of ~~legal~~cash flows ~~entities~~reconciles ~~such~~to asthe ~~limited~~balance ~~partnerships,~~sheet ~~limited~~if ~~liability~~restricted ~~corporations, and~~cash ~~securitization~~is ~~structures~~shown ~~(collateralized~~separately ~~debt~~from ~~obligations,~~cash ~~collateralized~~and ~~loan~~cash ~~obligations,~~equivalents ~~and~~on ~~mortgage-backed~~the ~~security transactions).~~balance sheet. ASU ~~2015~~2016-0218 is effective for interim and annual periods beginning after December 15, ~~2015.~~2017, ~~The~~with early adoption ofpermitted. ~~ASU~~The Company ~~2015-02~~ is ~~not~~in ~~expected to~~the ~~have~~process aof ~~material~~evaluating ~~effect on~~ the ~~Company’s~~impact ~~consolidated~~of ~~financial~~ASU ~~statements.~~2016-18 ~~Early~~on ~~adoption~~its isfinancial ~~permitted~~statements.

In September, 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805). Topic 805 requires that an acquirer retrospectively adjust provisional amounts recognized in a business combination, during the measurement period. To simplify the accounting for adjustments made to provisional amounts, the amendments in the Update require that the acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined. The acquirer is required to also record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. In addition an entity is required to present separately on the face of the income statement or disclose in the notes to the financial statements the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years beginning December 15, 2015. The adoption of ASU 2015-016 is not expected to have a material effect on the Company’s consolidated financial statements.

In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. The new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. This update is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. The Company does not anticipate the adoption of this ASU will have a significant impact on its consolidated financial position, results of operations, or cash flows.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The guidance in ASU No. 2016-02 supersedes the lease recognition requirements in ASC Topic 840, Leases (FAS 13). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the effect this standard will have on its consolidated financial statements.

F-9

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2015 AND 2014

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the United States Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

RECLASSIFICATIONS - Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows.

NOTE 3 - BALANCE SHEET INFORMATION

ACCOUNTS RECEIVABLE, NET

Accounts receivable, net at December 31, 2015 and 2014 consist of the following:

	2015		2014
Accounts receivable		-		757,896
Less allowance for doubtful accounts		-		(152,100	)
	$	-	$	605,796

PROPERTY AND EQUIPMENT, NET

Property and equipment, net at December 31, 2015 and 2014 consist of the following:

	2015			2014
Furniture and fixtures	$	3,940		$	2,150
Office equipment		5,641			4,824
		9,581			6,974
Less accumulated depreciation		(692	)		(593	)
	$	8,889		$	6,381

Depreciation expense for the years ended December 31, 2015 and 2014 was $1,259 and $593, respectively.

NOTE 4 - GOING CONCERN

The accompanying unaudited condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern. The Company has had minimal revenue since inception and had an accumulated deficit of $63,927,121 as of December 31, 2015. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to add profitable operating companies and to achieve a level of profitability. The Company intends on financing its future development activities and its working capital needs largely from the sale of public equity securities with some additional funding from other traditional financing sources, including term notes until such time that funds provided by operations are sufficient to fund working capital requirements.

The events or circumstances that may prevent the accomplishment of our business objectives, include, with limitation, (i) the fact that, if the Company does not raise a minimum of $30,000,000 within the next 12 months to pay debts incurred in connection with the Company’s acquisition of BHCA, SCI, Traditions Home Care, Inc., Grace Home Health Care, Inc. and Watson Health Care, Inc. and Affordable Nursing, Inc.

F-10

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

~~The~~In ~~unaudited~~October ~~condensed~~2016, ~~consolidated~~the ~~interim~~FASB ~~financial~~issued ~~statements~~ASU of2016-16, ~~the~~Income ~~Company~~Taxes do(Topic ~~not~~740): ~~include~~Intra-Entity ~~any~~Transfer ~~adjustments~~of ~~relating~~Assets toOther ~~the~~than ~~recoverability~~Inventory, ~~and~~which ~~classification~~requires the recognition of ~~recorded~~the ~~assets~~income tax consequences of an intra-entity transfer of an asset, orother than inventory, when the ~~amounts~~transfer occurs. ASU 2016-16 is effective for interim and ~~classifications~~annual ofperiods ~~liabilities~~beginning ~~that~~after ~~might~~December be15, ~~necessary~~2018, ~~should~~with ~~the~~early ~~Company~~adoption bepermitted. ~~unable~~The toCompany ~~continue~~is asin athe ~~going~~process ~~concern~~of evaluating the impact of ASU 2016-16 on its financial statements.

~~NOTE~~In 5August 2016, the FASB issued ASU 2016-15, ~~DISCONTINUED~~Statement ~~OPERATIONS~~of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance for targeted changes with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. ASU 2016-15 is effective for interim and annual periods beginning after December 15, 2017, with early adoption permitted. The Company is in the process of evaluating the impact of ASU 2016-15 on its statements of cash flows.

OnIn ~~December~~March 312016, ~~2014~~the FASB issued ASU 2016-09, ~~the~~Stock ~~Company~~Compensation ~~entered~~(Topic ~~into~~718), aImprovements ~~Separation~~to ~~Agreement~~Employee ~~with~~Share-Based AtPayment ~~Home~~Accounting. ASU ~~Health~~2016-09, ~~Services~~which ~~LLC~~amends several aspects of accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and ~~All~~statutory ~~Staffing~~tax ~~Services~~withholding requirements, ~~LLC~~ ~~(“LLC’s)~~and toclassification ~~terminate~~in the ~~purchase~~statement ~~agreement~~of ~~entered~~cash ~~into~~flows. ASU on2016-09 is effective for fiscal years beginning after December 1315, ~~2013.~~2016 ~~The~~and ~~historical~~interim ~~financial~~periods ~~results~~within annual periods beginning ofafter ~~the~~December ~~LLC’s~~15, ~~are~~2016, ~~reflected~~with inearly ~~the~~adoption permitted. The Company’s ~~unaudited~~is ~~condensed~~in ~~consolidated~~the ~~interim~~process ~~financial~~of ~~statements~~evaluating ~~and~~the ~~footnotes as~~impact ~~discontinued~~of ~~operations~~ASU ~~for~~2016-09 on ~~all~~its ~~periods~~financial ~~presented~~statements.

~~The~~In ~~following~~February ~~table~~2016, ~~displays~~the ~~summarized~~FASB ~~activity~~issued inASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities on the ~~Company’s~~balance ~~unaudited~~sheet ~~condensed~~and ~~consolidated~~requires ~~statements~~expanded ofdisclosures ~~operations~~about leasing arrangements. ASU 2016-02 is effective for ~~discontinued~~fiscal ~~operations~~years ~~during~~beginning ~~the~~after ~~year~~December ~~ended~~15, 2018 and interim periods in fiscal years beginning after December 3115, ~~2014~~2018, with early adoption permitted. The Company is in the process of evaluating the impact of ASU 2016-02 on its financial statements.

Net sales	$	741,406
Operating loss		(286,223	)
Loss before income taxes		(221,766	)
Income tax expense		-
Loss from discontinued operations, net of tax		(221,766	)

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. ASU 2014-15 requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and interim periods thereafter. Early adoption is permitted. The Company is in the process of evaluating the impact of ASU 2014-15 on its financial statements and disclosures.

AsIn ~~for~~May 2014, the ~~years~~FASB ~~ended~~issued ~~December~~ASU 312014-09, ~~2015,~~Revenue ~~there~~from ~~was~~Contracts nowith ~~activity~~Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the ~~Company’s~~contract. ~~unaudited~~The ~~condensed~~ASU ~~consolidated~~also ~~statement~~will require additional disclosure about the nature, amount, timing and uncertainty of ~~operations~~revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a ~~result~~cumulative-effect adjustment as of the ~~Separation~~date ~~Agreement~~of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on its financial statements and disclosures.

NOTE 6 - ACQUISITION – BEHAVIORAL HEALTH CARE ASSOCIATES, LTD.

On November 20, 2013, Accelera executed a Stock Purchase Agreement (the “SPA”) and its wholly owned subsidiary, Accelera Healthcare Management Service Organization LLC (“Accelera HMSO”), executed an Operating Agreement with Blaise J. Wolfrum, M.D. and Behavior Health Care Associates, Ltd. (“BHCA”). Accelera acquired 100% of the 100,000 issued and outstanding shares of BHCA from Dr. Wolfrum. Accelera HMSO as a wholly owned subsidiary of Accelera will operate BHCA in accordance with the Operating Agreement. The SPA was amended as of May 30, 2014 and further amended on May 31, 2015.

Pursuant the SPA, the Company agreed to pay to Dr. Wolfrum a purchase price of $4,550,000 for his shares of BHCA, of which $1,000,000 was payable on September 30, 2015, $750,000 is payable on November 30, 2015, and $2,800,000 is payable on December 31, 2015. Prior to Dr. Wolfram’s receipt of the $1,000,000 payment, he has the right to cancel and terminate the SPA. In addition, as consideration for entering into various amendments to the SPA, the Company issued Dr. Wolfrum a total of 50,000 shares of our common stock which the Company agreed to register for resale upon completion of a public offering of its securities. The payment due on September 30, 2015, November 30, 2015 and December 31, 2015 have not been paid and the acquisition loan is currently in default. See Note 18.

NOTE 7 - ACQUISITION – AT HOME AND ALL STAFFING

On December 13, 2013 Accelera entered into a Purchase Agreement with At Home Health Services LLC, All Staffing Services, LLC (together, the “Subject LLCs”) and Rose Gallagher, individually and as Trustee of the Rose M. Gallagher Revocable Trust dated November 30, 1994 (“Gallagher”), pursuant to which Accelera agreed to purchase and Gallagher agreed to sell, all of Gallagher’s interests in the Subject LLCs. The Company also entered into an Operating Agreement with the Subject LLCs.

F-11

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

~~Pursuant~~Management todoes ~~the~~not ~~Purchase~~believe ~~Agreement,~~that ~~Accelera~~any ~~agreed~~recently ~~to pay Gallagher or her assignee of $1~~issued,~~420,000,~~ ~~with~~but ~~the~~not ~~sum~~yet ~~of $500~~effective,~~000~~ ~~within~~accounting ~~ninety (90)~~standards ~~days~~could ofhave the Initial Closing Date, the sum of $420,000 dollars within eight (8) months of the Initial closing Date, the aforementioned payments dates has been verbally extended until the Company receives financing. Furthermore, Accelera shall pay a ~~sum~~material ~~equal~~effect to the Net Accounts Receivable, meaning the amount applicable to the Subject LLCs as of the Initial Closing Date equal to (a) the bank account balances plus (b) accrued accounts receivable balances, plus (c) a proration through the Initial Closing Date of the prepaid expenses, bonds, and licensing fees of the Subject LLCs, plus (d) an amount equal to the security deposit on the ~~lease~~accompanying ~~for~~financial ~~the business address minus (d) the balance of the accounts payables of the Subject LLCs as of the Initial Closing Date~~statements. ~~For the~~As ~~above~~new ~~purposes, the terms accounts receivable and accounts payable shall be determined in accordance with standard~~ accounting ~~principles~~ ~~within~~pronouncements ~~twelve~~are ~~(12) months of the Initial Closing Date and the sum of $500~~issued,~~000~~ ~~dollars within eighteen (18) months of~~ the ~~Initial~~Company ~~Closing~~will ~~Date.~~adopt ~~The~~those ~~Initial~~that ~~Closing~~are ~~Date~~applicable ~~was~~under ~~December 9, 2013,~~ the ~~Final Closing Date is June 12, 2015 at Gallagher’s~~ ~~office in Mokena, IL~~circumstances.

OnRECLASSIFICATIONS ~~December~~- ~~23,~~Certain ~~2014,~~prior ayear ~~Settlement~~amounts ~~Agreement~~have ~~(“Agreement”)~~been ~~was~~reclassified ~~executed~~to ~~between~~conform ~~the Company and its related entities and subsidiaries (“Accelera’’), Geoffrey Thompson, an Individual, and At Home Health Management, LLC, (collectively referred~~ to ~~as “Purchaser’’) and At Home Health Services, LLC, All Staffing Services, LLC and Georgia Peaches, LLC, and~~ the ~~Rose~~current Mperiod presentation. ~~Gallagher~~These ~~Revocable~~reclassifications ~~Trust dated November 30, 1994, and Rose Gallagher individually and as Trustee of the~~had ~~Rose~~no M.impact ~~Gallagher~~on ~~Revocable~~net ~~Trust dated November 30~~earnings, ~~1994,~~financial ~~and~~position ~~Daniel~~or ~~Gallagher,~~cash ~~individually (collectively referred to as “Seller’’)~~flows. ~~The Seller and Purchaser are collectively referred to as the “Parties”.~~

~~The~~NOTE ~~Agreement~~3 ~~indicated~~– ~~that~~BALANCE ~~there~~SHEET was a default under the purchase agreement and employment agreement with Rose M. Gallagher and Daniel Gallagher. The agreement also indicated that the Purchaser failed to pay the promissory note that had been executed with Georgia Peaches, LLC.INFORMATION

~~The~~PROPERTY ~~Parties~~AND to the Agreement agree to among other things to (1) terminate the purchase agreement; (2) terminate the employment agreements with Rose M. Gallagher and Daniel Gallagher; (3) a resolution under the purchase and employment agreements; (4) a resolution of the promissory note with Georgia PeachesEQUIPMENT, ~~LLC; and (5) additional matters as indicated in the Agreement.~~NET

~~The~~Property ~~Parties have agreed to resolve the disputes under the purchase~~ and ~~employment agreements as follows: (1) Seller has previously been issued Stock Certificate Number 1102 for 585~~equipment,~~000~~ ~~shares~~net ofat ~~Accelera~~December ~~Innovations~~31, ~~Inc.~~2016 ~~common~~and ~~stock.~~2015 Byconsist ~~execution~~ of ~~this Agreement, Purchaser irrevocably confirms that~~ the 585,000 shares are fully vested and rightfully owned by Seller and under no circumstance shall be cancelled, rescinded, or otherwise not honored by Purchaser; (2) Purchaser shall issue 500,000 shares each to Rose Gallagher and Daniel Gallagher as consideration under the Employment Agreements; and (3) Purchaser shall execute a term promissory note in the principal amount of $344,507.following:

The Parties have agreed to resolve the disputes under the promissory note to Georgia Peaches, LLC as follows: (1) included in the term promissory note of $344,507 (interest at a rate of 11% per annum shall begin to accrue on this note beginning January 1, 2015 and will be due and payable at time of final payment according to the Payment Schedule of $25,000 on March 1, 2015 and $337,602 on June 1, 2015) is the delinquent principal and interest under the original promissory note with Georgia Peaches, LLC and (2) Purchaser shall issue 10,000 shares to the Rose M. Gallagher Revocable Trust dated November 30, 1994. The Company is in default of the promissory note and has a 90 day cure period. The Company paid $5,000 on April 8, 2015. The Company did not cured the default within the 90 cure period.

	2016			2015

Furniture and fixtures	$	3,940		$	3,940
Office equipment		5,641			5,641
		9,581			9,581
Less accumulated depreciation		(2,692	)		(692	)
	$	6,889		$	8,889

~~NOTE~~Depreciation 8expense -for ~~ACQUISITION~~the –years ~~SCI~~ended ~~HOME~~December ~~HEALTH~~31, ~~INC~~2016 ~~(DBA~~and ~~ADVANCE~~2015 ~~LIFECARE~~was ~~HOME~~$2,000 ~~HEALTH)~~and $1,259, respectively.

OnNOTE ~~August~~4 ~~25,~~– ~~2014,~~GOING the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with SCI Home Health, Inc. (d/b/a Advance Lifecare Home Health) (“SCI”), Ethel dela Cruz, Virgilia Avila, Ma Lourdes Reyes Celicious, Cristina Soriano, Michelle Cartas and Jimmy Lacaba (collectively, the “Sellers”), pursuant to which the Company agreed to purchase, and the Sellers agreed to sell, all their SCI shares, collectively representing all of the outstanding shares of common stock of SCI, for an aggregate adjusted purchase price of $431,070 (the “Stock Purchase”).CONCERN

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred a net loss for the year ended December 31, 2016 of $1,925,294 and had an accumulated deficit of $61,612,829 as of December 31, 2016. In view of these matters, the Company’s ability to continue as a going concern is dependent upon the Company’s ability to add profitable operating companies and to achieve a level of profitability. The Company intends on financing its future development activities and its working capital needs largely from the sale of equity securities with some additional funding from other traditional financing sources, including term notes, until such time that funds provided by operations are sufficient to fund working capital requirements.

The Company’s only operating subsidiary is SCI. Revenues from SCI have significantly decreased primarily due to the sudden departure of the administrator of SCI. The Company has transitioned this position to a new administrator and filed these changes with the IDPH (Illinois Department of Public Health). There are claims to be processed and invoiced when IDPH approves; through the uniform process and the new SCI administrator, the Company expects this to be resolved in the near future.

The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

F-12

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

~~Pursuant~~NOTE to5 ~~the~~– ~~terms~~SHORT-TERM ofNOTES the Stock Purchase Agreement, the purchase price was paid as follows: (i) $20,000 via wire transfer concurrently with execution of the Stock Purchase Agreement, and (ii) $430,000 via wire transfer upon approval of the required license transfer by the Illinois Department of Public Health. Pursuant to the Stock Purchase Agreement, revenues generated by SCI, but received by the Company, after the closing of the Stock Purchase will belong to SCI, and SCI agreed to reimburse the Company for expenses generated by SCI after the closing of the Stock Purchase. The Stock Purchase Agreement contains customary representations and warranties and is subject to certain events of default.PAYABLES

~~NOTE~~Short-term 9notes -payable ~~SHORT-TERM~~at ~~NOTES~~December ~~PAYABLES~~31, 2016 and 2015 consisted of the following:

Short-term notes payable at December 31, 2015 and 2014 consisted of the following:

	2016		2015

At Home and All Staffing acquisition note payable (1)		344,507		344,507
AOK Property Investments (2)		525,000		525,000
Note dated May 28, 2015 for $35,000; daily payment of $184.73 for 252 days		16,659		32,014
	$	886,166	$	901,521

	2015		2014
At Home and All Staffing acquisition note payable (See Note 7)		344,507		344,507
AOK Property Investments (1)		525,000		500,000
Note dated May 28, 2015 for $35,000; daily payment of $184.73 for 252 days		32,014		-
	$	901,521	$	844,507

(1) The Company entered into a $344,507 promissory note (the “Trust Note”) with the Rose. M Gallagher Revocable Trust (the “Trust”) in conjunction with a settlement agreement dated December 23, 2014. The Trust Note bears interest at 11.0% per annum. The first payment of $25,000 was due on March 1, 2015, with the final principal and interest payment due on June 1, 2015. The Company is in default of the Trust Note and has a 90-day cure period. The Company paid $5,000 on April 8, 2015.

~~(1)~~If ~~The~~an ~~Company~~event ~~entered~~of ~~into~~default aunder ~~$344~~the Trust Note occurs,~~507~~ ~~promissory~~the ~~note~~Trust (may accelerate the “Trust Note”)’s ~~with~~maturity date so that the ~~Rose.~~unpaid principal Mamount, ~~Gallagher~~together ~~Revocable~~with ~~Trust (“Trust”)~~accrued interest, is immediately due in ~~conjunction~~its ~~with~~entirety. In addition, the ~~Settlement~~Company ~~Agreement~~promised ~~(see~~to ~~Note~~pay $1,000 ~~7).~~dollars ~~The~~as consideration for costs of collection of the Trust Note, ~~bears~~including ~~interest~~but atnot ~~11.0%~~limited ~~per~~to ~~annum.~~attorneys’ fees ~~The~~paid ~~first~~or ~~payment~~incurred on account of ~~$25~~such collection,~~000~~ iswhether ~~due~~or onnot ~~March~~suit 1,is ~~2015.~~filed ~~The~~with ~~final~~respect ~~principal~~thereto and ~~interest~~whether ~~payment~~such cost or expense is ~~due~~paid onor ~~June~~incurred, 1or to be paid or incurred, ~~2015~~prior to or after the entry of judgment. ~~The~~Pursuant ~~entire outstanding~~to ~~principal~~the ~~balance~~terms of the Trust Note, an ~~may~~event beof ~~prepaid~~default atoccurs if (i) the Company fails to make any ~~time,~~payment inrequired ~~whole~~by orthe inTrust ~~part~~Note when due, ~~without~~(ii) ~~premium~~the Company fails to observe or ~~penalty~~perform any covenant, ~~and~~condition ~~the interest~~or ~~accrued~~agreement onunder the ~~remaining~~Trust ~~principal~~Note, ~~balance~~(iii) ~~shall~~a beproceeding ~~adjusted~~with ~~accordingly.~~respect ~~The~~to the Company is incommenced ~~default~~for of the ~~Trust~~benefit ~~Note and~~of ~~has~~creditors, aincluding 90but ~~day~~not ~~cure~~limited ~~period.~~to ~~The~~any ~~Company~~bankruptcy ~~paid~~or ~~$5,000~~insolvency onlaw; ~~April~~or 8,(iv) ~~2015~~the Company becomes insolvent.

If an event of default under the Trust Note occurs the Trust may accelerate the Trust Note’s maturity date so that the unpaid principal amount, together with accrued interest, is immediately due in its entirety. In addition, the Company promises to pay one thousand dollars as consideration for costs of collection of the Trust Note, including but not limited to attorneys’ fees, paid or incurred on account of such collection, whether or not suit is filed with respect thereto and whether such cost or expense is paid or incurred, or to be paid or incurred, prior to or after the entry of judgment. Pursuant to the terms of the Trust Note, an event of default occurs if (i) the Company fails to make any payment required by the Trust Note when due, (ii) the Company fails to observe or perform any covenant, condition or agreement under the Trust Note, (iii) a proceeding with respect to the Company is commenced for the benefit of creditors, including but not limited to any bankruptcy or insolvency law; or (iv) the Company becomes insolvent.

(2) On October 1, 2014, AOK Property Investments LLC (“AOK”), a third party lender, lent the Company and its subsidiary, SCI, an aggregate of $500,000. In consideration of AOK’s delivery of an aggregate of $500,000 to the Company and ALM, the Company and ALM executed and delivered a promissory note (the “AOK Note”) in favor of AOK in the aggregate principal amount of $500,000. The AOK Note is due on January 15, 2015 and bears interest in the amount of 500,000 shares of the Company’s common stock, which interest is due and payable on or before January 15, 2015. If the Company and ALM fail to pay any portion of principal or interest when due, interest will continue to accrue and be payable to AOK at the rate of 1,667 shares of Company common stock per day until all principal and accrued interest is fully paid. On July 10, 2015, the Company and AOK entered in an amended note agreement whereby AOK loaned the Company an additional $25,000 and extended the due date of the note to December 31, 2015, and the Company agreed to issue an additional 500,000 shares of common stock for failing to pay the principal and interest on the loan when originally due. The Company recorded the issuance of 500,000 shares of common stock to AOK at a value of $1,360,907. The loan was not repaid on its extended due date and is currently in default.

F-13

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

If(2) On October 1, 2014, AOK Property Investments LLC (“AOK”), a third party lender, lent the Company and its subsidiary, Advanced Life Management, LLC (“ALM”) , an ~~event~~aggregate of ~~default~~$500,000. ~~under~~In ~~the~~consideration of AOK’s delivery ~~Note~~of ~~occurs~~an ~~AOK~~aggregate ~~may~~of ~~accelerate~~$500,000 to the Company and ALM, the Company and ALM executed and delivered a promissory note (the “AOK Note’s”) ~~maturity~~in ~~date~~favor soof ~~that~~AOK in the ~~unpaid~~aggregate principal amount, ~~together~~of ~~with~~$500,000. ~~accrued~~The ~~interest,~~AOK isNote ~~immediately~~was due inon ~~its~~January ~~entirety.~~15, ~~Pursuant~~2015 and tobears interest in the ~~terms~~amount of 500,000 shares of the ~~AOK~~Company’s ~~Note~~common stock, anwhich ~~event~~interest ofwas due and payable on ~~default~~or ~~occurs~~before ifJanuary ~~(i)~~15, 2015. If the Company orand ALM ~~fails~~fail to ~~make~~pay any ~~payment~~portion ~~required~~of byprincipal ~~the~~or ~~AOK~~interest ~~Note~~ when due, ~~(ii)~~interest ~~the~~will ~~Company or SCI~~continue ~~voluntarily~~to ~~dissolves~~accrue orand ~~ceases~~be payable to ~~exist~~AOK at the rate of 1,667 orshares ~~any~~of ~~final~~Company ~~and~~common ~~non-appealable~~stock ~~order~~per orday ~~judgment~~until all principal and accrued interest is ~~entered~~fully ~~against~~paid. On July 10, 2015, the Company ~~or SCI~~and ~~ordering~~AOK ~~its~~entered ~~dissolution,~~in ~~(iii)~~an amended note agreement whereby AOK loaned the Company oran ~~ALM~~additional $25,000 ~~fails~~and toextended ~~pay,~~the ~~becomes~~due ~~insolvent~~date orof ~~unable~~the note to ~~pay~~December 31, or2015, ~~admits~~and inthe ~~writing an~~Company ~~inability~~agreed to ~~pay~~issue ~~its~~an ~~debts~~additional as500,000 ~~they~~shares of ~~become~~common ~~due,~~stock orfor ~~makes~~failing ato ~~general~~pay ~~assignment~~the ~~for~~principal ~~the~~and ~~benefit~~interest ofon ~~creditors;~~the orloan ~~(iv)~~when aoriginally ~~proceeding with~~due. ~~respect~~The toCompany recorded the ~~Company~~issuance of or500,000 ~~ALM~~shares isof ~~commenced~~common ~~for~~stock ~~the~~to ~~benefit~~AOK at a value of ~~creditors~~$1,360,907. ~~including~~The ~~but~~loan was not ~~limited~~repaid toon ~~any~~its ~~bankruptcy~~extended ordue ~~insolvency~~date and is currently ~~law~~in default.

AIf ~~portion~~an event of default under the ~~proceeds~~AOK ofNote occurs, AOK may accelerate the ~~loan~~AOK ~~from~~Note’s maturity date so that the unpaid principal amount, together with accrued interest, is immediately due in its entirety. Pursuant to the terms of the AOK ~~was~~Note, ~~used~~an byevent of default occurs if (i) the Company or ALM fails to ~~fund~~make any payment required by the ~~Stock~~AOK ~~Purchase~~Note when due, (~~see~~ii) ~~Note~~the 8Company or SCI voluntarily dissolves or ceases to exist, or any final and non-appealable order or judgment is entered against the Company or SCI ordering its dissolution, (iii) the Company or ALM fails to pay, ~~which~~becomes ~~closed~~insolvent onor unable to pay, or admits in writing ~~October~~an 7inability to pay its debts as they become due, ~~2014~~or makes a general assignment for the benefit of creditors; or (iv) a proceeding with respect to the Company or ALM is commenced for the benefit of creditors, including but not limited to any bankruptcy or insolvency law.

NOTE 106 -– CONVERTIBLE NOTES

OnConvertible ~~August~~notes ~~28,~~at ~~2015,~~December ~~the Company issued a convertible note to an investor that provides for a maximum borrowing of $250~~31,~~000.~~ ~~During the~~2016 ~~2015, the Company borrowed $55,556 under this convertible note. The convertible note (i) is unsecured, (ii) contains a 10% original issue discount (iii) is interest free for the first 90 days~~ and ~~12%~~2015 ~~per~~consist ~~annum thereafter, and (iv) is due on August 28, 2017. The outstanding balance~~ of ~~under this convertible note is convertible at any time at~~ the option of the investor into shares of the Company’s common stock that is determined by dividing the amount to be converted by 60% of the lowest trading price in the 25 trading days prior to the conversion.following:

On December 16, 2015, the Company issued a convertible note payable in the amount of $118,685. The convertible note (i) is unsecured, (ii) bears interest at 8% per annum, and (iii) is due on October 11, 2016. The outstanding balance of under this convertible note is convertible at any time at the option of the holder into shares of the Company’s common stock that is determined by dividing the amount to be converted by 50% of the average of the lowest trading prices during the 10 trading days prior to the conversion.

	2016			2015
Convertible note dated August 28, 2015; interest of $6,667 due after 90 days; due August 28, 2017; convertible into shares of common stock at the lesser of $1.00 or 60% of the lowest trading price 25 days prior to conversion.	$	-		$	55,556
Convertible note dated December 16, 2015; non-interest bearing; convertible into shares of common stock at 50% of the market price on the date of conversion.		118,684			118,684
Convertible note dated March 10, 2016; interest of $3,333 due after 90 days; due August 28, 2017; convertible into shares of common stock at the lesser of $1.00 or 60% of the lowest trading price 25 days prior to conversion.		9,363			-
Convertible note dated May 5, 2016; interest at 8% per annum; due May 5, 2017; convertible into shares of common stock at 65% of the lowest trading price 20 days prior to conversion.		46,625			-
Total convertible notes		174,672			174,240
Unamortized debt discount		(19,395	)		(158,806	)
Convertible notes, net of discount		155,277			15,434
Less current portion		(152,952	)		-
Long-term portion	$	2,325		$	15,434

Due to the variable conversion price associated with these convertible notes, the Company has determined that the conversion feature is considered derivative liabilities. The embedded conversion feature at inception was calculated to be $305,325, which is recorded as a derivative liability as of the date of issuance. The derivative liability was first recorded as a debt discount up to the face amount of the convertible notes of $174,240 with the remaining $136,640 begin charge as a financing cost during 2015. The debt discount is being amortized over the term of the convertible note. The Company recognized additional interest expense of $15,434 during 2015 related to the amortization of the debt discount.

NOTE 11 - DERIVATIVE LIABILITY

The convertible note discussed in Note 10 has a variable conversion price which results in the conversion feature being recorded as a derivative liability.

The fair value of the derivative liability is recorded and shown separately under current liabilities. Changes in the fair value of the derivative liability is recorded in the statement of operations under other income (expense).

The Company uses the Black-Scholes-Merton option pricing model with the following assumptions to measure the fair value of derivative liability at December 31, 2015:

Stock price	$	0.141
Risk free rate		0.64	%
Volatility		325	%
Conversion/ Exercise price	$	0.07-.085
Dividend rate		0	%
Term (years)		0.8 to 1.7

F-14

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

~~The~~Due ~~following~~to ~~table~~the ~~represents~~variable conversion price associated with these convertible notes, the Company’s has determined that the conversion feature is considered a derivative liability. ~~activity~~The ~~for~~embedded conversion feature at inception is recorded as a derivative liability as of the ~~period~~date of issuance. The derivative liability was recorded as a debt discount up to the face amount of the convertible notes with the remaining amount being charge as a financing cost. The debt discount is being amortized over the term of the convertible notes. The Company recognized additional interest expense of $277,439 and $15,434 during the years ended December 31, 2016 and 2015:, respectively, related to the amortization of the debt discount.

	Amount
Derivative liability balance, December 31, 2014	$	-
Issuance of derivative liability during the period ended December 31, 2015		305,325
Change in derivative liability during the period ended December 31, 2015		(2,745	)
Derivative liability balance, December 31, 2015	$	302,580

A rollfoward of the convertible note from December 31, 2014 to December 31, 2016 is below:

NOTE 12 - COMMITMENTS

Convertible notes, December 31, 2014	$	-
Issued for cash		50,000
Accounts payable converted to convertible note		118,685
Issued for original issue discount		5,556
Debt discount related to new convertible notes		(174,241	)
Amortization of debt discounts		15,434
Convertible notes, December 31, 2015		15,434
Issued for cash		77,500
Issued for original issue discount		8,028
Conversion to common stock		(85,096	)
Debt discount related to new convertible notes		(138,028	)
Amortization of debt discounts		277,439
Convertible notes, December 31, 2016	$	155,277

~~Planned~~NOTE ~~Acquisition~~7 of– ~~Grace~~DERIVATIVE ~~Home Health Care, Inc.~~LIABILITY

OnThe ~~November~~convertible ~~25,~~note ~~2014,~~discussed ~~the~~in ~~Company~~Note ~~entered~~6 ~~into~~has a ~~stock~~variable ~~purchase~~conversion ~~agreement~~price (the “Grace SPA”) with Grace Home Health Care, Inc. (“Grace”), a provider of home health care services, as well as Angelito D. Cadiente, and Loida F. Cadiente (collectively the “Grace Sellers”), pursuant to which weresults agreed to purchase, and the Sellers agreed to sell, all of their Grace shares, collectively representing all of the outstanding shares of common stock of Grace, as well as all of Grace’s assets, for an aggregate purchase price of $5,250,000 (the “Grace Purchase Price”). The Grace Purchase Price is to be paid by us as follows: $2,625,000 on or before January 15, 2015 (the “Grace Closing Date”), $1,312,500 nine months after the Grace Closing Date, and $1,312,500.00 twelve months after the Grace Closing Date. However, the Company has the right to extend the Grace Closing Date by an additional forty-five (45) days, in ~~order for its to secure~~ the ~~requisite~~conversion ~~funding,~~feature sobeing ~~long~~recorded as ~~the~~ ~~Company~~a ~~gives~~derivative ~~notice to the Grace Sellers on or before December 15, 2014~~liability. On June 15, 2015, the agreement was amended to extend the final closing until October 1, 2015 and issued 50,000 shares to the Grace Sellers as consideration for the extension. On September 15, 2015, the parties agreed to extend the final closing until January 1, 2016. The Grace SPA contains customary representations and warranties and is subject to certain events of default.

The ~~Company~~fair ~~has~~value ~~also~~of ~~agreed to hire Angelo L. Cadiente as Grace’s Chief Executive Officer upon~~ the ~~Grace~~derivative ~~Closing~~liability ~~Date.~~is ~~Under the~~recorded ~~terms~~and ofshown ~~his~~separately ~~proposed~~under ~~employment~~current ~~agreement, Mr~~liabilities. ~~Cadiente~~Changes ~~will~~in ~~become~~ the ~~Chief~~fair ~~Executive~~value ~~Officer for Grace for a period~~ of ~~three years beginning on~~ the ~~Grace~~derivative ~~Closing~~liability ~~Date~~is ~~and~~recorded ~~pay him an annual base salary of $175,000 plus a bonus~~ in ~~an amount equal to 5% of~~ the ~~increase~~statement ~~in Grace’s gross revenue from the base gross revenue earned in the previous year and an additional amount equal to 10%~~ of ~~the~~operations ~~base~~under ~~earnings~~other ~~before~~income ~~interest, taxes, depreciation and amortization~~ (~~“EBITDA”~~expense) ~~increases of Grace from the base EBITDA of Grace in the previous year~~. In addition, Mr. Cadiente will be entitled to four weeks of vacation, twelve sick days and health benefits and reimbursement of out of pocket expenses for business entertainment in connection with his duties. Mr. Cadiente is subject to a restriction on solicitation of Grace’s customers or clients following termination of his employment agreement for a period of one year. Since no consideration has been paid as of December 31, 2015, the acquisition is consider incomplete and not final.

~~Planned~~The ~~Acquisition~~Company ofuses the ~~assets~~Black-Scholes-Merton ofoption ~~Watson~~pricing ~~Health~~model ~~Care,~~with ~~Inc.~~the ~~and~~following ~~Affordable~~assumptions ~~Nursing~~to measure the fair value of derivative liability at December 31, ~~Inc.~~2016 and 2015:

On November 25, 2014, the Company entered into an asset purchase agreement (the “Watson-Affordable Nursing APA”) with Watson Health Care, Inc. (“Watson”) and Affordable Nursing, Inc. (“Affordable”) (Watson and Affordable are collectively referred to as the “Sellers”), providers of home health care services, pursuant to which the Company agreed to purchase, and the Sellers agreed to sell, all of their assets, for an aggregate purchase price of $3,000,000 (the “Watson-Affordable Purchase Price”). The Watson-Affordable Purchase Price will be paid by us as follows: $1,000,000 on or before January 15, 2015 (the “Watson-Affordable Closing Date”), $1,000,000 on or before nine months after the Watson-Affordable Closing Date, and $1,000,000 on or before twelve months after the Watson-Affordable Closing Date. However, the Company has the right to extend the Watson-Affordable Closing Date by an additional sixty (60) days. On September 15, 2015, the parties agreed to extend the final closing until January 1, 2016. The Watson-Affordable APA contains customary representations and warranties and is subject to certain events of default. In addition, Kevin Watson, the sole owner of Watson and Affordable and the Company will mutually agree to a transition period where Mr. Watson will work with Watson and Affordable to transition their operations to the Company. Further, the Company, Watson and Affordable will identify certain employees of Watson and Affordable who will enter into employment agreements with the Company. Since no consideration has been paid as of December 31, 2015, the acquisition is consider incomplete and not final.

	2016			2015
Stock price	$	0.0051		$	0.141
Risk free rate		0.59	%		0.64	%
Volatility		325	%		325	%
Conversion/Exercise price	$	0.0025 - 0.007		$	0.07-0.085
Dividend rate		0	%		0	%
Terms (years)		0.1 to 0.7			0.8 to 1.7

F-15

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

~~Planned~~The ~~Acquisition~~following oftable ~~Traditions~~represents ~~Home~~the ~~Care~~Company’s derivative liability activity for the years ended December 31, ~~Inc.~~2016 and 2015:

On January 5, 2015, the Company entered into a stock purchase agreement (the “Traditions SPA”) with Traditions Home Care, Inc. (“Traditions”), a provider of home health care services, as well as Sonny Nix and John Noah (collectively the “Sellers”), pursuant to which the Company agreed to purchase, and the Sellers agreed to sell, all of their shares of Traditions, collectively representing all of the outstanding shares of common stock of Traditions, as well as all of Traditions’ assets, for an aggregate purchase price of $6,000,000 (the “Purchase Price”). The Purchase Price is to be paid by the Company as follows: $3,000,000 on or before December 31, 2015 (the “Closing Date”), $1,500,000 nine months after the Closing Date, and $1,500,000 twelve months after the Closing Date. However, the Company has the right to extend the Closing Date by an additional forty-five (45) days, in order for it to secure the requisite funding, so long as the Company gives notice to the Sellers on or before March 1, 2015. The Traditions SPA contains customary representations and warranties, and is subject to certain events of default.

Derivative liability at December 31, 2014	$	-
Derivative liability associated with new convertible note		305,325
Change in fair value of derivative liability during period		(2,745	)
Derivative liability at December 31, 2015		302,580
Derivative liability associated with new convertible note		265,533
Change in fair value of derivative liability during period		(418,844	)
Derivative liability at December 31, 2016	$	149,269

~~The~~NOTE ~~Company~~8 ~~has~~– ~~also agreed to hire Sonny Nix (“Nix”) as Traditions~~STOCKHOLDERS’ Chief Executive Officer, pursuant to the terms of the employment agreement attached as Exhibit B to the Traditions SPA (the “Employment Agreement”). The Employment Agreement will only become effective upon closing of the Traditions SPA. Under the Employment Agreement, Nix will become the Chief Executive Officer for Traditions for a period of three years beginning on the Closing Date and pay him an annual base salary of $150,000 plus a bonus in an amount equal to 5% of the increase in Traditions’ gross revenue from the base gross revenue earned in the previous year, and an additional amount equal to 10% of the base earnings before interest, taxes, depreciation and amortization (“EBITDA”) increases of Traditions from the base EBITDA of Traditions in the previous year. In addition, Nix will be entitled to three weeks of vacation, twelve sick days, and health benefits. Nix is subject to a restriction on solicitation of Traditions’ customers or clients following termination of his Employment Agreement for a period of one year. Since no consideration has been paid as of December 31, 2015, the acquisition is consider incomplete and not final. On July 6, 2015, the agreement was amended to extend the closing date to October 1, 2015. On September 15, 2015, the parties agreed to extend the final closing until January 1, 2016.DEFICIT

~~Termination~~The Company has two classes of ~~Chief~~stock, ~~Financial~~preferred ~~Officer~~stock and common stock. There are 10,000,000 shares of $.0001 par value preferred stock authorized, 500,000 of which were designated as 8% Convertible Preferred Stock as of May 7, 2015.

On May 8, 2015, the Company entered into a separation agreement with Daniel Freeman, the Company’s former Chief Financial Officer. Under the terms of the separation agreement, the Company agreed to pay Mr. Freeman $100,000 at such time as the Company closes on a financing transaction or offering of its securities where the Company receives a minimum of $2,000,000 in cash and accelerated the vesting of and awarded Mr. Freeman options to purchase 409,000 shares of the Company’s unregistered common stock at a price of $.0001 per share which expire on September 30, 2024. The separation agreement included a release of claims by Mr. Freeman in favor of the Company and other standard provisions included in separation agreements.

NOTE 13 - STOCKHOLDERS’ DEFICIT

The Company has two classes of stock, preferred stock and common stock. There are 10,000,000 shares of $.0001 par value preferred shares authorized, 500,000 of which have been designated as 8% Convertible Preferred Stock as of May 7, 2015.

The 500,000 shares of 8% Convertible Preferred Stock have the following the designations, rights, and preferences:

● The state value of each share is $4.00, ● Holders of shares of 8% Convertible Preferred Stock do not have any voting rights, ● The shares pay quarterly dividends in arrears at the rate of 8% per annum and on each conversion date. Subject to certain conditions, the dividends are payable at ~~our~~the Company’s option in cash or such dividends shall be accreted to, and increase, the outstanding ~~Stated~~stated ~~Value~~value, ● Each share is convertible into shares of the Company’s common stock at a conversion price of $4.00 per share, subject to adjustment, and ● The conversion price of the 8% Convertible Preferred is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.

There were 198,473 shares of 8% Convertible Preferred Stock issued and outstanding as of December 31, 2016.

There are 100,000,000 shares of $.0001 par value common shares authorized. The Company had 69,569,444 and 45,011,216 issued and outstanding shares as of December 31, 2016 and 2015, respectively.

During the year ended December 31, 2016, the Company issued 24,558,228 shares for the conversion of $87,106 of convertible notes payable.

F-16

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

	●	Each share is convertible into shares of our common stock at a conversion price of $4.00 per share, subject to adjustment discussed below, and
	●	The conversion price of the 8% Convertible Preferred is subject to proportional adjustment in the event of stock splits, stock dividends and similar corporate events.

The Company issued 3,810,290 shares for services with a fair value of $7,731,493 and 500,000 shares for an extension of loan payment terms with a fair value of $1,360,907 for the year ended December 31, 2015. In addition, the Company also issued 25,000 shares for cash proceeds of $15,000.

~~There~~NOTE ~~were~~9 ~~198,473~~– ~~shares~~STOCK-BASED ~~of 8% Convertible Preferred Stock issued and outstanding as of December 31, 2015.~~COMPENSATION

There are 100,000,000 shares of $.0001 par value common shares authorized. The Company has 45,011,216 and 40,445,926 issued and outstanding shares as of December 31, 2015 and 2014, respectively.

The Company issued 3,810,290 shares for services with a fair value of $7,731,493 and 500,000 shares for an extension of loan payment terms with a fair value of $1,360,907 for the years ended December 31, 2015. In addition, the Company also issued 25,000 shares for cash proceeds of $15,000.

On October 4, 2013, the Company entered into a Standby Equity Purchase Agreement with Lambert Private Equity, LLC, a Delaware limited liability company (the “Investor”). Pursuant to the Investment Agreement, the Investor committed to purchase, subject to certain restrictions and conditions, up to $100,000,000 (which can be extended to $200,000,000 under the same terms) of the Company’s common stock, over a period of 36 months from the first trading day following the effectiveness of the registration statement registering the resale of shares purchased by the Investor pursuant to the Investment Agreement (the “Equity Line”). As an inducement to Investor to enter in to the Investment Agreement and as consideration for the Investor making the investment the Investor received 285,710 shares of common stock and 100% warrant/option coverage. The option to purchase shares certified that for good and valuable consideration, the receipt and sufficiency of which was acknowledged, Lambert Private Equity, LLC is entitled effective as October 4, 2013, subject to the terms and conditions of the Option to purchase from the Company up to a total of 14,287,710 shares of the Company’s common shares at the price of the lesser of (a) $7.00 or (b) 110% of the lowest daily VWAP for the common stock as reported by Bloomberg during the thirty (30) trading days prior to the date the Investor exercised the Warrant prior to 5:00 pm New York time on September 3, 2018 the expiration date. As of December 31, 2015, no funds have been received from this agreement.

NOTE 14 - STOCK-BASED COMPENSATION

The Company recognizes stock-based compensation expense in its statement of operations based on the fair value of employee stock options and stock grant awards as measured on the grant date. For stock options, the Company uses the Black-Scholes option pricing model to determine the value of the awards granted. The Company amortizes the estimated value of the options as of the grant date over the stock options’ vesting period, which is generally four years.

The Company has estimated the value of common stock into which the options are exercisable at $4.00 per share for financial reporting purposes. This amount was determined based on the price ~~our~~the Company’s stock was sold for in past private placements, the minimum stock price required for listing on any Nasdaq market, and the amount also approximates a $85 million valuation for the entire Company, which is considered “micro-cap” by most equity analysts. The stock based compensation expense is an estimate and significant judgment was involved in attempting to determine the value of common stock. When a majority of the stock options were ~~issued~~granted, the Company’s common stock ~~has~~was not traded publicly, and no stock was traded in private markets either, except for privately negotiated sales to the founder and other private investors ~~of the company~~ and the founder of the technology from which the ~~company~~ Company subsequently licensed rights. The Company does not have any offers for purchase of its common stock in any stage, and no stock is currently registered for resale with the Securities and Exchange Commission.

The Company believes the only material estimate used in estimating the value of stock options was the estimated fair value of the ~~common~~ common stock, and that assumed volatility, term, interest rate and dividend yield changes would not result in material differences in in stock option valuations. The Company recognized stock-based compensation expense of $41,~~265~~616,~~889~~144 and $64,~~520~~265,~~378~~889 for the years ~~ended~~ ended December 31, ~~2015~~2016 and ~~2014~~2015, respectively, which were included in general and administrative expenses. As of December 31, ~~2015,~~ 2016, there was $130,~~646,144~~000 of total unrecognized compensation cost related to unvested stock-based compensation awards, which is ~~expected~~ expected to be recognized ~~over~~through ~~the~~September ~~weighted average remaining vested period of approximately 1~~2018.~~5 years.~~

The following is a summary of the outstanding options, as of December 31, 2016:

								Weighted
				Weighted		Weighted		Average
				Average		Average		Remaining
	Options			Intrinsic		Exercise		Contractual
	Outstanding			Value		Price		Life
Outstanding, December 31, 2014		5,888,583			4.00	$	0.0001		2.5
Granted		425,667			2.52
Exercised		-
Forfeited/Expired		(511,000	)
Outstanding, December 31, 2015		5,803,250			3.89		0.0001		1.5
Granted		-
Exercised		-
Forfeited/Expired		-
Outstanding, December 31, 2016		5,803,250			3.89		0.0001		0.5
Exercisable, December 31, 2016		5,777,000			3.89		0.0001		0.5

F-17

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

The following is a summary of the outstanding options, as of December 31, 2015:

								Weighted
				Weighted		Weighted		Average
				Average		Average		Remaining
	Options			Intrinsic		Exercise		Contractual
	Outstanding			Value		Price		Life
Outstanding, December 31, 2013		4,849,000
Granted		2,060,000		$	4.00	$	0.0001		3.0
Exercised		0
Forfeited/Expires		(1,020,417	)
Outstanding, December 31, 2014		5,888,583			4.00		0.0001		2.5
Granted		425,667			2.52
Exercised		0
Forfeited/Expires		(511,000	)
Outstanding, December 31, 2015		5,803,250			3.89		0.0001		1.5
Exercisable, December 31, 2015		5,188,929			3.89		0.0001		0.9

Weighted average assumptions in the calculation of option value:

Risk-free interest rate	0.83	%
Expected life of the options	4 years
Expected volatility	268	%
Expected dividend yield	0	%
Forfeiture rate	0	%

NOTE 1510 -– RELATED PARTY TRANSACTIONS

~~The~~On ~~Company~~December ~~and~~5, ~~Synergistic Holdings~~2014, ~~LLC~~the (“Company and Synergistic”), a ~~controlling~~major shareholder of the Company, agreed to cancel 796,671 shares of the Company’s common stock owned by Synergistic and forgive certain indebtedness owed by the Company to Synergistic in the amount of $1,018,618. In addition, the Company entered into an oral agreement to amend the ~~license~~licensing agreement entered into between the Company and Synergistic (the “Licensing Agreement”) to reduce the total amount of reimbursable distribution and commercialization expenses due under the ~~license~~Licensing agreement by $585,181 to $29,414,819 and defer the ~~commencement~~ date of ~~the~~certain ~~agreement~~payment ~~until~~obligations by the ~~payment~~Company ~~dates~~under ~~for~~ the ~~following~~Licensing ~~amounts~~Agreement as follows:

	(a)	$5,000,000 no later than December 31, 2015;

	(b)	An additional $7,500,000 no later than December 31, 2016;

	(c)	An additional $10,000,000 no later than December 31, 2017; and

	(d)	An additional $6,914,819 no later than December 31, 2018.

~~Tec~~No ~~Explorer~~payments ishave abeen ~~related~~made ~~party through common ownership. Tec Explorer supplied working capital~~ to ~~the Company to fund primarily software acquisition costs, accounting services, commissions and subcontract costs during 2010 through 2013~~date. ~~Synergistic Holdings, LLC assumed all obligations to Tec Explorer during 2014 and 2013 on behalf of the Company. This verbal agreement was agreed to by all three companies.~~

On May 7, 2015, the Company and Synergistic agreed to amend the Licensing Agreement to eliminate the Company’s $29,414,819 funding requirements under Article 3 and replace it with a requirement to pay a license fee in the amount of $10,000 upon completion and acceptance of each installation of the software at a location for each affiliate or subsidiary of the Company and the sum of $10,000 on each anniversary after each such installation during the period of time in which the software is used at such location. In addition, the Company will be responsible for the reasonable installation costs incurred by Synergistic in connection with the installation and setup of the software as required by the Company. The license fee may be paid in cash or the Company’s common stock. In addition, the Licensing Agreement was amended to delete the Company’s exclusive rights under such agreement.

At December 31, 2016 and 2015, advances from related party were $403,092 and $243,799, respectively. These advances are non-interest bearing and payable upon demand.

NOTE 11 – INCOME TAXES

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the periods presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses and other temporary differences, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not. As of December 31, 2016, the Company had a loss and for the period April 29, 2008 (date of inception) through December 31, 2016. The net operating losses resulting from operating activities result in deferred tax assets of approximately $23,552,000 at the effective statutory rates which will expire by the year 2033. The deferred tax asset has been offset by an equal valuation allowance. There are no current or deferred income tax expense or benefit recognized for the years ended December 31, 2016 and 2015.

F-18

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2015~~2016 AND ~~2014~~2015

OnA ~~May~~reconciliation 7,of ~~2015,~~income ~~the~~taxes ~~Company~~computed ~~and~~at ~~Synergistic agreed to amend~~ the ~~Synergistic~~United ~~Licensing~~States ~~Agreement~~federal tostatutory ~~eliminate~~income ~~the~~tax ~~Company’s $29,414,819~~rate ~~funding requirements under Article 3 and replace it with a requirement~~ to ~~pay a license fee in~~ the ~~amount~~provision ~~of 10,000 common shares upon completion and acceptance of each installation of the software at a location~~ for ~~each~~income ~~affiliate or subsidiary~~taxes offor the ~~Company~~years ~~and~~ended ~~the~~December ~~sum of $10~~31,~~000~~ on2016 ~~each~~and ~~anniversary~~2015 ~~after each such installation during the period of time in which the Software~~ is ~~used at such location. In addition, the Company will be responsible for the reasonable installation costs incurred by Synergistic in connection with the installation and setup of the software~~ as required by the Company. The license fee may be paid in cash or the Company’s common stock. In addition, the Synergistic Licensing Agreement was amended to delete the Company’s exclusive rights under such agreement.follows:

NOTE 16 - INCOME TAXES

	2016			2015

Federal statutory rates	$	786,859		$	(5,074,386	)
State income taxes, net of federal effect		118,376			(763,397	)
Gain on discontinued operations		(1,658,314	)		-
Other permanent differences		(2,296	)		88,259
Valuation allowance against net deferred tax assets		755,375			5,749,524
	$	-		$	-

The ~~Company has not recognized an income~~ tax ~~benefit~~effects ~~for~~of its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the periods presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses and other temporary differences, ~~the~~that ~~realization~~give ofrise ~~which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts~~ to besignificant ~~more~~portions ~~likely than not. As~~ of ~~December 31, 2015,~~ the ~~Company had a loss and for the period April 29, 2008 (date of inception) through December 31, 2015. The net operating losses resulting from operating activities result in~~ deferred tax ~~assets~~asset ~~of approximately $22,797,000~~ at the effective statutory rates which will expire by the year 2028. The deferred tax asset has been off-set by an equal valuation allowance. There are no current or deferred income tax expense or benefit recognized for the years ended December 31, ~~2015~~2016 and 2015 ~~2014.~~is as follows:

A reconciliation of income taxes computed at the United States federal statutory income tax rate to the provision for income taxes for the years ended December 31, 2015 and 2014 is as follows:

	2016			2015

Deferred income tax assets:
Net operation loss carryforwards		1,618,174			1,494,954
Property, equipment and intangibles		1,635,587			1,635,587
Share-based compensation		20,015,035			19,382,880
Book to tax differences for allowance for uncollectible accounts		283,658			283,658
Total deferred income tax assets		23,552,454			22,797,079
Less: valuation allowance		(23,552,454	)		(22,797,079	)
Total deferred income tax asset	$	-		$	-

	2015			2014
Federal statutory rates	$	(234,527	)	$	(774,183	)
State income taxes, net of federal effect		(35,283	)		(177,987	)
Stock Compensation		(5,255,049	)		(11,436,152	)
Impairment of intangibles		-			(1,635,587	)
Allowance for doubtful accounts		(224,665	)		(58,996	)
Valuation allowance against net deferred tax assets		5,749,524			14,082,905
	$	-		$	0

The valuation allowance increased by $755,375 and $5,749,524 in 2016 and 2015, respectively, as a result of the Company’s generating additional net operating losses.

The ~~tax~~Company ~~effects~~has recorded as of ~~temporary~~December ~~differences~~31, ~~that~~2016 ~~give~~and ~~rise~~2015 toa ~~significant~~valuation ~~portions~~allowance of $23,552,454 and $22,797,079, respectively; as management believes that it is more likely than not that the deferred tax ~~asset~~assets atwill ~~December~~not ~~31,~~be ~~2015~~realized ~~and~~in future years. Management has based ~~2014~~its isassessment ason ~~follows:~~the Company’s lack of profitable operating history.

	2015			2014
Deferred income tax assets:
Net operation loss carryforwards		1,494,954			1,225,144
Property, equipment and intangibles		1,635,587			1,635,587
Share-based compensation		19,382,880			14,127,831
Book to tax differences for allowance for uncollectible accounts		283,658			58,993
Total deferred income tax assets		22,797,079			17,047,555
Less: valuation allowance		(22,797,079	)		(17,047,555	)
Total deferred income tax asset	$	-		$	-

The Company annually conducts an analysis of its tax positions and has concluded that it had no uncertain tax positions as of December 31, 2016.

The Company has net operating loss carry-forwards of approximately $3,900,000. Such amounts are subject to IRS code section 382 limitations and begin to expire in 2033. The 2015 and 2016 tax years are still subject to audit.

NOTE 12 – RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

On November 11, 2013, the Company entered into a stock purchase agreement with Behavioral Health Care Associates, Ltd. (“BHCA”) to purchase 100% of the issued and outstanding share of BHCA common stock for $4,550,000. The purchase price was to be paid in installments over a period of approximately 24 months. The Company originally recorded the purchase of BHCA on November 11, 2013 and began consolidating the operating results of BHCA from that date. The Company never made any of the required installment payments in accordance with the stock purchase agreement and the stock of BHCA was never transferred to the Company. As a result, the Company has determined that the financial statements of BHCA should have never been consolidated with those of the Company since the Company was never able to take control of BHCA due to non-payment of the purchase price. The prior year financial statements have been restated to remove BHCA from the consolidated financial statements of the Company.

The following tables present the restated financial statements as of and for the year ended December 31, 2015. All the adjustments are a result of removing BHCA from the Company’s consolidated financial statements.

F-19

ACCELERA INNOVATIONS, INC. ~~AND SUBSIDIARIES~~

~~NOTES~~BALANCE ~~TO CONSOLIDATED FINANCIAL STATEMENTS~~SHEET

~~FOR~~AS ~~THE~~OF ~~YEARS ENDED~~ DECEMBER 31, 2015 ~~AND 2014~~

The valuation allowance increased by $5,749,524 and $14,082,902 in 2015 and 2014, respectively, as a result of the Company’s generating additional net operating losses.

	As Originally			Amount of
	Presented			Restatement			As Restated

ASSETS

Current Assets:
Cash	$	474,564		$	(474,564	)	$	0
Prepaid expenses		29,793			0			29,793
Total current assets		504,357			(474,564	)		29,793

Property and equipment, net		8,889			0			8,889
Security deposit		1,805			0			1,805

TOTAL ASSETS	$	515,051		$	(474,564	)	$	40,487

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities:
Cash overdraft	$	0		$	6,624		$	6,624
Short-term note payable		901,521			0			901,521
Subordinated unsecured note payable		4,550,000			(4,550,000	)		0
Advanced from related party		243,799			0			243,799
Accounts payable		474,510			(65,591	)		408,919
Accrued expenses		427,764			(105,183	)		322,581
Derivative liability		302,580			0			302,580
Total current liabilities		6,900,174			(4,714,150	)		2,186,024

Convertible note		15,434			0			15,434

TOTAL LIABILITIES		6,915,608			(4,714,150	)		2,201,458


STOCKHOLDERS’ DEFICIT
Preferred stock		20			0			20
Common stock		4,501			0			4,501
Additional paid-in capital		57,522,043			0			57,522,043
Accumulated deficit		(63,927,121	)		4,239,586			(59,687,535	)
Total stockholders’ deficit		(6,400,557	)		4,239,586			(2,160,971	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	515,051		$	(474,564	)	$	40,487

The Company has recorded as of December 31, 2015 and 2014 a valuation allowance of $22,797,079 and $17,047,555, respectively, as management believes that it is more likely than not that the deferred tax assets will not be realized in future years. Management has based its assessment on the Company’s lack of profitable operating history.

The Company annually conducts an analysis of its tax positions and has concluded that it had no uncertain tax positions as of December 31, 2015.

The Company has net operating loss carry-forwards of approximately $3,600,000. Such amounts are subject to IRS code section 382 limitations and begin to expire in 2028. The 2014 and 2015 tax year is still subject to audit.

NOTE 17 – RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS

As previously disclosed in the Company’s current report on Form 8-K filed with the SEC on July 21, 2015, the Company’s Board of Directors determined that the Company’s financial statements included in (i) its quarterly reports on Form 10-Q for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013, (ii) its annual report on Form 10-K for the year ended December 31, 2013, (iii) its quarterly reports on Form 10-Q for the periods ended March 31, 2014, June 30, 2014 and September 30, 2014, and (iv) its annual report on Form 10-K for the year ended December 31, 2014 could not be relied on.

The financial statements contained errors related to (i) issuances of the Company’s preferred stock, the receipt of funds related to these issuances and the accounting for the use of the proceeds from these sales in each of the periods covered by the financial statements disclosed above, (ii) disclosure of a related party transactions, and (iii) the valuation of shares of the Company’s common stock issued as compensation.

As more fully described in the financial statements contained herein, management determined that previously issued financial statements for the year ended December 31, 2014 contained an error, which was non-cash in nature, relating to the issuance of Company preferred stock, the receipt of funds related to such issuance and the accounting for the use of proceeds from such sale. The Company evaluated the impact of this error under the SEC’s authoritative guidance on materiality and determined that the impact of this error on the financial statements for the year ended December 31, 2104 was material. On July 20, 2015, after review by the Company’s independent registered public accounting firm, the Company’s Board of Directors concluded that the Company should restate its financial statements for the year ended December 31, 2014 to reflect the correction of the previously identified error in the financial statements for this period.

In order to reflect the error described herein, the Company restated its financial statements for the year ended December 31, 2014. There was no impact to our statement of operations or actual cash balances as a result of this error, and this error does not change net cash flows from operating activities, investing activities, and financing activities.

The Company’s affiliate received cash proceeds from investors for preferred stock subscriptions in the Company. The 48,562 shares of preferred stock have not been issued because the Company has not filed the Certificate of Designations with the State of Delaware, and the proceeds were deposited directly into the bank account of Synergistic, the Company’s affiliate. The preferred shares have not been issued to the investors and the Company has recorded the preferred stock subscriptions as a liability under preferred stock payable as of December 31, 2014.

After a detailed review of the facts, the Company has concluded that the common stock and preferred stock to be issued as of December 31, 2014 should have been recorded in the financial statements for the year ended December 31, 2014.

F-20

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

~~NOTES~~CONSOLIDATED TOSTATEMENTS ~~CONSOLIDATED~~OF ~~FINANCIAL STATEMENTS~~OPERATIONS

~~FOR~~YEAR ~~THE YEARS~~ ENDED DECEMBER 31, 2015 ~~AND 2014~~

The following tables present the restated items for the applicable date.

	As Originally			Amount of
	Presented			Restatement			As Restated

Revenues	$	3,623,131		$	(2,489,416	)	$	1,133,715
Cost of revenues		1,856,401			(1,698,690	)		157,711
Gross profit		1,766,730			(790,726	)		976,004

Operating expenses:
General and administrative expenses		14,892,236			(899,715	)		13,992,521
Total operating expenses		14,892,236			(899,715	)		13,992,521
Loss from operations		(13,125,506	)		108,989			(13,016,517	)

Other income (expense)
Interest expense and financing costs		(1,801,903	)		0			(1,801,903	)
Change in fair value of derivative liability		2,745			0			2,745
Total other income (expenses)		(1,799,158	)		0			(1,799,158	)

Loss before provision for taxes		(14,924,664	)		108,989			(14,815,675	)

Provision for income taxes		0			0			0

Net loss	$	(14,924,664	)	$	108,989		$	(14,815,675	)

Preferred stock dividend		41,413			0			41,413

Net loss attributed to common stockholders	$	(14,966,077	)	$	108,989		$	(14,857,088	)

Weighted average shares outstanding - basic and diluted		42,919,132			0			42,919,132

Loss per share - basic and diluted	$	(0.35	)	$	0.00		$	(0.35	)

	As Originally			Amount of
	Presented			Restatement			As Restated
ASSETS
Current Assets:
Cash	$	54,862		$	-		$	54,862
Accounts receivable, net		605,796			-			605,796
Prepaid expenses		6,026			-			6,026
Due from stockholder		-			109,620			109,620
Total current assets		666,684			109,620			776,304
Property and equipment, net		6,381			-			6,381
Security deposit		1,805			-			1,805
TOTAL ASSETS	$	674,870		$	109,620		$	784,490
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Short-term note payable	$	844,507		$	-		$	844,507
Advanced from related party		31,810			(31,810	)		-
Accounts payable		88,689			-			88,689
Preferred stock subscription payable		652,462			141,430			793,892
Accrued expenses		226,099			-			226,099
Unearned revenue		957			-			957
Total current liabilities		1,844,524			109,620			1,954,144
Long-term subordinated unsecured notes payable		4,550,000			-			4,550,000
TOTAL LIABILITIES		6,394,524			109,620			6,504,144
STOCKHOLDERS’ DEFICIT
Preferred stock		-			-			-
Common stock		4,046			-			4,046
Additional paid-in capital		43,278,757			-			43,278,757
Accumulated deficit		(49,002,457	)		-			(49,002,457	)
Total stockholders’ deficit		(5,719,654	)		-			(5,719,654	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	674,870		$	109,620		$	784,490

NOTE 18 - SUBSEQUENT EVENTS

The Company, Blaise J. Wolfrum, M.D., and Behavioral (the “Parties”) entered into a Stock Purchase Agreement dated on or about November 20, 2013, as amended. On March 31, 2016, the Parties executed a Termination Agreement by which the Stock Sale Agreement was terminated effect as of January 1, 2016. Behavioral will be accounted for as a discontinued operation in all future financial statements issued by the Company.

F-21

ACCELERA INNOVATIONS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CASH FLOWS

YEAR ENDED DECEMBER 31, 2015

	As Originally			Amount of
	Presented			Restatement			As Restated

OPERATING ACTIVITIES:
Net loss	$	(14,924,664	)	$	108,989		$	(14,815,675	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		1,259			0			1,259
Stock options expense		4,265,889			0			4,265,889
Shares issued for services		7,731,493			0			7,731,493
Shares issued for extending loan payment terms		1,437,487			0			1,437,487
Amortization of debt discount		15,434			0			15,434
Change in fair value of derivative liability		(2,745	)		0			(2,745	)
Financing costs associated with convertible note		136,640			0			136,640
Offering cost for preferred stock subscription		141,430			0			141,430
Change in current assets and liabilities:					0
Accounts receivable		605,796			(452,318	)		153,478
Prepaid expenses and current assets		(23,767	)		0			(23,767	)
Accounts payable		385,821			(65,591	)		320,230
Accrued expenses		200,708			(5,721	)		194,987
Net cash used in operating activities		(29,219	)		(414,641	)		(443,860	)

INVESTING ACTIVITIES:
Purchase of property and equipment		(3,767	)		0			(3,767	)
Net cash used in investing activities		(3,767	)		0			(3,767	)

FINANCING ACTIVITIES:
Proceeds from the sale of stock		15,000			0			15,000
Proceeds from convertible notes		50,000			0			50,000
Proceeds from notes payable		250,000			0			250,000
Payment on notes payable		(74,301	)		0			(74,301	)
Cash overdraft		0			(5,061	)		(5,061	)
Advances from (payments to) related parties		211,989			0			211,989
Net cash provided by financing activities		452,688			(5,061	)		447,627

NET INCREASE (DECREASE) IN CASH		419,702			(419,702	)		0

CASH, BEGINNING BALANCE		54,862			(54,862	)		0

CASH, ENDING BALANCE	$	474,564		$	(474,564	)	$	0

CASH PAID FOR:
Interest	$	0		$	0		$	0
Income taxes	$	0		$	0		$	0

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Convertible notes and accrued interest converted to common stock	$	0		$	0		$	0
Convertible note issued for liabilities	$	118,685		$	0		$	118,685

NOTE 13 – SUBSEQUENT EVENTS

Management has reviewed events between December 31, 2016 and April 14, 2017 and no significant events were identified.

F-22

Filing Compare · ACCELERA INNOVATIONS, INC.